Document:

<PAGE>

                                                                    Exhibit 10.1

                                            ***Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                            Under 17 C.F.R. (S)(S) 200.80(b)(4),
                                                            200.83 and 240.24b-2

               COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENT

<PAGE>

                Collaborative Development and Marketing Agreement

                                TABLE OF CONTENTS
                                -----------------

<TABLE>
<CAPTION>
                                                                                              Page No.
<S>                                                                                           <C>
1.   Definitions .............................................................................   1

     1.1   Additional Product ................................................................   1
     1.2   BLA ...............................................................................   1
     1.3   cGMP ..............................................................................   1
     1.4   Clinical Plan .....................................................................   1
     1.5   Clinical Program ..................................................................   2
     1.6   Clinical Supply ...................................................................   2
     1.7   Clinical Trial ....................................................................   2
     1.8   Clinical Trial Costs ..............................................................   2
     1.9   Collaboration Invention ...........................................................   2
     1.10  Collaboration Invention Patent Rights .............................................   3
     1.11  Commercial Supply .................................................................   3
     1.12  Commercially Reasonable and Diligent Efforts ......................................   3
     1.13  Commercialization Plan ............................................................   3
     1.14  Completion of Phase II (or Phase III) Clinical Trials .............................   3
     1.15  Confidential Information ..........................................................   3
     1.16  Controlled ........................................................................   3
     1.17  Covering ..........................................................................   3
     1.18  DENDREON/GNE Development Costs ....................................................   3
     1.19  Dendreon Know-how .................................................................   4
     1.20  Dendreon Patents Rights ...........................................................   4
     1.21  Dendreon Territory ................................................................   4
     1.22  Development Research ..............................................................   4
     1.23  Discovery Research ................................................................   4
     1.24  Effective Date ....................................................................   4
     1.25  FDA ...............................................................................   4
     1.26  Field .............................................................................   4
     1.27  FTE ...............................................................................   4
     1.28  FTE Costs .........................................................................   5
     1.29  Genentech Know-how ................................................................   5
     1.30  Genentech Patent Rights ...........................................................   5
     1.31  IND ...............................................................................   5
     1.32  Joint Project Team or JPT .........................................................   5
     1.33  Joint Steering Committee ..........................................................   5
     1.34  Joint Collaboration Invention .....................................................   5
     1.35  Joint Patent Rights ...............................................................   5
     1.36  Know-how ..........................................................................   5
     1.37  Licensed Product ..................................................................   5
     1.38  Licensed Trp-p8 Vaccine Product ...................................................   6
     1.39  Manufacturing Know-how ............................................................   6
     1.40  Monoclonal Antibody ...............................................................   6
</TABLE>

<PAGE>

<TABLE>
     <S>                                                                                      <C>
     1.41  Monoclonal Product ................................................................   6
     1.42  NDA ...............................................................................   6
     1.43  Net Sales .........................................................................   6
     1.44  Operating Profits and Losses ......................................................   7
     1.45  Other Molecule ....................................................................   7
     1.46  Party or Parties ..................................................................   7
     1.47  Patent Rights .....................................................................   7
     1.48  Permitted Assignee ................................................................   7
     1.49  Phase I Clinical Trial ............................................................   7
     1.50  Phase II Clinical Trial ...........................................................   7
     1.51  Phase III Clinical Trial ..........................................................   7
     1.52  Pivotal Trial .....................................................................   8
     1.53  Preclinical Plan ..................................................................   8
     1.54  Preclinical Program ...............................................................   8
     1.55  Preclinical Program Costs .........................................................   8
     1.56  Prevalent Cancer ..................................................................   8
     1.57  Product Development Program .......................................................   8
     1.58  Regulatory Agency .................................................................   8
     1.59  Regulatory Approval ...............................................................   8
     1.60  Regulatory Filings ................................................................   8
     1.61  Research Grade Material ...........................................................   8
     1.62  SM Product ........................................................................   8
     1.63  Small Molecule ....................................................................   9
     1.64  Term ..............................................................................   9
     1.65  Territory .........................................................................   9
     1.66  Third Party .......................................................................   9
     1.67  Third Party Costs .................................................................   9
     1.68  Trp-p8 ............................................................................   9
     1.69  Tumor Type ........................................................................   9
     1.70  Vaccine Product Patent Rights .....................................................   9
     1.71  Valid Claim .......................................................................   9

2.   Scope of the Product Development Program ................................................   9

     2.1   Product Development Program .......................................................   9
     2.2   Preclinical Program ...............................................................  10
     2.3   Monoclonal Product ................................................................  10
           2.3.1 Genentech Responsibilities ..................................................  10
           2.3.2 Dendreon Independent Activities .............................................  11
     2.4   Decision Point - Monoclonal Product ...............................................  11
     2.5   SM Product ........................................................................  11
           2.5.1 Dendreon Responsibilities ...................................................  11
           2.5.2 Genentech Independent Activities ............................................  12
           2.5.3 JSC Decision ................................................................  12
           2.5.4 Small Molecule Agreements ...................................................  12
     2.6   Genentech Option for SM Products ..................................................  13
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                            <C>
           2.6.1 Exclusive Option ............................................................  13
           2.6.2 Exercise of Option ..........................................................  13
           2.6.3 Early Exercise ..............................................................  14
     2.7   Licensed Trp-p8 Vaccine Products ..................................................  14
           2.7.1 Vaccine Products ............................................................  14
           2.7.2 Genentech First Right of Negotiation ........................................  14
     2.8   Preclinical Program Costs .........................................................  15
           2.8.1 Genentech Costs .............................................................  15
           2.8.2 Dendreon Costs ..............................................................  15
           2.8.3 Payment for Independent Activities ..........................................  16
     2.9   Clinical Program ..................................................................  16
     2.10  Phase I and Phase II Responsibilities .............................................  17
     2.11  Phase II Decision Point ...........................................................  17
     2.12  Phase I and II Clinical Trial Costs ...............................................  18
     2.13  Phase III Clinical Trials .........................................................  19
     2.14  SM Product and Monoclonal Product Cost Sharing ....................................  19
     2.15  First Monoclonal Product Phase III Results ........................................  20
     2.16  First SM Products Phase III Results ...............................................  20
     2.17  Additional Products and Other Molecules ...........................................  20
     2.18  Regulatory Filings, Communications and Reports ....................................  20
           2.18.1 Rights and Obligations of Dendreon .........................................  20
           2.18.2 Regulatory Filings for Manufacturing .......................................  21
           2.18.3 Cross Reference of Regulatory Filings ......................................  22
           2.18.4 Regulatory Meetings and Communications .....................................  22
     2.19  Information .......................................................................  22
     2.20  Adverse Drug Events and Complaints ................................................  23
     2.21  Other Activities ..................................................................  23
     2.22  Transfer of Materials .............................................................  24
     2.23  Thirty Party Academic Researchers/Institutions ....................................  24
     2.24  Contracts with Third Parties ......................................................  25

3.   Joint Steering Committee ................................................................  25

     3.1   Joint Steering Committee ..........................................................  25
     3.2   JSC Meetings ......................................................................  26
           3.2.1 Meeting Schedule ............................................................  26
           3.2.2 JSC Chair ...................................................................  26
     3.3   Decision-Making and Issue Resolution ..............................................  26

4.   Joint Project Team ......................................................................  27

     4.1   Establishment of Joint Project Team ...............................................  27
     4.2   Joint Project Team Responsibilities ...............................................  27
     4.3   Joint Project Team Decision-making ................................................  28
     4.4   Ceasing of Joint Project Team Operations ..........................................  28
     4.5   Annual Production Requirements ....................................................  28
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                            <C>
5.   Licenses and Rights .....................................................................  28

     5.1   Dendreon Grant ....................................................................  28
     5.2   Genentech Grant ...................................................................  29
     5.3   Dendreon Sublicense Rights ........................................................  30
     5.4   Genentech Sublicense Rights .......................................................  30
     5.5   Sublicense Obligations ............................................................  30
     5.6   Trademark License .................................................................  31
     5.7   Exclusions ........................................................................  31

6.   Payments ................................................................................  31

     6.1   Equity Investment .................................................................  31
     6.2   Additional Equity Investment ......................................................  31
     6.3   Monoclonal Product Milestones .....................................................  31
     6.4   SM Product ........................................................................  33
     6.5   Royalties to Dendreon .............................................................  34
     6.6   Royalties to Genentech ............................................................  34
     6.7   Currency and Payments .............................................................  34
     6.8   Royalty Reports ...................................................................  34
     6.9   Books and Records .................................................................  35
     6.10  Audit Rights ......................................................................  35
     6.11  Blocked Currency ..................................................................  35
     6.12  Taxes .............................................................................  35

7.   Commercialization in the Territory ......................................................  35

     7.1   Commercialization - General Roles .................................................  35
     7.2   Marketing and Sales by Dendreon ...................................................  36
     7.3   Option to Co-Promote Competing Products ...........................................  37
     7.4   Commercialization Plans ...........................................................  37
     7.5   Commercialization Efforts .........................................................  37
     7.6   Additional Genentech Responsibilities .............................................  38
     7.7   Commercialization Costs ...........................................................  38
     7.8   Trademarks and Domain Names .......................................................  38
           7.8.1 Single Product Trademarks ...................................................  38
           7.8.2 Acknowledgment of Ownership Rights ..........................................  38
           7.8.3 Use of Trademark Designations ...............................................  39
           7.8.4 Infringement of Product Trademarks ..........................................  39
     7.9   Manufacture and Supply ............................................................  39
           7.9.1 Clinical Supply .............................................................  39
           7.9.2 Clinical Supply for Monoclonal Antibodies ...................................  39
           7.9.3 Commercial Supplies .........................................................  40

8.   Inventions and Infringement .............................................................  40
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                            <C>
     8.1   Inventorship and Ownership ........................................................  40
           8.1.1 Inventorship ................................................................  40
           8.1.2 Collaboration Invention Patents .............................................  41
     8.2   Restrictions on Jointly-Owned Inventions ..........................................  41
     8.3   Prosecution and Maintenance of Genentech Patent Rights, Dendreon Patent
           Rights and Vaccine Product Patent Rights ..........................................  41
     8.4   Prosecution and Maintenance of Collaboration Patent Rights ........................  41
           8.4.1 Coordination ................................................................  41
           8.4.2 Outside Counsel .............................................................  42
           8.4.3 SM Products .................................................................  42
           8.4.4 Abandonment .................................................................  42
     8.5   Patent Interferences ..............................................................  43
     8.6   Patent Enforcement ................................................................  43
           8.6.1 Notice ......................................................................  43
           8.6.2 Enforcement of Genentech Patent Rights, Dendreon Patent Rights and
                 Vaccine Product Patent Rights ...............................................  43
           8.6.3 Enforcement of Collaboration Invention Patent rights ........................  43
           8.6.4 Collaboration Invention Patent Rights related to Small Molecules or SM
                 Licensed Product ............................................................  44
           8.6.5 Initiating Party ............................................................  44
           8.6.6 Prosecution .................................................................  44
     8.7   Defense of Claim of Infringement ..................................................  45
           8.7.1 Third Party Claims ..........................................................  45
           8.7.2 Defense of Claims ...........................................................  45
     8.8   Third Party Patents and Royalties .................................................  45

9.   Representation, Warranties and Indemnities ..............................................  46

     9.1   Dendreon's Representations and Warranties .........................................  46
     9.2   Genentech's Representations and Warranties ........................................  46
     9.3   Disclaimers .......................................................................  47
     9.4   Except As Expressly Set Forth Herein Each Party Disclaims .........................  47
     9.5   Dendreon's Indemnities ............................................................  47
     9.6   Genentech's Indemnities ...........................................................  48
     9.7   Indemnity Conditions ..............................................................  48
     9.8   Insurance .........................................................................  49
     9.9   Uninsured Losses ..................................................................  49

10.  Term and Termination ....................................................................  49

     10.1  Term ..............................................................................  49
     10.2  Term of Licenses to Dendreon and Royalties to Genentech ...........................  50
     10.3  Early Termination for Product Failure .............................................  50
     10.4  Early Termination by Genentech without Cause ......................................  50
           10.4.1 Termination Following Phase II Clinical Trial ..............................  50
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                            <C>
           10.4.2 Termination Following Phase III Clinical Trial .............................  51
     10.5  Termination for Cause .............................................................  53
           10.5.1 Material Breach ............................................................  53
           10.5.2 Bankruptcy .................................................................  53
     10.6  Effect of Termination for Cause Under Section 10.5 ................................  53
           10.6.1 Termination by Genentech ...................................................  53
           10.6.2 Termination by Dendreon ....................................................  54
     10.7  No Limitation .....................................................................  55
     10.8  Survival ..........................................................................  55
     10.9  Bankruptcy ........................................................................  55
     10.10 Effect of Expiration or Termination on Intellectual Property ......................  55

11.  Confidentiality; Use of Names ...........................................................  56

     11.1  Confidential Information ..........................................................  56
     11.2  Exceptions ........................................................................  56
     11.3  Permitted Disclosure ..............................................................  56
     11.4  Term of Confidentiality ...........................................................  56
     11.5  Return of Information .............................................................  57
     11.6  Press Releases and Announcements ..................................................  57
     11.7  Scientific Publications and Presentations .........................................  57

12.  General Provisions ......................................................................  57

     12.1  Future Acts .......................................................................  57
     12.2  Independent Contractors ...........................................................  57
     12.3  Assignment ........................................................................  58
     12.4  Waiver ............................................................................  59
     12.5  Force Majeure .....................................................................  59
     12.6  Severability ......................................................................  59
     12.7  Headings ..........................................................................  60
     12.8  Legal Counsel .....................................................................  60
     12.9  Dispute Resolution and Governing Law ..............................................  60
           12.9.1 Disputes ...................................................................  60
           12.9.2 Arbitration ................................................................  60
           12.9.3 Determination of Patents and Other Intellectual Property ...................  61
           12.9.4 Governing Law ..............................................................  61
     12.10 Notices ...........................................................................  61
     12.11 Amendment .........................................................................  61
     12.12 Entire Agreement ..................................................................  61
     12.13 Counterparts ......................................................................  62
</TABLE>

EXHIBIT A     Trp-p8
EXHIBIT B     Financial Planning, Accounting and Reporting
EXHIBIT C     Itakura/Riggs Patents
EXHIBIT D     Equity Investment Agreement

<PAGE>

                                            ***Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                              Under 17 C.F.R.(S)(S)200.80(b)(4),
                                                            200.83 and 240.24b-2

               Collaborative Development and Marketing Agreement

         This Collaborative Development and Marketing Agreement (the
"Agreement") is entered into as of August 1, 2002 by and between Dendreon
Corporation, 3005 First Avenue, Seattle, Washington 98121, a Delaware
corporation ("Dendreon") and Genentech, Inc., 1 DNA Way, South San Francisco,
California 94080, a Delaware corporation ("Genentech").

                             Preliminary Statement

     A.     Dendreon is engaged in the development of immunotherapies for the
            treatment of cancers and owns certain rights to a molecule referred
            to as Trp-p8.
     B.     Genentech possesses resources and capabilities for the clinical
            development, marketing, and manufacturing of therapeutic biologic
            and drug products.
     C.     The Parties believe that properties of Trp-p8 make it a viable
            target candidate for therapeutic monoclonal antibodies, small
            molecules, and other therapeutic molecules and therapeutic vaccines.
     D.     Dendreon and Genentech desire to collaborate in the development,
            clinical testing and commercialization of such monoclonal
            antibodies, small molecules, and other molecules and therapeutic
            vaccines directed to Trp-p8 on the terms and conditions set forth in
            this Agreement.

         Now, therefore, the Parties agree as follows:

                                   Agreement

     1.  Definitions.  The following terms shall have the following meanings in
         this Agreement:

         1.1    "Additional Product" means a Licensed Product that is being
                developed by Dendreon and Genentech in the United States for a
                different Tumor Type than that Tumor Type for which such
                Licensed Product: (a) is already being developed by the Parties
                hereunder or (b) has already been developed by the Parties and
                has received Regulatory Approval for sale in the United States.

         1.2    "BLA" means a Biologics License Application made to obtain
                approval from the FDA for commercial sale of a Licensed Product.

         1.3    "cGMP" means the regulatory requirements as in effect from time
                to time for current good manufacturing practices as promulgated
                by the FDA under the U.S. Food, Drug and Cosmetic Act and the
                regulations promulgated thereunder, including without
                limitation, at 21 CFR Parts 210, 211, 600-610 and 820, as
                appropriate.

         1.4    "Clinical Plan" means that written plan, as may be amended from
                time to time, prepared by the JPT and approved by the JSC,
                describing the clinical research plan for the Clinical Program,
                as described in Section 2.9 and Article 4 below. The Clinical
                Plans, approved by the JSC as described herein below, are
                incorporated into this Agreement by reference.

                                       1

<PAGE>

         1.5    "Clinical Program" means the clinical program for Phase I, Phase
                II and Phase III Clinical Trials described in Clinical Plans.

         1.6    "Clinical Supply" means supplies of Monoclonal Product and/or
                SM Product, manufactured, packaged and labeled in compliance
                with cGMP, for use in Clinical Trials hereunder and in an amount
                adequate for such purposes. To the extent that Genentech is
                manufacturing Clinical Supply for use in the Dendreon Territory
                pursuant to Section 7.9.2 below, Clinical Supply will also
                include, under the terms and conditions hereunder, Monoclonal
                Product and/or SM Product for use in clinical trials conducted
                by Dendreon or by a Dendreon licensee in the Dendreon Territory.

         1.7    "Clinical Trial" means any clinical study of a Licensed Product
                in human subjects that is sponsored by, and conducted by or on
                behalf of, Dendreon or Genentech hereunder in the Territory. A
                Clinical Trial is commenced when the first patient receives the
                first dose of the Licensed Product as the investigational
                therapeutic drug under the protocol applicable to that clinical
                study.

         1.8    "Clinical Trial Costs" means the FTE Costs and Third Party Costs
                incurred in conducting a Clinical Trial, including, without
                limitation, the costs to prepare and file an IND (as applicable
                to each Party under the terms of this Agreement), and the fees
                paid to Third Party investigators, consultants, and contract
                research organizations; provided, however, that the term does
                not include the costs of cGMP manufacturing of Licensed Product,
                manufacturing scale-up, engineering or other costs to enable
                cGMP manufacturing of larger volumes of Licensed Product, or
                Regulatory Filings or Regulatory Approvals associated with the
                manufacture of Licensed Product incurred through the Completion
                of Phase II Clinical Trials for such Licensed Product.

         1.9    "Collaboration Invention" means inventions or discoveries
                (whether patentable or not) made after the Effective Date during
                the course of, in furtherance of, and as a direct result of the
                activities of the Parties hereunder and which directly relate to
                Trp-p8, or any Licensed Product (including for purposes of this
                definition, Small Molecules and SM Products), its manufacture or
                its use. A "Collaboration Invention" may be made solely by one
                or more employees or consultants of Dendreon (a "Dendreon
                Collaboration Invention"), solely by one or more employees or
                consultants of Genentech (a "Genentech Collaboration
                Invention"), or jointly by employees or consultants of Dendreon
                and Genentech ("Joint Collaboration Inventions"), as determined
                according to U.S. patent law. For purposes of this definition,
                "Licensed Product" shall not include Licensed Trp-p8 Vaccine
                Products. Collaboration Inventions shall include inventions or
                discoveries (whether patentable or not) that directly relate to
                Licensed Trp-p8 Vaccine Products only following execution of an
                agreement hereunder between Dendreon and Genentech applicable to
                Licensed Trp-p8 Vaccine Products and then only during the course
                of, in furtherance of, and as a direct result of activities
                under such agreement.

                                       2

<PAGE>

         1.10   "Collaboration Invention Patent Rights" means Patent Rights to
                the extent such Patent Rights claim any Collaboration Invention.

         1.11   "Commercial Supply" means the supplies of Licensed Product,
                manufactured, packaged and labeled in compliance with cGMP, in
                such form and strength as approved for sale by applicable
                Regulatory Agencies for commercial sale for use in the Field in
                the Territory pursuant to this Agreement. To the extent that
                Genentech is manufacturing Commercial Supply for use in the
                Dendreon Territory pursuant to Section 7.9.3 below, Commercial
                Supply will also include, under the terms and conditions
                hereunder, Monoclonal Product and SM Product approved for sale
                by applicable Regulatory Agencies in the Dendreon Territory.

         1.12   "Commercially Reasonable and Diligent Efforts" means, with
                respect to development and commercialization hereunder, a
                Party's use of best efforts and resources consistent with the
                exercise of prudent scientific and business judgment, as applied
                by such Party to other pharmaceutical products of similar
                potential, market size and competitive environment.

         1.13   "Commercialization Plan" has the meaning set forth in Section
                7.4.

         1.14   "Completion of Phase II (or Phase III) Clinical Trials" means
                the delivery of a final report to the JPT on the outcome of the
                Phase II or Phase III Clinical Trial, as the case may be.

         1.15   "Confidential Information" means all nonpublic and/or
                proprietary information of a Party disclosed to, observed by or
                otherwise obtained by the other Party in the course of this
                Agreement. It includes information relating to employees,
                methods, techniques and processes, technical and scientific
                data, biological material, know-how, specifications, patent
                applications algorithms, programs, designs, drawings, formulae,
                and engineering, manufacturing, marketing, financial and
                business plans and data. It may include information other than
                that which derives actual or potential economic value from not
                being generally known to or accessible by proper means and by
                other persons who can gain economic value from it.

         1.16   "Controlled" means, with respect to a particular item, material,
                or intellectual property right, that a Party owns or has a
                license to such item, material or intellectual property right
                and the ability to grant to the other Party access to and/or a
                license or sublicense under such item, material or intellectual
                property right as provided for herein without violating the
                terms of any agreement or other arrangement with any Third
                Party.

         1.17   "Covering" (including variations such as "Covered," "Covers" and
                the like) shall mean that the use, manufacture, sale, offer for
                sale or importation of Trp-p8 or of a Licensed Product(s) would
                infringe a Valid Claim in a patent, or a claim in a patent
                application which would be a Valid Claim if such claim issued in
                a patent, in the absence of rights under such patent or patent
                application, as determined on a country-by-country basis.

         1.18   "DENDREON/GNE Development Costs" shall have the meaning defined
                in Exhibit B.

                                       3

<PAGE>

         1.19   "Dendreon Know-how" means Know-how Controlled by Dendreon;
                provided, however, that Dendreon Know-how excludes any Know-how
                licensed to Dendreon by Genentech under this Agreement and
                excludes Dendreon Know-how related to Licensed Trp-p8 Vaccine
                Products unless Genentech obtains a license to Licensed Trp-p8
                Vaccine Products pursuant to this Agreement. In the event
                Genentech obtains such a license, the term Dendreon Know-how
                shall also include Know-how related to Licensed Trp-p8 Vaccine
                Products.

         1.20   "Dendreon Patent Rights" means Patent Rights Controlled by
                Dendreon as of the Effective Date and hereafter during the Term
                of this Agreement, but excluding (a) Vaccine Product Patent
                Rights, (b) Dendreon's interest in Collaboration Invention
                Patent Rights and (c) the rights granted under this Agreement to
                Dendreon by Genentech under Genentech Patent Rights.

         1.21   "Dendreon Territory" means the following countries: Japan,
                Australia, New Zealand, the Peoples Republic of China (including
                Hong Kong and Macao), Taiwan, South Korea, North Korea,
                Mongolia, Vietnam, Laos, Cambodia, Thailand, Myanmar,
                Philippines, Brunei, Singapore, Indonesia and Malaysia.

         1.22   "Developmental Research" means that portion of the Preclinical
                Program for Monoclonal Products and SM Products conducted
                hereunder to determine the potential efficacy, safety and
                toxicity of promising Small Molecules and Monoclonal Antibodies,
                through studies in animal models, and other research by the
                Party or Parties to evaluate the suitability of such Small
                Molecules and Monoclonal Antibodies for Clinical Trials.
                Developmental Research hereunder shall begin at the point in
                time when the lead Monoclonal Antibodies and/or Small Molecules
                are to be chosen for such evaluation and the JPT is formed
                hereunder.

         1.23   "Discovery Research" means that research portion of the
                Preclinical Program conducted hereunder to discover and evaluate
                Monoclonal Antibodies and Small Molecules in order to identify
                potential lead Monoclonal Antibodies and Small Molecules that
                exhibit sufficient Trp-p8 binding and other characteristics to
                warrant further evaluation in Developmental Research.

         1.24   "Effective Date" means the date that this Agreement becomes
                effective which shall be the date first written above.

         1.25   "FDA" means the United States Food and Drug Administration.

         1.26   "Field" means any human or animal use.

         1.27   "FTE" means a full-time equivalent employee of a Party who
                performs work in the Preclinical or Clinical Program for
                Licensed Products hereunder.

                                       4

<PAGE>

         1.28   "FTE Costs" means the cost of an FTE working for one year
                (including normal holidays and vacation), which shall be based
                upon the cost systems of each Party, as confirmed by the
                financial representatives of each of the Parties.

         1.29   "Genentech Know-how" means Know-how Controlled by Genentech,
                excluding Know-how related to the manufacture of Licensed
                Product and any other Manufacturing Know-how, and excluding
                Know-how licensed to Genentech by Dendreon under this Agreement.

         1.30   "Genentech Patent Rights" means all Patent Rights Controlled by
                Genentech as of the Effective Date and hereafter during the Term
                of this Agreement, but excluding (a) Genentech's interest in
                Collaboration Invention Patent Rights, (b) the Itakura/Riggs
                Patents listed on Exhibit C attached hereto and incorporated
                herein, and (c) the rights granted under this Agreement to
                Genentech by Dendreon under Dendreon Patent Rights.

         1.31   "IND" means an effective Notice of Claimed Investigational New
                Drug Exemption, as defined in Title 21 of the U.S. Code of
                Federal Regulations.

         1.32   "Joint Project Team" or "JPT" means the committee established
                pursuant to Article 4 below.

         1.33   "Joint Steering Committee" or "JSC" means the committee
                established pursuant to Article 3 below.

         1.34   "Joint Collaboration Invention" shall have the meaning set forth
                in Section 1.8 above.

         1.35   "Joint Patent Rights" means Patent Rights to the extent such
                Patent Rights claim any Joint Collaboration Invention as well as
                Patent Rights established pursuant to Section 8.1.2 below.

         1.36   "Know-how" means all proprietary information, trade secrets,
                techniques and data of a Party, including Confidential
                Information, which directly relates to Trp-p8 or Licensed
                Products, which is necessary for the activities under this
                Agreement and that is Controlled by such Party as of the
                Effective Date or hereafter during the Term of this Agreement,
                including, but not limited to, formulae, materials, practices,
                methods, knowledge, know-how, processes, experience, test data
                (including pharmacological, toxicological and clinical
                information and test data), analytical and quality control data,
                batch records, marketing, pricing, distribution, cost and sales
                data or descriptions. "Know-how" may be made prior to the
                Effective Date or during and in furtherance of the collaboration
                hereunder solely by employees or consultants of Dendreon, solely
                by employees or consultants of Genentech, jointly by employees
                or consultants of Dendreon and Genentech, or jointly by Dendreon
                or Genentech employees or consultants and a Third Party.

         1.37   "Licensed Product" means any formulation containing a Monoclonal
                Antibody, Small Molecule, or any other molecule that selectively
                and/or specifically binds to Trp-p8 or that is a Licensed Trp-p8
                Vaccine Product. "Licensed Product" shall exclude Small
                Molecules and SM Products unless Genentech exercises its option
                in accordance with Section 2.6.2

                                       5

<PAGE>

                 below; in the event Genentech does so exercise such option, the
                 term "Licensed Product" shall also include Small Molecules and
                 SM Products. "Licensed Product" shall exclude Licensed Trp-p8
                 Vaccine Products unless Genentech and Dendreon enter into an
                 agreement, by way of amendment to this Agreement, for the
                 development and/or commercialization of Licensed Trp-p8 Vaccine
                 Products hereunder in accordance with Section 2.7 below; in the
                 event Genentech and Dendreon enter into such an agreement the
                 term "Licensed Product" shall also include Licensed Trp-p8
                 Vaccine Products, subject to the terms of such amendment and to
                 the extent set forth therein.

         1.38    "Licensed Trp-p8 Vaccine Product" means a formulation that is
                 designed to specifically induce a T-cell response primarily to
                 Trp-p8.

         1.39    "Manufacturing Know-how" means any Know-how concerning the
                 engineering, manufacturing and quality/or assurance testing of
                 a Licensed Product.

         1.40    "Monoclonal Antibody" means a monoclonal antibody that
                 specifically and selectively binds Trp-p8, including, without
                 limitation, such monoclonal antibodies that are humanized
                 antibodies.

         1.41    "Monoclonal Product" means a Licensed Product that is a
                 formulation containing a Monoclonal Antibody.

         1.42    "NDA" means a New Drug Application made to obtain approval from
                 the FDA for commercial sale of a Licensed Product or any
                 comparable filing with any relevant Regulatory Agency in any
                 country in the Territory other than the United States

         1.43    "Net Sales" in United States shall have the meaning defined in
                 Exhibit B. "Net Sales" for countries in the Territory outside
                 the United States and in the Dendreon Territory shall mean
                 Gross Sales of a Licensed Product less applicable Sales Returns
                 and Allowances where:

                 (a)   "Gross Sales" means, for purposes of the calculation of
                       royalties by the Party paying royalties, the gross amount
                       invoiced for sales of a Licensed Product by such Party or
                       its sublicensee to Third Parties in the Territory outside
                       the United States or in the Dendreon Territory as the
                       case may be;
                 (b)   "Sales Returns and Allowances" means, for purposes of the
                       calculation of royalties by the Party paying royalties,
                       the sum of (i) and (ii), where: (i) is a provision,
                       determined by such Party or its sublicensee in accordance
                       with commonly accepted accounting principles in the
                       country in which the sale occurred for sales of Licensed
                       Products for (1) trade, cash and quantity discounts or
                       rebates on Licensed Products (other than price discounts
                       granted at the time of invoicing and which are included
                       in the determination of Gross Sales), (2) credits or
                       allowances given or made for rejection or return of, and
                       for uncollectable amounts on, previously sold Licensed
                       Products or for retroactive price reductions (including
                       Medicare and other government rebates and chargebacks),
                       (3) taxes (excluding local, state or national taxes on
                       the income of such Party or its sublicensee), duties or
                       other governmental charges levied on or measured by the
                       billing amount for Licensed Products, as

                                        6

<PAGE>

                         adjusted for rebates and refunds, (4) charges for
                         freight and insurance directly related to the
                         distribution of Licensed Products, to the extent
                         included in Gross Sales, (5) credits for allowances
                         given or made for wastage replacement, and (6) other
                         special sales programs agreed to by the Parties for
                         Licensed Products; and (ii) is a periodic adjustment of
                         the provision determined in (i) to reflect amounts
                         actually incurred by such Party for items (1), (2),
                         (3), (4), (5), and (6) in clause (i).

         1.44    "New Molecule" means a Monoclonal Antibody or Small Molecule
                 for which the JSC approves development hereunder for a Licensed
                 Product and that (i) with respect to a Monoclonal Antibody has
                 a different amino acid sequence from the Monoclonal Antibody
                 contained in the formulation of the Monoclonal Product already
                 being developed by the Parties in the collaboration hereunder
                 or that has received Regulatory Approval in the United States
                 and (ii) with respect to a Small Molecule is of a different
                 chemical composition than the Small Molecule contained in the
                 formulation of the SM Product already being developed by the
                 Parties in the collaboration hereunder or that has received
                 Regulatory Approval in the United States.

         1.45    "Operating Profits and Losses" shall have the meaning defined
                 in Exhibit B.

         1.46    "Party" or "Parties" mean Dendreon or Genentech or both of
                 them, respectively.

         1.47    "Patent Rights" means all U.S. and foreign patents and patent
                 applications and any patents issuing therefrom, and any
                 reissues, extensions, registrations, continuations, divisions,
                 continuations-in-part, reexaminations, substitutions or
                 renewals thereof, and supplementary protection certificates
                 based thereon to the extent the above contain one or more
                 claims Covering Trp-p8 or any Licensed Product.

         1.48    "Permitted Assignee" means any entity to which assignment is
                 permitted in accordance with Section 12.3.

         1.49    "Phase I Clinical Trial" means, for any Licensed Product, a
                 study in the Territory that constitutes a clinical evaluation
                 of the safety of the Licensed Product in human subjects to
                 provide information about the medical risks and
                 pharmacokinetics associated with the use of such Licensed
                 Product, and a preliminary indication of its potential
                 efficacy.

         1.50    "Phase II Clinical Trial" means, for any Licensed Product, a
                 study in the Territory conducted under this Agreement that
                 constitutes a controlled clinical evaluation of the
                 effectiveness of the Licensed Product in human patients with
                 the disease under study to provide information about
                 dose-response, pharmacokinetics/pharmacodynamics, dose regimen,
                 safety and efficacy of the Licensed Product, and which is
                 conducted after a Phase I Clinical Trial of such Licensed
                 Product.

         1.51    "Phase III Clinical Trial" means, for a Licensed Product, a
                 study in the Territory conducted under this Agreement to
                 confirm the safety and efficacy of such Licensed Product in the
                 treatment of patients with the disease under study. A Phase III
                 Clinical Trial is undertaken with the intent that, should
                 sufficient positive study data result, a BLA or NDA will be
                 submitted to a Regulatory Agency.

                                        7

<PAGE>

         1.52    "Pivotal Trial" is a Phase II Clinical Trial that produces
                 positive study data that the FDA determines in a pre-BLA
                 meeting is sufficient to warrant submission of a BLA or NDA
                 without data from a Phase III Clinical Trial.

         1.53    "Preclinical Plan" means that written plan for the Preclinical
                 Program, as may be amended from time to time, prepared by one
                 or both of the Parties.

         1.54    "Preclinical Program" means that program of Discovery Research
                 and Developmental Research for Small Molecules and Monoclonal
                 Antibodies conducted hereunder prior to filing an IND for such
                 Small Molecules and Monoclonal Antibodies in order to conduct
                 the first Clinical Trial for such Licensed Product. The
                 Preclinical Program is generally described in Sections 2.3 and
                 2.5 and more specifically described in the Preclinical Plan for
                 such Licensed Product.

         1.55    "Preclinical Program Costs" means all FTE Costs and Third Party
                 Costs incurred for a Preclinical Program.

         1.56    "Prevalent Cancer" means primary neoplastic disease of one of
                 the following human organs, at any stage of such disease:
                 prostate, breast, lung, ovarian, colon, and skin (i.e.
                 melanoma).

         1.57    "Product Development Program" means the efforts of the Parties
                 hereunder to generate commercially viable Licensed Products, as
                 described in Article 2.

         1.58    "Regulatory Agency" means any federal, state or local agency,
                 department, bureau or other governmental entity, within a
                 regulatory jurisdiction in the Territory, with the authority to
                 grant any approvals, licenses, registrations or authorizations
                 necessary for the clinical development, manufacture or sale of
                 a Licensed Product under this Agreement.

         1.59    "Regulatory Approval" means any approval (including price and
                 reimbursement approvals), licenses, registrations or
                 authorizations by any Regulatory Agency necessary for the
                 clinical development, manufacture, use, storage, import,
                 transport, marketing, distribution or sale of a Licensed
                 Product in a regulatory jurisdiction.

         1.60    "Regulatory Filings" means a filing with a Regulatory Agency
                 that relates to a Regulatory Approval.

         1.61    "Research Grade Material" means Licensed Product that is not
                 manufactured in accordance with cGMP and is suitable for use
                 only in vitro or in animals.

         1.62    "SM Product" means a Licensed Product that is a formulation
                 containing a Small Molecule.

                                        8

<PAGE>

         1.63    "Small Molecule" means a molecule that selectively binds to
                 Trp-p8 and that has a molecular weight under approximately 1000
                 daltons.

         1.64    "Term" shall have the meaning specified in Section 10.1.

         1.65    "Territory" means worldwide except the Dendreon Territory.

         1.66    "Third Party" means any person other than a Party to this
                 Agreement.

         1.67    "Third Party Costs" means expenses, other than FTE Costs,
                 incurred by a Party as payments to Third Parties in connection
                 with conducting the applicable portion of a Preclinical or
                 Clinical Program.

         1.68    "Trp-p8" means the gene sequence described in Exhibit A
                 attached hereto and incorporated herein, any portions thereof,
                 and any allelic variant thereof, and any proteins encoded by
                 this sequence or such variant.

         1.69    "Tumor Type" means a primary neoplastic disease of a singular
                 histology, including any metastasis thereof, as accepted in
                 standard medical practice.

         1.70    "Vaccine Product Patent Rights" means Patent Rights Controlled
                 by Dendreon that relate to a Licensed Trp-p8 Vaccine Product,
                 excluding Dendreon Patent Rights and excluding Dendreon's
                 interest in Collaboration Invention Patent Rights.

         1.71    "Valid Claim" means an unexpired claim in an issued unexpired
                 patent within the Patent Rights that has not been revoked,
                 abandoned, disclaimed or withdrawn, or held unenforceable,
                 unpatentable or invalid by a court of competent jurisdiction in
                 a final judgment that has not been appealed within the time
                 allowed by law or from which there is no further appeal.

2.       Scope of the Product Development Program

         2.1     Product Development Program.

                 (a)   Dendreon and Genentech hereby establish, pursuant and
                       subject to the terms of this Agreement, a Product
                       Development Program to develop Licensed Products, with
                       the primary goal of obtaining Regulatory Approval in the
                       United States of Licensed Products in Prevalent Cancers
                       and commercially significant other indications. The
                       Parties efforts in this Product Development Program will
                       initially be the development of Monoclonal Products and
                       Small Molecule Products. Each Party shall use
                       Commercially Reasonable and Diligent Efforts to perform
                       its respective tasks and obligations in conducting all
                       development work ascribed to it in the Preclinical Plans
                       and Clinical Plans for Monoclonal Products and SM
                       Products hereunder.

                                        9

<PAGE>

                 (b)   The Product Development Program shall consist of two
                       principal phases: the Preclinical Program and the
                       Clinical Program. The Preclinical and Clinical Programs
                       are generally described in this Article 2 below and shall
                       be more fully detailed in written Preclinical Plans and
                       Clinical Plans. The Product Development Program shall be
                       approved and guided by the Joint Steering Committee, as
                       described in Article 3. The costs of the Product
                       Development Program shall be borne by the Parties as
                       described in this Article 2.

         2.2     Preclinical Program. The Preclinical Program for Monoclonal
                 Products and SM Products will consist of Discovery Research
                 followed by Developmental Research, and will commence on a
                 start date that is not later than sixty (60) days following the
                 Effective Date. By such start date, Genentech will develop an
                 initial written Preclinical Plan for a Monoclonal Product to
                 guide its efforts in such Preclinical Program that shall be
                 incorporated by reference into this Agreement. By such start
                 date, Dendreon will develop an initial written Preclinical Plan
                 for an SM Product to guide its efforts in such Preclinical
                 Program that shall be incorporated by reference into this
                 Agreement. The Preclinical Plans for Monoclonal Products and SM
                 Products shall include a description of any proposed material
                 Third Party contractual relationships for goods or services to
                 carry out the plan. The Preclinical Plan for SM Products shall
                 be submitted to the JSC for review and comment; provided,
                 however, that following Genentech's exercise of its option as
                 provided in Section 2.6, any revisions to the Preclinical Plan
                 for SM Products, including budgets, shall be submitted to the
                 JSC for review, comment, and JSC approval of milestones,
                 timelines and deliverables. The Preclinical Plan for Monoclonal
                 Products shall be submitted to the JSC for review, comment, and
                 JSC approval of milestones, timelines, and deliverables. The
                 comments of the other Party and of the JSC shall be taken into
                 consideration by the Party authoring the Plan. Neither Party
                 shall materially modify or amend its Preclinical Plan without
                 first submitting the Plan to the JSC for review and approval or
                 comment as provided above. The Parties intend that their
                 respective research employees shall regularly discuss and share
                 information about ongoing activities under their respective
                 Preclinical Plans.

         2.3     Monoclonal Product.

                 2.3.1 Genentech Responsibilities. Genentech will be primarily
                 responsible for the Preclinical Program for Monoclonal Products
                 and the identification of potential lead Monoclonal Antibodies.
                 Genentech's Preclinical Plan for Monoclonal Product shall
                 address, without limitation, the following elements:

                 (a)    An initial phase research program that will (i) generate
                        [...***...] for [...***...], (ii) develop [...***...] to
                        [...***...] and [...***...], (iii) develop [...***...],
                        (iv) evaluate the [...***...] and [...***...] of
                        [...***...], (v) generate [...***...], (vi) identify an
                        [...***...] to the [...***...] that [...***...], (vii)
                        evaluate [...***...] in [...***...], and (viii) develop
                        a [...***...].
                 (b)    Estimated milestones, timelines, and deliverables for
                        each key component of the program.
                 (c)    Assignment of specific tasks to Dendreon, if applicable,
                        as agreed by the Parties.
                 (d)    An estimate of each Party's FTE resources that will be
                        devoted to the Preclinical Program each calendar year.

                                            *** Confidential Treatment Requested

                                       10

<PAGE>

                  Genentech shall provide all necessary Research Grade Material,
                  at its sole expense, for the Preclinical Program for
                  Monoclonal Product as further described in Section 7.9.2
                  below. Dendreon will promptly transfer to Genentech all of its
                  available reagents to develop and evaluate Monoclonal
                  Antibodies to Trp-p8. Dendreon may conduct activities for such
                  Preclinical Program at Genentech's request as agreed by the
                  Parties through the JSC (or through the JPT during
                  Developmental Research). Genentech and Dendreon shall each
                  exercise Commercially Reasonable and Diligent Efforts to
                  complete such tasks and activities in accordance with accepted
                  professional standards and the Preclinical Plan for Monoclonal
                  Product, and shall provide information and reports on the
                  results of their efforts, as requested by the JSC or JPT for
                  discussion at their respective meetings. Each Party shall
                  maintain scientific staff, laboratories, and other facilities
                  necessary to carry out its tasks under such Preclinical Plan.

                  2.3.2   Dendreon Independent Activities. With the approval of
                  the JSC, Dendreon may also pursue its own Preclinical Program
                  activities hereunder for the discovery of a lead Monoclonal
                  Antibody candidate(s), without Genentech's request for such
                  activities, at its sole cost. In that event, Dendreon shall
                  provide the JSC with an annual report of the Preclinical
                  Program Costs to date and an estimated budget for such costs
                  anticipated to be incurred in the succeeding year. In
                  addition, Dendreon will provide information on the status of
                  its efforts as reasonably requested by the JSC or JPT for
                  discussion at their respective meetings.

         2.4      Decision Point - Monoclonal Product. Within ninety (90) days
                  after the conclusion of the Preclinical Program for Monoclonal
                  Products, as defined in the applicable Preclinical Plan and
                  confirmed by the JPT and approved by the JSC, the JPT will
                  identify a lead Monoclonal Antibody(ies) and determine (as
                  approved by the JSC) whether, given the results of such
                  Preclinical Program and the objective of the Product
                  Development Program, to proceed to Clinical Trials for such
                  lead Monoclonal Antibody(ies). If the JSC approves the
                  decision to proceed to such Clinical Trials, Dendreon will
                  prepare and file an IND pursuant to Section 2.18.1 below, and
                  the Parties will proceed to the Clinical Program for one or
                  more Monoclonal Products. A decision not to proceed to such
                  Clinical Trials shall not affect the obligation of Genentech
                  to reimburse Dendreon for Preclinical Program Costs incurred
                  in accordance with Section 2.8.1 below.

         2.5      SM Product.

                  2.5.1   Dendreon Responsibilities. Dendreon shall be primarily
                  responsible for the Preclinical Program for SM Products and
                  the identification of a lead Small Molecule. The Preclinical
                  Plan for SM Products, which shall be prepared by Dendreon with
                  input by Genentech, shall address, without limitation, the
                  following elements:

                  (a)     A research program that will include (i) assay
                          development, (ii) lead Small Molecule identification;
                          (iii) optimization of identified leads; (iv) efficacy
                          studies; (v) toxicology studies; (vi)
                          pharmacokinetics and pharmacodynamics studies; and
                          (vii) manufacturing.

                                       11

<PAGE>

         (b)   Estimated milestones, timelines, and deliverables for each key
               component of the program.
         (c)   Assignment of specific tasks to Genentech, if applicable, as
               agreed by the Parties.
         (d)   An estimate of each Party's FTE resources that will be devoted to
               the Preclinical Program each calendar year.

         Dendreon shall provide all necessary Research Grade Material, at its
         sole expense, for the Preclinical Program for SM Product as further
         described in Section 7.9.1below. Genentech may conduct activities for
         such Preclinical Program at Dendreon's request as agreed by the Parties
         through the JSC (or through the JPT during Developmental Research).
         Dendreon and Genentech shall each use Commercially Reasonable and
         Diligent Efforts to complete its respective tasks in accordance with
         accepted professional standards and the Preclinical Plan for SM Product
         and provide information and reports about the results of their efforts
         as requested by the JSC or JPT for discussion at their respective
         meetings. Each Party shall maintain scientific staff, laboratories, and
         other facilities necessary to carry out its tasks under such
         Preclinical Plan.

         2.5.2 Genentech Independent Activities. Genentech may pursue its own
         Preclinical Program activities for the discovery of a lead Small
         Molecule candidate(s) without Dendreon's request for such activities,
         at its sole cost. In that event, Genentech shall obtain the approval of
         the JSC for such activities and provide the JSC with an annual report
         of all Preclinical Program costs to date of the report and an estimated
         budget for such costs anticipated to be incurred in the succeeding
         year. In addition, Genentech will provide information on the status of
         its efforts as reasonably requested by the JSC or JPT for discussion at
         their respective meetings.

         2.5.3 Decision Point - SM Products. If Genentech has exercised its
         option for SM Products in accordance with Section 2.6, then within
         ninety (90) days after the conclusion of the Preclinical Program for SM
         Products as defined in the applicable Preclinical Plan and confirmed by
         the JPT and approved by the JSC, the JPT will identify a lead Small
         Molecule(s) and determine (as approved by the JSC) whether, given the
         results of the Preclinical Program and the objective of the Product
         Development Program, to proceed to Clinical Trials for such lead Small
         Molecule(s). If, as of the completion of the Preclinical Plan for SM
         Products, Genentech has not yet exercised such option, Genentech will
         first be given the opportunity to exercise its option in Section 2.6.2.
         Following such exercise, the JPT and JSC will make the determinations
         described above. If Genentech does not exercise such option, Dendreon
         shall be free to proceed independently as provided in Section 2.6.1.

         2.5.4 Small Molecule Agreements. The Parties anticipate that Dendreon
         will use Third Parties to conduct Small Molecule screening and other
         Small Molecule Discovery Research or Developmental Research activities
         and that it may be necessary or desirable to compensate such Third
         Parties by way of royalties. Before Genentech elects to exercise the
         option provided in Section 2.6, Dendreon will obtain the advance
         consent of the Genentech members of the JSC to any proposed agreement
         that entails the payment of royalties to a Third Party based upon sales
         of SM Product or imposes any other

                                       12

<PAGE>

                  commitment or obligation on the collaboration hereunder or
                  that impairs the express rights of the Parties under this
                  Agreement. Following Genentech's exercise of such option, the
                  advance consent of the JSC shall also be required for any such
                  agreement. The foregoing consents shall not be unreasonably
                  delayed or denied. The advance consent of Genentech, which
                  shall not be unreasonably delayed and may be denied in its
                  sole discretion, shall be required at any time for any
                  agreement involving a license by Dendreon of Patent Rights to
                  such Third Party related to SM Product; provided, however,
                  that if Genentech does not exercise such option as provided in
                  Section 2.6, then Dendreon shall be free to proceed with such
                  Third Party licenses and royalty agreements without notice to
                  or the consent of the JSC or Genentech.

         2.6      Genentech Option for SM Products.

                  2.6.1 Exclusive Option. Genentech shall have an exclusive
                  option to participate in the clinical development and
                  commercialization of SM Products. Genentech may exercise this
                  option as provided in Sections 2.6.2 and 2.6.3 below. Unless
                  and until Genentech exercises its option as provided therein
                  and pays the option exercise fee set forth in Section 6.4.2
                  below, Genentech shall have no license, title or property
                  interest in Dendreon Patent Rights or Dendreon's interests in
                  Collaboration Inventions with respect to any SM Product except
                  as set forth in Section 5.1(b) and 8.1.2 below. If Genentech
                  does not exercise its option pursuant to Section 2.6.2 or
                  2.6.3, Dendreon shall be free to proceed, alone or with a
                  Third Party, to develop and commercialize Small Molecules and
                  SM Products, and Genentech shall have no obligation to make
                  the milestone payments for SM Product set forth in Section 6.4
                  below. In addition, (i) the license to Genentech in Section
                  5.1(b) and (c) shall be deemed terminated, and (ii) Genentech
                  shall take the actions required by Section 8.4.3.

                  2.6.2 Exercise of Option. Upon completion of the Small
                  Molecule Preclinical Plan, as defined in such Preclinical Plan
                  and as confirmed by the JPT and approved by the JSC, for lead
                  Small Molecule(s) for SM Product(s), Dendreon will provide
                  Genentech with: (1) data on such lead Small Molecule(s),
                  including oral bioavailability data in two species, potency,
                  selectivity, absorption, transport, specificity, efficacy
                  (including any in vivo efficacy), metabolism, toxicology,
                  manufacturing (if any), and pharmacokinetic data including
                  oral bioavailability that relate to proceeding with Clinical
                  Trials of such lead Small Molecules for development as a SM
                  Product, and (2) reagents to validate such Small Molecule
                  leads in Genentech models. Genentech may request additional
                  information, including reasonable data on other Small
                  Molecules and derivatives thereof generated by Dendreon during
                  its research efforts to identify a lead Small Molecule, which
                  Dendreon will make reasonable efforts to supply. Genentech
                  shall have sixty (60) days from receipt of all of the Small
                  Molecule information required under the first sentence of this
                  subsection to exercise its option to collaborate with Dendreon
                  in a Clinical Program for this and all other SM Products and
                  any resulting commercialization hereunder of such products.
                  Genentech shall exercise its option by delivery of written
                  notice to Dendreon within such sixty (60) day period and
                  payment of the required option exercise fee pursuant to
                  Section 6.4.2. A decision by Genentech not to exercise this
                  option shall not alter Dendreon's obligation to reimburse
                  Genentech for Preclinical Program costs pursuant to Section
                  2.8.2 .

                                       13

<PAGE>

                  2.6.3  Early Exercise. In addition to the option exercise
                  provisions in Section 2.6.2 above, Genentech shall also have
                  the right to exercise its option to SM Products at any time
                  prior to such Preclinical Plan completion by giving Dendreon
                  written notice of such exercise and paying the required option
                  exercise fee pursuant to Section 6.4.2.

           2.7    Licensed Trp-p8 Vaccine Products.

                  2.7.1  Vaccine Products. The Parties acknowledge that prior to
                  the Effective Date, Dendreon has independently conducted, and
                  may continue to conduct, certain research and development work
                  for Licensed Trp-p8 Vaccine Products, at its sole cost.
                  Dendreon will conduct such activities independently and
                  without the oversight or input of the JSC or JPT.

                  2.7.2  Genentech First Right of Negotiation.

                  (a)    Genentech shall have the exclusive first right to
                         negotiate an agreement with Dendreon to participate in
                         the development and/or commercialization of Licensed
                         Trp-p8 Vaccine Products in the Territory as provided in
                         this Section. When Dendreon first decides to enter into
                         a development and/or commercialization agreement for
                         Licensed Trp-p8 Vaccine Products, Genentech shall have
                         the exclusive first right to negotiate an agreement
                         with Dendreon to participate in the development and
                         commercialization of Licensed Trp-p8 Vaccine Products,
                         as follows. Dendreon shall provide Genentech with: (1)
                         written notice of its intent to seek a development
                         and/or commercialization agreement for Licensed Trp-p8
                         Vaccine Products with a Third Party and (2) summary
                         data and information regarding toxicity, generation of
                         immune response against the vaccine target, clinical
                         efficacy data, and any manufacturing issues for the
                         Licensed Trp-p8 Vaccine Product. Such data and
                         information shall be deemed to be Confidential
                         Information and subject to the provisions of Section
                         11.1 of this Agreement. Dendreon will use reasonable
                         efforts to provide additional information reasonably
                         requested by Genentech. Genentech shall have sixty (60)
                         days from the receipt of written notice from Dendreon
                         and the data and information described in (2) above
                         within which to negotiate a mutually agreeable, fully
                         executed term sheet for the purpose of amending this
                         Agreement to include Licensed Trp-p8 Vaccine Products.
                         If the parties do not execute such a term sheet within
                         the sixty (60) day period then, by the end of such
                         period, Genentech may provide Dendreon with a term
                         sheet expressly designated as its last, best and final
                         offer ("Last Term Sheet Offer"). Upon expiration of the
                         sixty (60) day period without agreement upon the term
                         sheet by the Parties, Dendreon shall be free to
                         negotiate with any Third Party for the development
                         and/or commercialization of Licensed Trp-p8 Vaccine
                         Products; provided that an agreement reached with a
                         Third Party with respect to Licensed Trp-p8 Vaccine
                         Products may not be on terms that, considered as a
                         whole, are materially less favorable to Dendreon than
                         the Last Term Sheet Offer.

                  (b)    If the Parties execute such term sheet with respect to
                         Licensed Trp-p8 Vaccine Products, Genentech will pay
                         Dendreon a reservation fee of [...***...] within five
                         (5) working days of such execution and the Parties
                         shall thereafter have one

                                             ***Confidential Treatment Requested

                                       14

<PAGE>

                         hundred eighty (180) days to negotiate and execute a
                         final and binding amendment to this Agreement based
                         upon such term sheet. If the Parties execute such an
                         amendment within that period, the reservation fee shall
                         be applied to the earliest license fees payable with
                         respect to Licensed Trp-p8 Vaccine Products under such
                         amendment. If the Parties are unable to reach an
                         agreement within such 180 day period, Dendreon shall
                         refund the reservation fee to Genentech (without
                         interest) and shall thereafter be free to negotiate
                         with any Third Party for the development and/or
                         commercialization of Licensed Trp-p8 Vaccine Products;
                         provided that an agreement with a Third Party with
                         respect to Licensed Trp-p8 Vaccine Products may not be
                         on terms that, considered as a whole, are materially
                         less favorable to Dendreon than the terms last offered
                         by Genentech's to Dendreon during such 180 day
                         negotiation period.

                  (c)    Notwithstanding the use of the term "Licensed Products"
                         in this Agreement, the Parties expect that the
                         amendment contemplated above may make substantially
                         different provisions for license fees, milestones,
                         sharing of profits and losses, royalties, and the
                         Parties' respective roles and responsibilities with
                         respect to development and/or commercialization of such
                         Licensed Trp-p8 Vaccine Products. The Parties further
                         expect that the terms of this Agreement with respect to
                         Patent Rights and Know-How and the terms of Articles
                         3,4, 5, 8, 9, 10, 11, and 12 will remain substantially
                         unchanged by such amendment. In all cases, the terms of
                         the amendment as agreed by the Parties shall control
                         with respect to Licensed Trp-p8 Vaccine Products.

          2.8  Preclinical Program Costs.

               2.8.1     Genentech Costs. Genentech shall bear all of the
               Preclinical Program Costs for Monoclonal Antibodies and
               Monoclonal Products. If Genentech requests that Dendreon complete
               tasks under the Monoclonal Product Preclinical Plan and Dendreon
               agrees to complete such tasks, then Genentech shall promptly
               reimburse Dendreon for its Preclinical Program Costs in
               completing such Preclinical Plan tasks that do not exceed the
               amount specified in the budget agreed upon by the Parties for
               those activities by more than [...***...]. Notwithstanding the
               above, Dendreon will bear the costs of any Preclinical Program
               activities for Monoclonal Antibodies that it conducts not
               specifically requested by Genentech. Genentech also shall bear
               all Preclinical Program costs, if any, for Additional Products
               and New Molecules, except to the extent Dendreon has elected to
               share DENDREON/GNE Development Costs pursuant to Section 2.14.

               2.8.2     Dendreon Costs. Dendreon shall bear all of the
               Preclinical Program Costs for Small Molecules and SM Products. If
               Dendreon requests that Genentech complete tasks under the SM
               Product Preclinical Plan and Genentech agrees to complete such
               tasks, then Dendreon shall promptly reimburse Genentech for its
               Preclinical Program Costs in completing such Preclinical Plan
               tasks that do not exceed the amount specified in the budget
               agreed upon by the Parties for those activities by more than
               [...***...]. Notwithstanding the above, Genentech will bear the
               costs of any Preclinical Program activities for Small Molecules
               that it conducts not specifically requested by Dendreon.

                                             ***Confidential Treatment Requested

                                       15

<PAGE>

          2.8.3 Payment for Independent Activities.

          (a)  Notwithstanding Section 2.8.1 above, in the event that Dendreon,
               instead of Genentech, discovers or otherwise brings a Monoclonal
               Antibody to the JSC (or JPT if the JPT is established at that
               time) which is then approved by the JSC to be the lead Monoclonal
               Antibody for the first Monoclonal Product and for evaluation in
               Clinical Trials, then Genentech shall reimburse Dendreon, within
               sixty (60) days after the JSC's approval to proceed to Clinical
               Trials for such Monoclonal Antibody, for all of Dendreon's
               Preclinical Program Costs incurred directly related to such lead
               Monoclonal Antibody.

          (b)  Notwithstanding Section 2.8.2 above, in the event that Genentech,
               instead of Dendreon, discovers or otherwise brings a Small
               Molecule to the JSC (or JPT if the JPT is established at that
               time) which is then approved by the JSC to be the lead Small
               Molecule for the first SM Product and for evaluation in Clinical
               Trials, then Dendreon shall reimburse Genentech, within sixty
               (60) days after the JSC's approval to proceed to Clinical Trials
               for such Small Molecule, for all of Genentech's Preclinical
               Program Costs incurred directly related to such lead SM Molecule.

     2.9  Clinical Program. The JPT will develop, for the JSC's approval, a
          written Clinical Plan for Phase I and II Clinical Trials for
          Monoclonal Product within ninety (90) days after approval by the JSC
          to conduct a Clinical Program with respect to a lead Monoclonal
          Antibody(ies). If Genentech has exercised its option, the JPT will
          develop for the JSC's approval a written Clinical Plan for Phase I and
          II Clinical Trials for SM Product within ninety (90) days after the
          JSC's approval to conduct a Clinical Program for a lead Small
          Molecule. Upon approval by the JSC of such Clinical Plans for
          Monoclonal Product and SM Product, as evidenced by written, approved
          JSC minutes, such Clinical Plans shall be incorporated herein by
          reference. The Clinical Plans, which may be amended by the JPT, with
          approval of the JSC, from time to time, shall include, without
          limitation, the following components:

          (a)  The Monoclonal Product and Small Molecule Product, and
               indications, for which Clinical Trials will be conducted. The
               Parties anticipate that the first three indications selected
               shall be for Prevalent Cancers.
          (b)  Summaries of the protocols anticipated for each Clinical Trial
               along with the timeframe for patient enrollment, forecasts of the
               Clinical Supply required for such Clinical Trials, and the
               anticipated retention of consultants and contract research
               organizations to support the Clinical Trials.
          (c)  Milestones, timeframes and deliverables for each key component of
               the Clinical Program for each Monoclonal Product and Small
               Molecule Product.
          (d)  A budget for Phase I and Phase II Clinical Trials.
          (e)  Assignment of specific tasks to each Party.

          All Clinical Plans shall be drafted so as to conform to the regulatory
          requirements of applicable Regulatory Agencies.

                                       16

<PAGE>

     2.10 Phase I and Phase II Responsibilities.

          (a)  Dendreon shall be solely responsible for sponsoring Phase I and
               Phase II Clinical Trials and for all tasks associated with
               conducting each Phase I and Phase II Clinical Trial at its sole
               expense, except for manufacturing and supply of Clinical Supplies
               of Licensed Product, for the first Monoclonal Product and SM
               Product until the first of the following occurs with respect to
               each: (i) as there is a Pivotal Trial; (ii) the JSC determines to
               proceed which Phase III Clinical Trials; or (iii) the JSC decides
               to terminate development efforts for such Licensed Product.
               Dendreon's responsibilities under this Section 2.10(a) shall
               include the preparation and filing of any required Regulatory
               Filings including, without limitation, INDs to conduct such
               Clinical Trials.
          (b)  Genentech shall provide Clinical Supply of Licensed Product for
               all Phase I and Phase II Clinical Trials, at its sole expense,
               pursuant to a Clinical Supply Agreement to be entered into by the
               Parties and shall prepare and file, at its sole expense, any
               necessary Regulatory Filing for the manufacture of such Clinical
               Supply in the Territory. In addition, Genentech shall be
               responsible for all tasks associated with Phase I and Phase II
               Clinical Trials for Additional Products and New Molecules at its
               sole expense, except to the extent that Dendreon has elected to
               share DENDROEN/GNE Development Costs pursuant to Section 2.14.
               Genentech's responsibilities under this Section 2.10(b) shall
               include the preparation and filing of any required Regulatory
               Filings to conduct such Clinical Trials.
          (c)  Each Party shall exercise Commercially Reasonable and Diligent
               Best Efforts to complete its work responsibilities in accordance
               with accepted professional standards, applicable laws and
               regulations, and the applicable Clinical Plan. Each Party shall
               maintain scientific staff, laboratories, offices and other
               facilities necessary to carry out its assigned tasks under the
               applicable Clinical Plan.

     2.11 Phase II Decision Point.

          (a)  If Phase II Clinical Trials for Monoclonal Product or SM Product
               are not Pivotal Trials, then the JSC will determine whether to
               approve proceeding with Phase III Clinical Trials based upon an
               assessment of whether the results of the Phase II Clinical Trials
               warrant proceeding with Phase III Clinical Trials. Within thirty
               (30) days after notice from the FDA during any pre-BLA meeting
               following Phase II Clinical Trials for a Monoclonal Product or SM
               Product that the FDA will accept a BLA or NDA filing based upon
               such Phase II Clinical Trial data (i.e. that such Phase II
               Clinical Trial is a Pivotal Trial), Genentech will initiate the
               preparation of a BLA or NDA for filing with the FDA and the
               commercialization efforts for such Monoclonal Product and SM
               Product in accordance with Article 7 below. The decisions of the
               JSC under this Section shall be binding on the Parties.
          (b)  If, with respect to each of the first Monoclonal Product or first
               SM Product for which Phase I and II Clinical Trials are conducted
               hereunder, the JSC agrees not to proceed with Phase III Clinical
               Trials for such first Monoclonal Product or first SM Product,
               then the JSC will determine in good faith whether to proceed with

                                       17

<PAGE>

               development of such Monoclonal Product or SM Product, as the case
               may be. The decision of the JSC will be binding upon the Parties.
               If the JSC cannot agree whether or not to proceed with Phase III
               Clinical Trials, but Genentech wishes to proceed to Phase III
               Clinical Trials, then Genentech may proceed with Phase III
               Clinical Trials upon written notice to Dendreon. Dendreon shall
               then have the right within thirty (30) days after receipt of such
               notice to make the election provided in Section 2.14 to share
               DENDREON/GNE Development Costs and Operating Profits and Losses
               with respect to such Licensed Product. If Dendreon does not elect
               to share in DENDREON/GNE Development Costs and Operating Profits
               and Losses for such Licensed Product, Genentech shall be free to
               independently conduct Phase III Clinical Trials, and all other
               development and commercialization, for such Licensed Product and
               Dendreon shall receive the royalty provided in Section 6.5. If
               the JSC cannot agree whether or not to proceed with Phase III
               Clinical Trials, and Dendreon wishes proceed to Phase III
               Clinical Trials, the issue shall be referred to the Chief
               Executive Officers of Dendreon and Genentech for resolution in
               accordance with Section 12.9.1.

     2.12 Phase I and II Clinical Trial Costs.

          (a)  Dendreon shall be responsible for all Clinical Trial Costs for
               all Phase I and Phase II Clinical Trials as provided in Section
               2.10(a). For each SM Product or Monoclonal Product, if Phase II
               Clinical Trials are Pivotal Trials , or if the JSC decides to
               proceed with Phase III Clinical Trials, then within thirty (30)
               days after such decision Genentech shall reimburse Dendreon for
               all Phase I and Phase II Clinical Trial Costs incurred by
               Dendreon for such Licensed Product. If, however, the completion
               date of any Phase I or Phase II Clinical Trial for such Licensed
               Product is delayed by more than three (3) months beyond the
               completion date stated in the applicable Clinical Plan for such
               Clinical Trial, or the Clinical Trial Costs for any Phase I or
               Phase II Clinical Trial are more than [...***...] over the dollar
               budget amount in the Clinical Plan for such Clinical Trial, for
               any reason other than: (i) unexpected regulatory action by the
               FDA with respect to such Clinical Trial(s) that is not the fault
               of Dendreon, (ii) unexpected safety issues that require a
               material change to the protocol(s) of such Clinical Trial(s),
               (iii) unexpected adverse safety information about a similar small
               molecule or monoclonal antibody product that binds to or
               manipulates a transmembrane channel and that significantly
               impacts the rate of patient accrual for such Clinical Trial(s),
               (iv) manufacturing problems that significantly delay the supply
               of such Licensed Product for such Clinical Trial(s) or (v)force
               majeure under Section 12.5 below, then Genentech shall reimburse
               Dendreon for only [...***...] of the Clinical Trial Costs for
               such Phase I and/or Phase II Trials. For purposes of this Section
               2.12(a), the completion date of a Phase I or Phase II Clinical
               Trial is the date that the last patient is enrolled in the study.
          (b)  Genentech shall be responsible and shall pay the Clinical Trial
               Costs for the Phase I and Phase II Clinical Trials for which it
               is responsible pursuant to Section 2.10(b); provided, however,
               that Dendreon may elect to share such costs in accordance with
               Section 2.14.

                                             ***Confidential Treatment Requested

                                       18

<PAGE>

     2.13 Phase III Clinical Trials. If Dendreon has elected to share
          DENDREON/GNE Development Costs and Operating Profits and Losses in
          accordance with Section 2.14, then within sixty (60) days of the
          approval of the JSC to proceed with Phase III Clinical Trials for a
          Licensed Product, the JPT shall amend the Clinical Plan, for JSC
          approval, as necessary for the Phase III Clinical Trials for such
          Licensed Product. If Dendreon has not made the foregoing election,
          then Phase III Clinical Trials shall be conducted by Genentech without
          any oversight or control by the JSC or JPT. The amended Clinical Plan
          shall address, without limitation, the following:

          (a)  Plans for the Clinical Trials that include a summary of the
               anticipated protocol, a timeframe for patient accruals, the
               identification of some of the prospective investigators, the
               projected quantity of Clinical Supply required of such Licensed
               Product, and the retention of initial consultants and contract
               research organizations to support the Clinical Trials.
          (b)  Clinical Trial endpoints, milestones and deliverables for each
               key component of the trials.
          (c)  Objective Protocol primary endpoints to determine whether the
               results of the Phase III Clinical Trials are sufficient to obtain
               Regulatory Approval by the FDA to sell such Licensed Product.

          Genentech shall be solely responsible at its sole expense for
          manufacturing the Clinical Supply of each Licensed Product for the
          Phase III Clinical Trial(s) for that Licensed Product, pursuant to the
          Clinical Supply Agreement, for all associated Regulatory Filings
          necessary to manufacture such Clinical Supply in the Territory, and
          for all expense associated with conducting the Phase III Clinical
          Trials, including all related Regulatory Filings, as appropriate.
          Notwithstanding the foregoing, if Dendreon has elected to share in the
          costs for a Licensed Product as provided in Section 2.14 below, then
          Dendreon shall share in the expense for all such Clinical Trial
          activities and Clinical Supply, as provided in Exhibit B and Section
          2.14 below. Genentech shall exercise Commercially Reasonable and
          Diligent Efforts to complete its responsibilities in accordance with
          accepted professional standards and the amended Clinical Plan, and
          shall maintain scientific staff, laboratories, offices and other
          facilities necessary to carry out its assigned tasks under the
          applicable Clinical Plan.

     2.14 SM Product and Monoclonal Product Cost Sharing.

          (a)  The Parties acknowledge that in consideration for Dendreon
               conducting Phase I and Phase II Clinical Trials as provided in
               Section 2.10(a), that Dendreon shall have the right to elect to
               share in Operating Profit and Loss as provided herein. For the
               first SM Product and Monoclonal Product for which Phase II
               Clinical Trials are Pivotal Trials or as to which the JSC
               approves proceeding with Phase III Clinical Trials, Dendreon may
               elect, by giving Genentech written notice within thirty (30) days
               after notice from the FDA in the pre-BLA meeting that the FDA
               will accept a BLA filing based upon data from a Pivotal Trial or
               JSC approval to proceed with Phase III Clinical Trials, to share
               with Genentech all DENDREON/GNE

                                       19

<PAGE>

               Development Costs for the Phase III Clinical Trials and Clinical
               Trials thereafter, manufacturing costs, other costs, revenues,
               and the resulting Operating Profits and Losses in the United
               States, for such Licensed Product thereafter, with [...***...]
               Genentech in accordance with the Financial Planning, Accounting
               and Reporting Procedures set forth in Exhibit B. This election
               shall be made once for each Monoclonal Antibody and shall apply
               to the Licensed Product, and all Additional Products, containing
               such Monoclonal Antibody. This election also shall be made once
               for each Small Molecule and shall apply to the Licensed Product,
               and all Additional Products, containing such Small Molecule.
          (b)  If the JSC approves a Preclinical Program for a New Molecule or
               Clinical Trials for a Licensed Product containing a New Molecule
               then, as to such New Molecule and Licensed Products containing
               such New Molecule, Dendreon may elect, by giving written notice
               within thirty (30) days after such JSC approval, to share
               DENDREON/GNE Development Costs and Operating Profits and Losses
               in the United States as provided above and in Exhibit B.

     2.15 First Monoclonal Product Phase III Results. For the first Monoclonal
          Product, the JSC will review the data from the Phase III Clinical
          Trial results, and will determine how best to commercialize such
          Monoclonal Product or any corresponding Additional Product. The
          decision of the JSC under this Section shall be binding on the
          Parties.

     2.16 First SM Products Phase III Results. For the first SM Product, the JSC
          will review the data from the Phase III Clinical Trial results, and
          will determine how best to commercialize such SM Product or any
          corresponding Additional Product. The decision of the JSC under this
          Section shall be binding on the Parties.

     2.17 Additional Products and Other Molecules. The JSC shall determine
          whether to develop Additional Products, or New Molecules as a Licensed
          Product, and whether to continue development of any such Licensed
          Products following completion of each stage of Clinical Trials. The
          decision of the JSC shall be binding on the Parties.

     2.18 Regulatory Filings, Communications and Reports

          2.18.1 Rights and Obligations of Dendreon.

          (a)  Dendreon will be responsible for, and will use Commercially
               Reasonable and Diligent Efforts in, preparing and filing, at its
               cost, the INDs for the Phase I and Phase II Clinical Trials that
               it conducts under this Agreement, and Dendreon will own all such
               INDs. Genentech will be responsible for, and will use
               Commercially Reasonable and Diligent Efforts in, preparing and
               filing, at its cost, (i) the INDs for all other Clinical Trials
               conducted under the Agreement and (ii) all comparable Regulatory
               Filings for its Licensed Product development activities in the
               Territory outside the United States. Genentech will own all such
               INDs and Regulatory Filings. In addition, Genentech will own, and
               be responsible for preparing and filing, at its cost, all BLAs
               and NDAs submitted to obtain Regulatory Approvals for Licensed
               Products in the Territory. Notwithstanding the foregoing, if
               Dendreon

                                             ***Confidential Treatment Requested

                                       20

<PAGE>

               has elected to share in DENDREON/GNE Development Costs and
               Operating Profits and Losses hereunder, the costs of preparing
               and filing INDs, BLAs and NDAs in the United States will be
               shared in accordance with Exhibit B for such filings and
               submissions prepared and filed from the date of such election by
               Dendreon.
     (b)       Prior to Dendreon's submitting any IND, the Parties, through the
               Joint Project Team, shall consult with the other Party regarding
               the scope and general content of such IND. The Parties will
               consult and cooperate in sharing information from their Licensed
               Product development activities hereunder that is necessary for
               the preparation of such Regulatory Filings. Genentech shall have
               the right to review and comment on all INDs in accordance with
               specific timelines or other arrangements agreed upon by the Joint
               Project Team, and such comments will be given all due
               consideration by the other Party. Regulatory documents shall be
               centralized and held at the offices of the Party responsible for
               such IND filing.
     (c)       If Dendreon is sharing DENDREON/GNE Development Costs and
               Operating Profits and Losses hereunder for a Licensed Product,
               prior to filing by Genentech of an IND, BLA or NDA for such
               Licensed Product, the Parties, through the Joint Project Team,
               shall consult regarding the scope and general content of such
               Regulatory Filing. Dendreon shall further have the right to
               review and comment upon such Regulatory Filing in accordance with
               specific timelines or other arrangements agreed upon by the JPT,
               and such comments will be given all due consideration by
               Genentech.
     (d)       Neither Party shall transfer title or otherwise attempt in any
               manner to dispose of any such INDs, BLAs, or NDAs for Licensed
               Products, or otherwise impair the other Party's rights in such
               INDs, BLAs or NDAs, without the prior written consent of the
               other Party, except that Genentech shall have the right to
               require Dendreon to permit Genentech's sublicensee to reference
               or cross-reference any such INDs in connection with a license
               granted to such sublicensee in accordance with Section 5.4 below.

     2.18.2 Regulatory Filings for Manufacturing.

     (a)  Genentech will be responsible for preparing and filing any necessary
          Regulatory Filings, and obtaining necessary Regulatory Approval, for
          the manufacture of Clinical Supply and Commercial Supply in the
          Territory. The costs of such Regulatory Filings and Regulatory
          Approvals shall be borne by Genentech in the Territory outside of the
          United States. The costs of such Regulatory Filings and Regulatory
          Approvals in the United States will be borne by Genentech; provided
          that if Dendreon has elected to share in the DENDREON/GNE Development
          Costs and Operating Profits and Losses for a Licensed Product in
          accordance with Section 2.14 above such costs for such Licensed
          Product will be shared by the Parties pursuant to Exhibit B.
     (b)  Dendreon will be responsible for preparing and filing any necessary
          Regulatory Filings, and obtaining necessary Regulatory Approval, for
          the manufacture of Clinical Supply and Commercial Supply in the
          Dendreon Territory, at its sole cost.

                                       21

<PAGE>

          2.18.3 Cross Reference of Regulatory Filings. Each Party shall have
          the right to cross reference, in any regulatory document of such
          Party, the INDs, BLAs, and NDAs of the other Party, for the purpose of
          conducting Clinical Trials and seeking Regulatory Approval under this
          Agreement in the Territory. With respect to the manufacturing of
          Licensed Product hereunder, Genentech may prepare and submit to the
          FDA a Drug Master File, and with respect to the Dendreon Territory, an
          equivalent regulatory file. Dendreon will have the right to rely upon
          and to cross reference such Drug Master File, and equivalent
          regulatory file with respect to the Dendreon Territory, as required
          for conducting Clinical Trials hereunder, and manufacturing, and
          clinical trials and other development activity in the Dendreon
          Territory.

          2.18.4 Regulatory Meetings and Communications.

          (a)  The Party primarily responsible for conducting a Clinical Trial
               hereunder will be responsible for conducting meetings and
               discussions, and routine telephone communications with the FDA
               related to such Clinical Trial. To the extent practical, a
               reasonable number of representatives of the other Party will be
               given the opportunity to participate in substantive discussions
               and meetings with the FDA which relate to such Clinical Trial.
               The Party primarily responsible will have decision making
               authority regarding the number of, and which, representatives of
               the other Party may attend such meetings, but in any case at
               least one representative of the other Party may participate. The
               other Party will have the right to give input and comments to
               pre-meeting documents and packages that are prepared for FDA
               meetings regarding Clinical Trials.
          (b)  Genentech will be solely responsible for conducting all meetings
               and discussions with Regulatory Agencies regarding BLAs and NDAs
               in the Territory, including without limitation all pre-BLA
               meetings held with the FDA. Dendreon may participate in such
               discussions and meetings with the FDA to the extent described in
               2.18.4(a) above. Dendreon will not have the right to participate,
               however, in discussions or meetings with Regulatory Agencies
               regarding Licensed Product being developed or sold by Genentech
               in the Territory outside the United States.
          (c)  Notwithstanding Section 2.18.4(a) and (b) above, the primarily
               responsible Party will not be obligated to permit representatives
               of the other Party to attend any Regulatory Agency meetings
               related specifically to an inspection at such Party's premises by
               any Regulatory Agency.
          (d)  To the extent either Party receives written, or material oral
               communication from the FDA relating to a Licensed Product, the
               Party receiving such communication shall notify the other Party
               of the substance of the communication and provide a copy of any
               written communication as soon as reasonably practicable.

     2.19 Information. Genentech and Dendreon will disclose and make available
          to each other in a timely manner all preclinical and clinical
          information concerning Licensed Products known by Genentech or
          Dendreon at any time during the Term of this Agreement. During
          collaborative Licensed Product development, and co-promotion,
          activities hereunder, each Party will use Commercially Reasonable and
          Diligent Efforts to disclose to the other Party all significant
          information directly related to Licensed Products promptly after it is
          learned or its significance is appreciated.

                                       22

<PAGE>

     2.20 Adverse Drug Events and Complaints. The Parties recognize that the
          Party that is the holder of the IND for the applicable Clinical Trials
          hereunder, and Genentech as the holder of a BLA or NDA, will be
          required to submit information and file reports to various
          governmental agencies on compounds under clinical investigation,
          compounds proposed for marketing, or marketed drugs. Information must
          be submitted at the time of initial filing for investigational use in
          humans and at the time of a request for market approval of a new drug.
          In addition, supplemental information must be provided on compounds at
          periodic intervals and adverse drug experiences must be reported at
          more frequent intervals depending on the severity of the experience.
          Each Party shall promptly provide to the other Party, in connection
          with the collaborative Clinical Program hereunder or as long as
          Dendreon is sharing Operating Profits and Losses hereunder, a copy of
          any such adverse drug experience reports with respect to serious
          adverse events. In addition, the Parties agree to the following
          provisions, which may be modified by the Joint Project Team:

          (a)  Each Party shall provide to the other Party, for initial and/or
               periodic submission to Regulatory Agencies, significant
               information on Licensed Products from its preclinical laboratory,
               animal toxicology and pharmacology studies;
          (b)  In connection with Clinical Trials under the Clinical Program,
               each Party shall report to the other Party within three (3) days
               of the initial receipt of a report of any serious adverse
               experience (as defined by applicable law or regulation) with the
               applicable Licensed Products, or sooner if required for other
               Party to comply with regulatory requirements; and
          (c)  In connection with any marketed Licensed Product for which
               Dendreon co-promotes hereunder, Dendreon shall provide to
               Genentech (i) a copy within three (3) business days of any
               adverse drug experience report it receives with respect to such
               Licensed Product, and (ii) shall notify Genentech of any serious
               complaint about the quality or efficacy of a Licensed Product
               received by it in sufficient detail. Each Party also agrees that
               if it contracts with a Third Party for research to be performed
               by such Third Party on the Licensed Products, that Party agrees
               to require such Third Party to report to the contracting Party
               the information set forth in subsections 2.20(a), (b) and (c)
               above.

     2.21 Other Activities. During the Term of this Agreement, neither Party
          shall engage in research or development involving Licensed Products in
          the Territory directly or indirectly other than pursuant to this
          Agreement. Dendreon shall use commercially reasonable efforts to
          coordinate its Licensed Product research and development activities in
          the Dendreon Territory, including those activities conducted with its
          licensees and sublicensees, so as not to impede research and
          development activities under this Agreement, and shall endeavor to
          achieve a free flow of information to the JSC about such activities in
          the Dendreon Territory. Genentech shall use commercially reasonable
          efforts to coordinate its Licensed Product research and development
          activities in the Territory conducted outside the United States,
          including those activities conducted with its sublicensees, so as not
          to impede research and development activities under this Agreement,
          and shall endeavor to achieve a free flow of information to the JSC
          about such activities in the Territory conducted outside the United
          States. Both Parties shall retain full rights to conduct independent
          research and development work outside the scope of this Agreement
          directly or through Third Parties.

                                       23

<PAGE>

     2.22 Transfer of Materials. During the collaboration hereunder, each Party
          may transfer certain of its proprietary materials to the other Party.
          Each Party agrees that it will use such materials of the other Party
          only for the purposes of the collaboration hereunder, and will not
          transfer such materials to any Third Party without the prior written
          consent of the other Party hereunder. Except as expressly provided in
          this Agreement, the transfer of any such proprietary materials by one
          Party to another shall not be deemed to be a grant of any rights in
          the proprietary material. All right, title and interest in and to all
          such proprietary materials (and any patent rights relating thereto)
          shall remain in the Party transferring such materials. Proprietary
          materials made or assembled by a Party during and in furtherance of
          the collaboration hereunder, and which are directly related to
          Licensed Product, shall be considered jointly-owned proprietary
          material. Each Party shall have the right to use such jointly-owned
          proprietary materials solely for the purposes of the collaboration
          hereunder or for internal research purposes and shall not transfer,
          license or sublicense any such proprietary materials to any Third
          Party without the prior written consent of the other Party. Any
          Collaboration Invention Patent Rights arising from a Party's use of
          such proprietary materials shall be owned as provided in Section 8.1.

     2.23 Third Party Academic Researchers/Institutions.

          (a)  The Parties acknowledge that it may be beneficial to the
               collaboration hereunder for each Party to transfer certain Trp-p8
               reagents, Monoclonal Antibodies, Small Molecules and/or Licensed
               Products to academic researchers or governmental research
               institutions, under material transfer agreements and
               collaboration agreements, for additional research on such
               molecules ("Third Party Research Agreements"). The obligations of
               the Parties under such Third Party Research Agreements may
               include providing such researchers with research quantities of
               Trp-p8 reagents, Monoclonal Antibody, Small Molecule or Licensed
               Product. The Parties shall agree upon and coordinate all such
               Third Party Research Agreements, and amendments or extensions
               thereto, and the transfer of Monoclonal Antibodies, Small
               Molecules and Licensed Products thereunder, through the Joint
               Project Team, in a manner to conserve the available quantities of
               the Parties' research materials and to avoid compromise of the
               Parties' abilities to fulfill their obligations under the any
               Preclinical Plan or Clinical Plan hereunder. Any such Third Party
               Research Agreements shall be substantially in the form of a
               "Material Transfer Agreement" or "Research Collaboration
               Agreement" to be agreed upon by the Parties. Each Party agrees to
               promptly provide the other Party with all data, reports and
               information that such Party receives under such Third Party
               Research Agreements.
          (b)  In the event that research conducted under any Material Transfer
               Agreement or Research Collaboration Agreement, entered into by
               one or both of the Parties and an academic or governmental Third
               Party, results in an invention or know-how made jointly or solely
               by a Third Party that relates to Licensed Products, the Parties

                                       24

<PAGE>

               shall determine whether a license (exclusive or non-exclusive)
               can and should be obtained under the rights of such Third Party
               to such invention or know-how. If the Parties agree that such
               license can and should be obtained, then the Parties will enter
               into a license agreement to jointly license such rights.
               Milestone payments and royalties payable to a Third Party, due to
               such a license granted pursuant to a Material Transfer Agreement
               or Collaboration Agreement, shall be chargeable in full to the
               collaboration as Cost of Sales in accordance with Exhibit B. If
               the Parties do not share DENDREON/GNE Development Costs and
               Operating Profits and Losses under this Agreement or if a
               milestone payment is due prior to the initiation of such sharing,
               then any such milestone payments and royalties will, unless the
               Parties agree otherwise, [...***...].

     2.24 Contracts with Third Parties. In addition to agreements made with
          academic researchers and governmental research institutions as
          provided in Section 2.23 above, during the Term the Parties may
          jointly or individually enter into written contracts with other Third
          Parties for activities to be performed in furtherance of the
          activities of the Parties hereunder, including, without limitation,
          Third Party consultants and clinical investigators. Each such contract
          shall incorporate the confidentiality obligations required under
          Section 11.1 below. In addition, Dendreon and Genentech each shall use
          commercially reasonable efforts to require, as an obligation under
          such contracts, that: (a) such Third Party consultants assign to
          Dendreon and Genentech as joint owners all inventions made by such
          consultants during the course of their consulting services, and (b)
          such Third Party clinical investigators assign to Dendreon and
          Genentech as joint owners, or grant an option to Dendreon and
          Genentech to co-exclusively license, all inventions made by such
          clinical investigators during the course of conducting clinical trials
          hereunder.

3.   Joint Steering Committee.

     3.1  Joint Steering Committee. The Parties hereby establish a Joint
          Steering Committee, or JSC, to oversee and direct the Product
          Development Program for Monoclonal Products and SM Products as
          provided in this Agreement. During the Preclinical Programs for
          Monoclonal Products and SM Products, each Party, through the JSC, will
          review the periodic information and reports of the other Party
          hereunder, and will be able to have input and offer suggestions
          regarding the Preclinical Program of the other Party. The JSC shall be
          comprised of up to three (3) representatives of each Party, who shall
          be appointed (and may be replaced at any time) by such Party on
          written notice to the other Party in accordance with this Agreement.
          Such representatives shall include individuals within the senior
          management of each Party with expertise in drug development and
          commercialization. Any member of the JSC may designate a substitute to
          attend and perform the functions of that member at any meeting of the
          JSC. The Parties shall designate the members of the JSC within twenty
          (20) days after the Effective Date of this Agreement. The JSC shall
          have the following authority and obligations with respect to Licensed
          Products:

          (a)  To approve the overall strategy for, and to review and approve,
               the Product Development Program and Clinical Plans for Monoclonal
               Products and SM Products (with respect to SM Products, upon
               exercise of Genentech's SM Product option) and their related
               budgets.

                                             ***Confidential Treatment Requested

                                       25

<PAGE>

          (b)       To provide direction to the Joint Project Team as provided
                    herein, and to review and approve all activities delegated
                    to the JPT under this Agreement.

          (c)       To oversee and approve the activities of the Parties
                    required to perform the Product Development Program.

          (d)       To evaluate the results of the Preclinical and Clinical
                    Programs for Monoclonal Products and SM Products.

          (e)       To review and approve the selection by the Joint Project
                    Team of development decision criteria, and of indications
                    for which Licensed Products are developed.

          (f)       To perform such other functions as set forth in this
                    Agreement or as appropriate to further the purposes of this
                    Agreement and the development of Licensed Product as
                    determined by the Parties.

     3.2  JSC Meetings.

          3.2.1     Meeting Schedule. The JSC shall act at meetings held
          regularly on reasonable notice during the Term of this Agreement, but
          no less often than two (2) times per year or more often as agreed by
          the JSC. At least one (1) meeting annually must be conducted in
          person. The balance may be conducted by telephone or videoconference
          or other acceptable electronic means.

          3.2.2     JSC Chair. The JSC shall appoint one of the representatives
          of a Party to chair its meetings for a term of six (6) months. The
          term of an incumbent chair may not be extended and the successor shall
          be appointed from among the representatives of the other Party. The
          Chair shall coordinate and prepare the agenda with input from the
          other Party, and insure the orderly conduct of the JSC meetings. The
          Party hosting the JSC meeting shall appoint one person (who need not
          be a member of the JSC) to record the minutes of the meeting in
          writing. Such minutes shall reflect the matters discussed and the
          actions taken at the meetings. A copy of the minutes shall be provided
          to each Party promptly following a meeting for review and comment. Any
          modifications to a Clinical Plan (including the work, budget and
          timeline therefore) approved at a JSC meeting shall be considered
          approved and shall constitute an amendment to the Clinical Plan upon
          JSC ratification of the meeting minutes related thereto.

     3.3  Decision-Making and Issue Resolution. All decisions of or actions
          taken by the JSC shall be taken at a duly called meeting. The
          representatives from Dendreon will collectively have one vote and the
          representatives from Genentech will collectively have one vote in
          decisions, with decisions made by unanimous vote. The vote shall be
          reflected in the minutes of the meeting at which it was taken. If the
          JSC fails to reach agreement on an issue needing resolution, the
          matter shall be resolved by the Parties under the terms of Section
          12.9.1 below. The JSC may act on a specific issue without a meeting if
          it is documented in a written consent signed by all of the members of
          the JSC.

                                       26

<PAGE>

4.   Joint Project Team.

     4.1  Establishment of Joint Project Team. The Parties shall establish a
          Joint Project Team (JPT) at the time that the decision is to be made,
          as determined by the JSC, to select the first lead Monoclonal
          Antibodies or Small Molecules, as the case may be, to place into the
          Developmental Research phase of the Product Development Program. The
          JPT shall coordinate all activities for the Developmental Research and
          Clinical Program for Licensed Products (including SM Products if
          Genentech exercises its option under Section 2.6above) in the Field in
          the United States, including post-Regulatory Approval development
          studies. Each Party shall appoint representatives to the JPT and the
          JPT shall consist of such number of representatives of each Party as
          are reasonably necessary to accomplish the goals of the JPT hereunder.
          The number of such representatives may change from time to time. Such
          representatives will include, without limitation, individuals with
          expertise and responsibilities in the areas of clinical development,
          process sciences, regulatory affairs, product development and
          marketing, as applicable to the stage of development of the Licensed
          Product. One such representative from each Party shall be designated
          as that Party's "Project Team Leader" to act as the primary Joint
          Project Team contact for that Party. Either Party may replace any or
          all of its representatives at any time upon written notice to the
          other Party. Any member of the Joint Project Team may designate a
          substitute to attend and perform the functions of that member at any
          meeting of the Joint Project Team. The Joint Project Team will meet as
          provided in this Agreement or as otherwise agreed by the Joint Project
          Team or the JSC.

     4.2  Joint Project Team Responsibilities. The Joint Project Team shall be
          responsible for:

          (a)  formulating the overall Clinical Program and the initial and
               subsequent annual Clinical Plans and related annual budgets in
               accordance with the schedule set forth in Sections 2.9 or as
               otherwise determined by the JSC;

          (b)  formulating life cycle plans, full product development plans, and
               Commercialization Plans;

          (c)  making overall decisions regarding the priority and design of all
               Clinical Trials for new indications;

          (d)  developing a publication strategy and a calendar of key
               scientific and clinical meetings and other events for Licensed
               Products;

          (e)  exchanging information and facilitating cooperation and
               coordination between the Parties as they exercise their
               respective rights and meet their respective obligations under
               this Agreement;

          (f)  determining the priority with respect to seeking Regulatory
               Approval of Licensed Products; and

          (g)  implementing all activities approved by the JSC.

          In addition, the Joint Project Team may designate subteams as
          appropriate to facilitate coordination and cooperation in key areas.
          Specifically, the Joint Project Team will designate a Joint Regulatory
          Subteam to coordinate efforts as may be necessary for IND filing and
          other regulatory activities.

                                       27

<PAGE>

     4.3  Joint Project Team Decision-making. As a general principle, the Joint
          Project Team will operate by consensus. In the event that the Joint
          Project Team members do not reach consensus with respect to a matter
          that is within the purview of the Joint Project Team herein, the Joint
          Project Team representatives of Dendreon shall collectively have one
          vote and the representatives of Genentech one vote for purposes of
          decision-making hereunder with respect to such matters, with decisions
          made by unanimous vote. If the Joint Project Team is unable to resolve
          a dispute regarding a matter within the purview of the JPT, such
          dispute shall be resolved by the JSC.

     4.4  Ceasing of Joint Project Team Operations. The Joint Project Team will
          cease operations and have no further function hereunder on the later
          of (i) the date on which the Parties are no longer developing or
          commercializing any Licensed Product hereunder or (ii) if applicable,
          the date on which the Parties are no longer sharing Dendreon/GNE
          Development Costs or Operating Profits or Losses with respect to any
          Licensed Product in the United States.

     4.5  Annual Production Requirements. The Joint Project Team shall be
          responsible for submitting annual Licensed Product supply requirement
          reports to the JSC for approval. Such reports shall include the
          forecasted requirements for Clinical Supply, Commercial Supply and
          Licensed Product placebo, pursuant to the Clinical Supply Agreement
          and Commercial Supply Agreement to be entered into by the Parties in
          accordance with Sections 7.9.2 and 7.9.3 hereof, and any other related
          information requested by the JSC. Each such report shall be submitted
          to the JSC with the annual Clinical Plan or Commercialization Plan and
          respective budget for each Licensed Product for the subsequent
          calendar year.

5.   Licenses and Rights.

     5.1  Dendreon Grant.

          (a)  Dendreon hereby grants to Genentech an exclusive license under
               Dendreon Patent Rights and Dendreon Know-how, and Dendreon's
               rights under Joint Patent Rights, to use, make, have made, sell,
               offer for sale and import Trp-p8 and Licensed Products (other
               than SM Products and Licensed Vaccine Products) in the Field in
               the Territory. Such license shall be co-exclusive with Dendreon
               with respect to the use of Trp-p8 and such Licensed Products in
               the United States in Preclinical and Clinical Programs hereunder.
               In the event that the JSC approves Dendreon conducting its
               Preclinical Program activities or any Clinical Trials in any
               country in the Territory outside of the United States, then such
               license to use such Licensed Products shall be co-exclusive with
               Dendreon with respect to those activities in such country. In the
               event that Dendreon co-promotes any Licensed Product pursuant to
               Section 7.2 below, then such license shall also be co-exclusive
               with Dendreon with respect to the sale or offer for sale of such
               Licensed Products in the Field in the United States.

          (b)  Dendreon hereby grants to Genentech a nonexclusive license
               without right of sublicense under Dendreon Patent Rights and
               Dendreon Know-how, and Dendreon's rights under Joint Patent
               Rights, to use, make and have made Small Molecules and SM
               Products in the Field in the United States from the Effective
               Date until the completion of the SM Product Preclinical Program
               under this Agreement.

                                       28

<PAGE>

          (c)  Effective upon Genentech's exercise of its SM Product option
               rights in accordance with Section 2.6 above, Dendreon hereby
               grants to Genentech an exclusive license under Dendreon Patent
               Rights and Dendreon Know-how, and Dendreon's rights under Joint
               Patent Rights use, make, have made, sell, offer for sale and
               import Small Molecules and SM Products in the Field in the
               Territory. Such license shall be co-exclusive with Dendreon with
               respect to: (i) the use of SM Products in the United States in
               Clinical Trials, and (ii) in the Preclinical Program for SM
               Products if Genentech exercises its option prior to the
               completion of such Preclinical Program. In the event that
               Dendreon conducts any JSC approved SM Product Clinical Trials in
               any country in the Territory other than the United States, then
               such license for the use of such SM Product shall be co-exclusive
               with Dendreon with respect to those Clinical Trials in such
               county. In the event that Dendreon co-promotes any SM Product
               pursuant to Section 7.2 below, then such license shall also be
               co-exclusive with Dendreon with respect to the sale or offer for
               sale of such SM Product in the Field in the United States.

          (d)  Effective upon execution of an agreement between Dendreon and
               Genentech pertaining to Licensed Trp-p8 Vaccine Products pursuant
               to Section 2.7 above, Dendreon hereby grants to Genentech a
               co-exclusive license under the Vaccine Product Patent Rights and
               Vaccine Product Know-how, and Dendreon's rights under Joint
               Patent Rights to use, make, and have made, offer for sale, sell
               and export Licensed Trp-p8 Vaccine Products in the Field in the
               Territory.

     5.2  Genentech Grant.

          (a)  Genentech hereby grants to Dendreon a nonexclusive license to use
               (and to make and have made during Dendreon's Discovery Research
               and Developmental Research) Monoclonal Antibodies, Monoclonal
               Products, Small Molecules and SM Products under Genentech Patent
               Rights, Genentech Know-how in the United States for the purpose
               of carrying out Dendreon's activities under the Preclinical Plans
               and Clinical Plans under this Agreement. Genentech also hereby
               grants to Dendreon a license, co-exclusive with Genentech, under
               Genentech Patent Rights, Genentech Know-how, and Genentech's
               rights under Joint Patent Rights to sell and offer for sale
               Licensed Products in the Field in the United States, but only to
               the extent that Dendreon co-promotes any Licensed Product in the
               United States pursuant to Section 7.2 below.

          (b)  Genentech hereby grants to Dendreon a nonexclusive royalty
               bearing license with right of sublicense through multiple tiers
               of sublicensees under Genentech Patent Rights, Genentech Know-how
               and Genentech's interest in the Joint Patent Rights to use, sell,
               offer for sale and import Licensed Products in the Field in the
               Dendreon Territory.

          (c)  For clarification, the license rights granted under this Section
               5.2 do not include any right under Genentech Patent Rights or
               Genentech Know-how to make products other than Small Molecules,
               SM Products, Monoclonal Antibodies, and Monoclonal Products as
               granted in 5.2(a) above.

                                       29

<PAGE>

     5.3  Dendreon Sublicense Rights. Dendreon may sublicense its co-exclusive
          license rights granted under Section 5.2(b) above through multiple
          tiers of sublicensees to enable its sublicensees to use sell, offer
          for sale and import Trp-p8 and Licensed Products in the Dendreon
          Territory.

     5.4  Genentech Sublicense Rights.

          (a)  Genentech shall have the right to sublicense the license rights
               to Licensed Products (other than SM Products) granted to it under
               Section 5.1 above, through multiple tiers of sublicensees, in the
               Territory outside of the United States without the consent of
               Dendreon. Upon exercise of its option under Section 2.6,
               Genentech shall also have the right to sublicense the license
               rights to SM Products granted to it under Section 5.1 above,
               through multiple tiers of sublicensees, in the Territory outside
               of the United States without the consent of Dendreon.
          (b)  With respect to sublicensing within the United States, following
               the [...***...] and payment of the associated milestone as
               provided in section 6.2, Genentech shall have the right to
               sublicense the license rights granted to it under Section 5.1(a),
               through multiple tiers of sublicensees, in the United States,
               without the consent of Dendreon, to a Third Party with product
               revenues and product development experience similar to that of
               Genentech at the time of the execution of this Agreement.
          (c)  Following Genentech's exercise of its option for SM Products as
               provided in Section 2.6 and the decision of the JSC to proceed to
               Clinical Trials for an SM Product, Genentech shall have the right
               to sublicense the license rights granted to it under Section
               5.1(c), through multiple tiers of sublicensees, in the United
               States, without the consent of Dendreon, to a Third Party with
               product revenues and product development experience similar to
               that of Genentech at the time of the execution of this Agreement.
          (d)  With respect to either Monoclonal Product(s) or SM Product(s), if
               a potential Third Party sublicensee does not meet these revenue
               and experience criteria in Sections 5.4(b) and 5.4(c), Genentech
               shall have the right to sublicense its rights under Section
               5.1(a) and (c), through multiple tiers of sublicensees, with the
               prior written consent of Dendreon, which consent shall not be
               unreasonably withheld or delayed.
          (e)  With respect to Licensed Trp-p8 Vaccine Products, the rights, if
               any, of Genentech to sublicense shall be set forth in the written
               agreement of the parties for Licensed Trp-p8 Vaccine Products
               described in Section 2.7 above.

     5.5  Sublicensee Obligations. If any Party grants a sublicense in the
          Territory as permitted under this Agreement, all of the terms and
          conditions of this Agreement shall apply to the sublicensee to the
          same extent as they apply to such Party for all purposes. The
          sublicensing Party assumes full responsibility for the performance of
          all obligations so imposed on such sublicensee, including, without
          limitation, all payments due under this Agreement by reason of the
          operation of any such sublicense. Such sublicense shall not constitute
          a novation of this Agreement or otherwise relieve the sublicensing
          Party from obligations under this Agreement.

                                             ***Confidential Treatment Requested

                                       30

<PAGE>

     5.6  Trademark License. Genentech hereby grants to Dendreon, a co-exclusive
          (co-exclusive with Genentech), non-transferable, non-sublicenseable
          license and right to use the Product Trademarks solely within the
          United States and solely in connection with Dendreon's Licensed
          Product development, and co-promotion of Licensed Product if
          applicable, under this Agreement.

     5.7  Exclusions. Other than as provided in this Article 5 or Article 8
          below, this Agreement does not provide, nor shall it be interpreted,
          construed or otherwise deemed to imply or provide, either Party with
          any additional grants, licenses, options or other rights under the
          Dendreon Patent Rights, Genentech Patent Rights, Joint Patent Rights,
          Collaboration Inventions or to Know-how, or to any rights to any other
          patents, know-how or proprietary technology or materials of the other
          Party.

6.   Payments.

     6.1  Equity Investment. In consideration of this Agreement, the Parties
          will enter into an Equity Investment Agreement of even date herewith
          by which Genentech will purchase $2 million in common stock of
          Dendreon within ten (10) working days of the Effective Date.

     6.2  Additional Equity Investment. Within thirty (30) days after the
          [...***...] that binds to Trp-p8 on intact cells, Genentech shall pay
          Dendreon a non-refundable fee of $2.5 million through the purchase of
          Dendreon common stock on the terms set forth in the Equity Investment
          Agreement. For purposes of this Section 6.2 an [...***...] means the
          [...***...]. In the event that Dendreon is acquired by a Third Party,
          by merger, consolidation, purchase or otherwise prior to such $2.5
          million fee becoming payable hereunder, Genentech, as its sole option,
          may elect to pay such $2.5 million fee in cash in lieu of such equity
          investment.

     6.3  Monoclonal Product Milestones. Subject to the other terms and
          conditions of this Agreement, Genentech will pay Dendreon the
          following milestone payments for Monoclonal Products:

                                             ***Confidential Treatment Requested

                                       31

<PAGE>

<TABLE>
          <S>                                                                           <C>
          (a)  FDA acceptance of first IND filing for the first Monoclonal              [...***...]
               Product

          (b)  Upon the first determination by the FDA in a pre BLA meeting that        [...***...]
               the FDA will consider the first BLA for the first Tumor Type in a
               Prevalent Cancer filed based upon data from a Pivotal Trial

          (c)  Acceptance by the FDA of the first BLA based upon data from a            [...***...]
               Pivotal Trial for the first Monoclonal Product

          (d)  Administration of investigational Monoclonal Product to the first        [...***...]
               subject in the first Phase III Clinical Trial in the United
               States for each Tumor Type in a Prevalent Cancer or for the first
               Pivotal Trial in the United States for a Monoclonal Product for
               the second or any subsequent Tumor Type in a Prevalent Cancer

          (e)  Notice from the FDA of its acceptance for review of the first BLA        [...***...]
               based upon data from a Phase III Clinical Trial for the first
               Monoclonal Product

          (f)  First Commercial Sale of the first Monoclonal Product in the             [...***...]
               first Tumor Type approved in the United States

          (g)  First Commercial Sale in the United States of a Monoclonal               [...***...]
               Product approved for second Tumor Type that is a Prevalent Cancer

          (h)  First Commercial Sale in the United States of a Monoclonal               [...***...]
               Product approved for a third Tumor Type that is a Prevalent
               Cancer
</TABLE>

          Milestone payment (b), however, will be paid only in lieu of milestone
          payment (d) as to the first Monoclonal Product in the first Tumor Type
          and only in the event that no Phase III Clinical Trial is conducted
          for that first Monoclonal Product in the first Tumor Type because the
          Phase II Clinical Trial for such Monoclonal Product is a Pivotal
          Trial. Milestone payment (c) will be paid only in lieu of milestone
          payment (e), and only in the event that the FDA accepts the first BLA
          for such first Monoclonal Product based upon such Pivotal Trial data.

                                             ***Confidential Treatment Requested

                                       32

<PAGE>

          In the event that the BLA based on such Pivotal Trial is not
          ultimately accepted by the FDA, or does not result in Regulatory
          Approval by the FDA of such first Monoclonal Product in the first
          Tumor Type, and a Phase III Clinical Trial is ultimately conducted for
          the first Monoclonal Product in the first Tumor Type, then the
          following provisions apply: (i) If a Phase III Clinical Trial is
          ultimately commenced for such first Monoclonal Product in the first
          Tumor Type after milestones (b) and (c) have been paid by Genentech,
          but the BLA filing based on such Pivotal Trial for such Monoclonal
          Product did not result in Regulatory Approval by the FDA, then
          milestone (d) for such Phase III Clinical Trial will not be paid by
          Genentech; (ii) If a Phase III Clinical Trial is ultimately commenced
          for such Monoclonal Product in the first Tumor Type after milestone
          (b) has been paid by Genentech but the BLA filing based on the Pivotal
          Trial for such Monoclonal Product was not accepted by the FDA and
          milestone (c) therefore not paid, milestone (d) for such Monoclonal
          Product shall be reduced to [...***...].

     6.4  SM Product.

          6.4.1 As consideration for the option granted in Section 2.6,
          Genentech shall pay Dendreon the sum of $1,000,000 within ten (10)
          business days of the execution of this Agreement.

          6.4.2 As the fee to exercise the SM Product option provided in Section
          2.6, Genentech shall pay to Dendreon the sum of [...***...] within ten
          (10) business days of its delivery to Dendreon of Genentech's notice
          of exercise of the option under Section 2.6.

          6.4.3 Subject to the other terms and conditions of this Agreement,
          Genentech shall pay Dendreon the following one time milestone payments
          upon the first occurrence of such event with respect to the first SM
          Product to achieve the relevant milestone:

<TABLE>
          <S>                                                                                   <C>
          Administration of investigational SM Product to the first subject in                  [...***...]
          first Phase II Clinical Trial in the United States

          Administration of investigational SM Product to the first subject in
          the first Phase III Clinical Trial in the United States for a                         [...***...]
          Prevalent Cancer

          Notice from the FDA of its acceptance of the first NDA for a SM
          Product. If the notice follows a Pivotal Trial, the milestone shall be                [...***...]
          increased by [...***...]

          First Commercial Sale of SM Product in the United States                              [...***...]
</TABLE>

                                             ***Confidential Treatment Requested

                                       33

<PAGE>

     6.5  Royalties to Dendreon.

          (a)  If Dendreon elects to pay [...***...] of Phase III Clinical Trial
               Costs for a Licensed Product (other than Licensed Trp-p8 Vaccine
               Products) as provided in Section 2.14, then Dendreon and
               Genentech shall share the Operating Profits and Losses (as such
               terms are defined in Exhibit B hereto) for such Licensed Product
               in the United States [...***...] to Dendreon and [...***...] to
               Genentech in accordance with Exhibit B. In the event that, with
               respect to a Licensed Product, Dendreon does not elect to make
               such payment and share in the Operating Profits and Losses above,
               then Genentech shall pay to Dendreon a royalty of [...***...] of
               Net Sales of such Licensed Product by Genentech and its
               sublicensees in the United States. In all cases, Genentech shall
               pay to Dendreon a royalty of [...***...] of Net Sales of Licensed
               Products by Genentech and its sublicensees in countries in the
               Territory other than the United States. Such royalty obligations
               shall terminate in accordance with Section 10.1(a).
          (b)  If royalty payments are to be paid to Dendreon pursuant to
               Section 6.5(a) above, and the sale of a Licensed Product by
               Genentech in any country in the Territory requires the payment of
               royalties to a Third Party, then Genentech shall have the right
               to deduct an amount up to [...***...] of such royalties actually
               paid to such Third Party from its royalty obligation to Dendreon
               hereunder, provided, however, that in no event shall the royalty
               to Dendreon for such Licensed Product be reduced below
               [...***...] (the "Floor"); provided, however, that the Floor
               shall be [...***...] if Dendreon does not fulfill its obligation
               hereunder to complete Phase I and Phase II Clinical Trials for
               the Licensed Product for which the royalty payment is made.

     6.6  Royalties to Genentech. Dendreon shall pay to Genentech a royalty of
          [...***...] of Net Sales of Licensed Products (other than Licensed
          Trp-p8 Vaccine Products) by Dendreon, its licensees and sublicensees
          in the Dendreon Territory. Such royalty obligation shall terminate in
          accordance with Section 10.2

     6.7  Currency and Payments. All milestone and royalty payments due to the
          other Party hereunder shall be made in cash within thirty (30) days of
          the applicable milestone, or, with respect to royalties, quarterly
          within sixty (60) days after the last day of each calendar quarter,
          all in U.S. dollars by means of wire or electronic transfer to the
          other Party's account in a bank in the United States to be designated
          by the other Party. All associated bank wire charges shall be borne by
          the payee. When conversion of payments from any foreign currency is
          required, such conversion shall be at an exchange rate equal to the
          average of the rates of exchange for the currency of the country from
          which the royalties are payable as published by Reuter's (or if not
          available, by Bloomberg, L.P.) for the quarterly period for which a
          payment is due.

     6.8  Royalty Reports. Each royalty payment shall be accompanied by a report
          summarizing in suitable detail as determined by the JSC the Net Sales
          of Licensed Product during the relevant three-month period.

                                             ***Confidential Treatment Requested

                                       34

<PAGE>

     6.9  Books and Records. Each Party shall keep accurate and complete
          accounting information, reports and other records, along with
          supporting documentation as necessary for the proper determination of
          amounts due to the other Party under this Agreement. Such records
          shall be maintained for at least four (4) years after the date of the
          payment to which the records relate.

     6.10 Audit Rights. Each Party, upon reasonable advance notice to the other,
          shall permit a certified public accountant reasonably acceptable to
          the audited Party to have access, during ordinary business hours once
          each calendar year, to such records under Section 6.9 as may be
          necessary to determine the accuracy of any amounts due by the audited
          Party under Sections 6.5 or 6.6, as applicable. The auditor shall be
          required to maintain all information obtained in the course of the
          audit as Confidential Information and report to the other Party only
          that information necessary to verify the calculation of amounts due.
          The audited Party shall be copied with any information provided by the
          auditor to the Party initiating the audit. Any under-payment or
          over-payment of amounts due to a Party shall be promptly paid or
          refunded as the case may be. The Party initiating the audit shall be
          solely responsible for the expenses of the audit unless the audit
          determines that with respect to the total amounts paid to the
          initiating Party during a calendar year, the initiating Party was
          underpaid by five percent (5%). In that event, the audited Party shall
          promptly reimburse the initiating Party for the expenses of the audit.

     6.11 Blocked Currency. In each country where the local currency is blocked
          and cannot be removed from the country, royalties accrued in that
          country shall be paid to the receiving Party in the country in local
          currency by deposit in a local bank designated by the receiving Party.

     6.12 Taxes. The receiving Party shall pay any and all taxes levied on
          account of such payments it receives under this Agreement. If laws or
          regulations require that taxes payable by the receiving Party be
          withheld, the other Party shall (i) deduct those taxes from the
          remittable payment, (ii) timely pay the taxes to the proper taxing
          authority, (iii) send proof of payment to and receipt by the taxing
          authority to the receiving Party.

7.   Commercialization in the Territory

     7.1  Commercialization - General Roles.

          (a)  Provided that Dendreon is sharing in Operating Profits and Losses
               with respect to Licensed Product as provided in Section 2.14,
               then the provisions of this Section 7.1 through 7.7 shall apply
               with respect to such Licensed Product. In such event, the JSC
               shall have the responsibility and authority to (i) approve
               commercialization strategy plans and (ii) monitor, review and
               approve the budget and costs incurred in commercialization
               activities. The JPT shall have the responsibilities set forth in
               Section 4.2 and the responsibility for branding and trademark
               strategy, developing Clinical Trial plans for post-approval
               Clinical Trials, and review and approval of overall
               commercialization budgets and costs.

                                       35

<PAGE>

          (b)  Genentech has established the infrastructure and expertise for
               the marketing and sales of therapeutic drugs. Whether or not
               Dendreon is co-promoting Licensed Product pursuant to Section 7.2
               below, Genentech shall have the responsibility for the design and
               implementation of product launch activities and, subject to
               Section 7.2 below, the promotion, marketing and sales of Licensed
               Products in the United States. Dendreon shall have input on the
               overall commercialization and promotion strategy and related
               overall budgets in the United States through the JSC and JPT as
               provided herein.
          (c)  If Dendreon is not sharing in Operating Profits and Losses for
               Licensed Product under Section 2.14, then Genentech will have
               full and sole responsibility and decision making authority for
               all commercialization activities in the United States with
               respect to such Licensed Product. Whether or not Dendreon is
               sharing in Operating Profits and Losses or co-promoting a
               Licensed Product hereunder, Genentech shall have the full
               responsibility of and decision making for all commercialization
               activities in the Territory outside of the United States. In
               either case in this Section 7.1(c), the JSC and JPT will have no
               oversight or responsibility for such commercialization
               activities.

     7.2  Marketing and Sales by Dendreon. Provided that Dendreon is sharing in
          Operating Profits and Losses for a Monoclonal or SM Product and
          demonstrates to the reasonable satisfaction of Genentech that Dendreon
          has met all of the following conditions, Dendreon shall have the right
          to co-promote such Monoclonal or SM Product in the United States: (a)
          Dendreon has the capability to adequately co-promote such Monoclonal
          or SM Product in that Dendreon has established, at its own cost,
          adequate sales infrastructure and personnel (including for example,
          and without limiting the foregoing, an adequate sales force, customer
          service, etc.); (b) such co-promotion efforts by Dendreon will benefit
          the collaboration by resulting in incremental Operating Profits; and
          (c) such co-promotion by Dendreon does not create an overly burdensome
          impact on Genentech's promotion infrastructure or sales force for such
          Monoclonal or SM Product pursuant to an existing or currently proposed
          Commercialization Plan. The Parties agree that the determination, to
          the reasonable satisfaction of Genentech, that Dendreon has or has not
          met these criteria shall be made on a Licensed Product by Licensed
          Product basis following good faith discussion between the Parties.
          Further, unless Dendreon has entered into an agreement with Genentech
          as provided in Section 7.3 below, Dendreon shall not have the right to
          co-promote such Licensed Product if: (i) Dendreon is filing or has
          filed a BLA or NDA for or is selling a Competing Product, or (ii) is
          conducting a Phase III clinical trial evaluating a Competing Product
          with endpoints designed to position the Competing Product as a
          substitute product for such Licensed Product. For purposes of this
          Section 7.2, a "Competing Product" means a product that satisfies both
          of the following: (i) it is or will be labeled for the treatment of
          the same Tumor Type as the relevant Licensed Product, and (ii) it is
          or will be marketed as a substitution for the such Licensed Product in
          the United States.

                                       36

<PAGE>

     7.3  Genentech's Option to Co-Promote Competing Products. If Dendreon
          satisfies the criteria in Section 7.2, to the reasonable satisfaction
          of Genentech, to co-promote a Monoclonal or SM Product and Dendreon
          desires to so co-promote such Monoclonal or SM Product, but Dendreon
          is engaged in the development or commercial sale of a Competing
          Product(s) (as defined in Section 7.2 above) then Genentech shall have
          a right of first refusal to co-promote such Competing Product(s) on
          the same terms and conditions and in the same territory as proposed in
          a bona fide offer by a Third Party. Dendreon shall provide Genentech
          with thirty (30) days written notice of a bona fide offer to so
          co-promote, describing the financial and other general terms of such
          offer and providing summary information about such Competing Product
          sufficient to evaluate the efficacy and safety of such Competing
          Product. Genentech shall have thirty (30) days from the date of
          receipt of such notice and such information and data to agree to
          co-promote the Competing Product(s) upon the financial and other
          general terms specified in the notice by giving written notice to
          Dendreon. If Genentech elects not to exercise its right of first
          refusal, Dendreon shall have one hundred eighty (180) days thereafter
          to enter into an agreement with the Third Party upon terms
          substantially the same as those described in the notice to Genentech.
          In no event may Dendreon enter into such an agreement with a Third
          Party on terms that are, considered as a whole, materially less
          favorable to Dendreon than those proposed to Genentech above. If
          Dendreon has not entered into such an agreement within said one
          hundred eighty (180) day period, Dendreon shall not thereafter enter
          into an agreement with a Third Party to co-promote a Competing
          Product(s) without providing Genentech with a right of first refusal
          as described above. If Genentech elects not to enter into an agreement
          with Dendreon to co-promote such Competing Product upon such terms, or
          as long as Dendreon conducts development of, or sells, such Competing
          Product with or without any Third Party, then Dendreon shall not have
          the right to co-promote a Monoclonal or SM Product hereunder with
          which the Competing Product competes, as defined in Section 7.2 above.

     7.4  Commercialization Plans. For each Monoclonal or SM Product, all
          commercialization activities in the United States shall be conducted
          in accordance with a written five-year commercialization plan and an
          annual commercialization plan and budget to be prepared by Genentech
          (each a "Commercialization Plan") and approved by the JSC. Within
          sixty (60) days after NDA or BLA submission, Genentech shall submit to
          the JSC a five year Commercialization Plan, including budget, for the
          commercialization of the relevant Licensed Product in the United
          States. Thereafter, Genentech shall update such Commercialization Plan
          and present the updated plan to the JSC on a yearly basis as follows:
          an updated life cycle plan by the end of the first calendar quarter,
          an updated three year brand plan by the end of the third calendar
          quarter, and an updated annual tactical plan and budget by the end of
          the fourth calendar quarter. A Commercialization Plan shall address
          all overall activities that contribute to the successful marketing and
          commercialization of a Monoclonal or SM Product including, without
          limitation, overall budgets, product positioning, pre-launch
          preparation, launch of the product, ongoing marketing and commercial
          development, and forecasting, promotion, label expansion, regulatory
          strategy and the like.

     7.5  Commercialization Efforts. Each Party, to the extent that such Party
          is participating in the marketing of Monoclonal or SM Products, shall
          use Commercially Reasonable and Diligent Efforts in marketing such
          Monoclonal or SM Products in the United States in accordance with the
          relevant Commercialization Plan.

                                       37

<PAGE>

     7.6  Additional Genentech Responsibilities. Notwithstanding any
          co-promotion of Licensed Product by Dendreon under Section 7.2 and the
          activities of the JSC and JPT under Sections 7.1 and 7.4 above,
          Genentech shall be responsible for the design of promotional
          materials, shall file such promotional materials with the FDA as
          required under applicable law, and shall be designated by Dendreon as
          the Party responsible for filing such materials. Further, subject to
          Section 2.18,Genentech will have primary responsibility for and final
          approval of any and all activities that are regulated by FDA
          regulations, guidelines or oversight. Genentech will also be solely
          responsible for the following activities with respect to a Licensed
          Product: sales training, market research, tactical plans, booking
          sales, handling all returns, handling all aspects of order processing,
          invoicing and collection, receivables, providing customer medical
          information, collection of data of sales to hospitals and other end
          users, distribution, inventory, data collection and warehousing.

     7.7  Commercialization Costs. Except as otherwise provided herein, if
          Dendreon has elected to share in Operating Profits and Losses for
          Licensed Product pursuant to Section 2.14 above, all costs related to
          the commercialization of such Monoclonal or SM Product in the United
          States shall be shared by the Parties as provided in Exhibit B.

     7.8  Trademarks and Domain Names.

          7.8.1 Single Product Trademark. It is the intent of the Parties that a
          single product trademark shall be developed for use on and in
          connection with Licensed Products in the United States ("Product
          Trademark"). Genentech shall develop a Product Trademark for each
          Licensed Product before Regulatory Approval of such product in the
          United States and shall reasonably consider Dendreon's comments and
          suggestions thereon. Genentech shall be responsible for all activities
          necessary or desirable to procure and maintain the trademark
          registration of such Product Trademark in the United States, and any
          other Licensed Product trademarks in each country in the Territory
          outside of the United States, and any corresponding domain names and
          domain name registrations. Genentech shall exclusively own the Product
          Trademark, and any other trademarks, for Licensed Products in all
          countries in the Territory and any domain names. If Dendreon is
          participating in the Profit/Loss sharing under Exhibit B, the costs
          for such procurement and maintenance of trademark and domain name
          registration in the United States shall be a Trademark Cost under
          Exhibit B.

          7.8.2 Acknowledgment of Ownership Rights. Dendreon acknowledges and
          agrees that all use of the Product Trademarks hereunder by Dendreon
          will inure to the exclusive benefit of Genentech, the owner of Product
          Trademarks. Dendreon undertakes to make use of the Product Trademarks
          in such a way that the ownership rights of Genentech in said marks
          will not be jeopardized or compromised. Dendreon shall not use the
          Product Trademarks as all or part of any corporate name, trade name,
          trademark, service mark, certification mark, collective membership
          mark, domain name, or any other designation confusingly similar to the
          Product Trademarks in any way that damages the Product Trademarks. If
          any application for registration is or has been filed on the behalf of
          Dendreon in any country and relates to any mark which, in the
          reasonable opinion of Genentech, is confusingly similar, deceptive, or
          misleading with respect to, or dilutes or in

                                       38

<PAGE>

          any other way damages the Product Trademarks, Dendreon shall, at
          Genentech's request, abandon all use of such mark and any registration
          or application for registration. If Dendreon declines to do so, the
          Party prevailing in any opposition or related proceeding instigated by
          Genentech or its authorized representative thereafter in response to
          such filing shall be entitled to reimbursement from the other Party
          for its costs and expenses, including reasonable attorneys' fees.

          7.8.3 Use of Trademark Designations. Dendreon agrees to use its
          commercially reasonable best efforts to use the(TM)designation in
          conjunction with Dendreon's use of the Product Trademarks as permitted
          hereunder within the United States until such time as U.S.
          registrations issue. Once the U.S. registrations issue, Dendreon
          agrees to use the(R) designation with Dendreon's uses hereunder of the
          Product Trademarks.

          7.8.4 Infringement of Product Trademarks. Each Party shall notify the
          Joint Project Team promptly upon learning of any actual, alleged or
          threatened infringement of a Product Trademark applicable to a
          Licensed Product in the Territory, or of any unfair trade practices,
          trade dress imitation, passing off of counterfeit goods, or like
          offenses in the Territory. Genentech shall have the sole and exclusive
          right to enforce the Product Trademarks. If the Parties share
          Operating Profits and Losses for a Licensed Product, all of the costs,
          expenses and legal fees in bringing, maintaining and prosecuting any
          action to maintain, protect or defend a Product Trademark for such
          Licensed Product in the United States shall be Trademark Costs shared
          in accordance with Exhibit B. Any recovery from such action(s) shall
          be Other Income, which shall be shared by the Parties in accordance
          with Exhibit B. If the Parties are not sharing Operating Profits and
          Losses for a Licensed Product in the United States and in all cases of
          infringement in the Territory outside the United States, all such
          costs with respect to such Licensed Product shall be borne solely by
          Genentech and all such recoveries shall be retained solely by
          Genentech.

     7.9  Manufacture and Supply.

          7.9.1 Clinical Supply. Dendreon shall provide or cause to be provided,
          at its cost, all Small Molecules for the completion of its Preclinical
          Plan. Dendreon may enter into one or more manufacturing and supply
          agreement(s) with a Third Party contract manufacturer(s) covering the
          manufacture, supply and quality control of such Small Molecules. If an
          agreement with a Third Party contract manufacturer will include
          Clinical Supply, such Third Party contract manufacturer(s), and
          manufacturing and supply agreement, shall be submitted to the JSC for
          review and approval prior to execution of such agreement.

          7.9.2 Clinical Supply for Monoclonal Antibodies. Genentech shall
          provide or cause to be provided, at its cost, all supplies of
          Monoclonal Antibodies for the completion of its Preclinical Plan, and
          all Clinical Supply of SM Product and Monoclonal Product for all
          Clinical Trials hereunder at its sole expense; provided, however, that
          Dendreon shall share in the costs of Clinical Supply for Phase III
          Clinical Trials for a Monoclonal or SM Product if it elects to share
          Dendreon/GNE Development Costs and Operating Profits and Losses for
          such Monoclonal or SM Product pursuant to Section 2.14. As shall be

                                       39

<PAGE>

          addressed in the Clinical Supply Agreement, it is the intention of the
          Parties that process development and other activities related to scale
          up to manufacture of Commercial Supply of Monoclonal Product and SM
          Product in the United States will be completed prior to the
          commencement of Phase III Clinical Trials for each Licensed Product.
          As long as Genentech is providing Clinical Supply of a SM Product or
          Monoclonal Product for Clinical Trials hereunder, Genentech will
          supply Clinical Supply of the same SM Product or Monoclonal Product in
          amounts agreed upon by the Parties for Dendreon and Dendreon's
          licensees' clinical trials in the Dendreon Territory. The detailed
          terms of the supply by Genentech of Clinical Supply will be governed
          by a manufacturing and supply agreement negotiated in good faith and
          entered into between the Parties (the "Clinical Supply Agreement") as
          soon as practicable after the execution of this Agreement.

          7.9.3 Commercial Supplies. Genentech shall be responsible for
          establishing a commercial manufacturing process and for supplying or
          causing to be supplied Commercial Supply of SM and Monoclonal
          Products, at the scale and in the amounts required to meet demand for
          such products in the Territory. As long as Genentech is manufacturing
          a Monoclonal or SM Product for commercial sale in the Territory,
          Genentech will be responsible for supplying Commercial Supply of such
          Monoclonal Product or SM Product for Dendreon and its licensees in the
          Dendreon Territory, in quantities to be agreed upon by the Parties.
          The detailed terms of the supply by Genentech of Commercial Supply
          will be governed by a manufacturing and supply agreement (the
          "Commercial Supply Agreement") and a quality assurance/quality control
          agreement (the "Quality Agreement"), each negotiated in good faith and
          entered into between the Parties prior to the end of the first Phase
          III Clinical Trials hereunder. Genentech may enter into a supply
          agreement with a Third Party contract manufacturer (which may be the
          same manufacturer used by Dendreon for preclinical supplies) covering
          the manufacture, supply and quality control of Commercial Supply as
          soon as practicable after the JSC has determined that a Phase II
          Clinical Trial is a Pivotal Trial or at the end of Phase III Clinical
          Trials. A proposed contract manufacturing agreement shall be submitted
          to the JSC for review and comment prior to execution. Genentech shall
          give reasonable consideration to the views of the Dendreon members of
          the JSC with respect to the selection of the contract manufacturer and
          the financial and other terms of the agreement, but the final decision
          on contract manufacturer and such contract terms shall be made by
          Genentech.

          7.9.4 Cost for Dendreon Territory. The costs to Dendreon for Clinical
          and Commercial Supply of Monoclonal Product and SM Product in the
          Dendreon Territory shall be Genentech's Fully Burdened Manufacturing
          Costs plus [...***...].

8.   Inventions and Infringement.

     8.1  Inventorship and Ownership.

          8.1.1 Inventorship. Inventorship of Collaboration Inventions shall be
          determined in accordance with the U.S. patent laws. Each Party's
          patent counsel shall determine inventorship, and in the case of
          disagreements regarding inventorship, the Parties shall refer the same
          to mutually acceptable outside counsel. All such determinations shall
          be

                                             ***Confidential Treatment Requested

                                       40

<PAGE>

          documented to ensure that any patent applications reflect appropriate
          inventorship and that inventions and patent rights are assigned to the
          appropriate Party under Section 10.8. Each Party will promptly
          disclose to the other all Collaboration Inventions made by it during
          the Term of this Agreement. Subject to Section 8.1.2 below, as between
          the Parties, Dendreon shall own all Dendreon Collaboration Inventions,
          Genentech shall own all Genentech Collaboration Inventions, and Joint
          Collaboration Inventions shall be jointly owned by Dendreon and
          Genentech. Subject to Section 8.1.2 below, Dendreon and Genentech each
          shall require all of their respective employees and consultants to
          assign all Collaboration Inventions made by them during the Term of
          this Agreement to Dendreon or to Genentech, respectively, as the case
          may be.

          8.1.2 Collaboration Invention Patents. Notwithstanding the foregoing,
          and subject to the provisions of Section 10.10 below, any
          Collaboration Invention that is the subject of a patent application or
          patent and that is made solely by employee(s) or consultant(s) of
          Dendreon or solely by employee(s) or consultant(s) of Genentech or
          jointly by employee(s) or consultant(s) of both Dendreon and Genentech
          shall be jointly owned by Dendreon and Genentech during the Term of
          this Agreement; provided, however, that the Party whose employee(s)
          were not named inventors shall not assign, license, sublicense,
          transfer, or otherwise dispose of or encumber any portion of its
          interest in any such jointly owned Collaboration Invention Patent
          Rights without the prior written consent of the other Party, which
          consent shall be at such other Party's sole discretion Dendreon and
          Genentech each shall require all of its employees and consultants to
          assign all Collaboration Inventions made by them during the Term of
          this Agreement that are the subject of patent applications to Dendreon
          and Genentech as joint owners.

     8.2  Restrictions on Jointly-Owned Collaboration Inventions. During the
          Term of this Agreement, neither Party shall, in the Territory, license
          (except to the other Party pursuant to the license grant under Article
          5 above), sublicense, assign, dispose of, encumber or otherwise impair
          any portion of its interest in any jointly owned Collaboration
          Invention, other than as permitted under Article 5 to a permitted
          sublicensee hereunder for purposes of such sublicense or to a
          Permitted Assignee hereunder, without the prior written consent of the
          other Party in its sole discretion.

     8.3  Prosecution and Maintenance of Genentech Patent Rights, Dendreon
          Patent Rights and Vaccine Product Patent Rights. Genentech shall have
          the sole responsibility to file, prosecute, defend and maintain
          Genentech Patent Rights worldwide and shall bear all expenses
          associated therewith, and Dendreon shall have the sole responsibility
          to file, prosecute, defend and maintain Dendreon Patent Rights and
          Vaccine Product Patent Rights worldwide and shall bear all expenses
          associated therewith.

     8.4  Prosecution and Maintenance of Collaboration Invention Patent Rights.

          8.4.1 Coordination. The Parties intend to prosecute and manage
          Collaboration Invention Patent Rights on a coordinated basis so that
          such Collaboration Invention Patent Rights provide the broadest
          possible protection for Licensed Products. To that end, the Parties
          will share information and each Party will consider the views of the
          other Party

                                       41

<PAGE>

          with respect to the scope of claims and decisions regarding the
          prosecution and maintenance of Collaboration Invention Patent Rights,
          to the extent possible. The Parties' patent counsel will regularly
          review with the Parties the status of all pending applications and
          issued patents within Collaboration Invention Patent Rights.

          8.4.2 Outside Counsel. Outside counsel mutually acceptable to
          Genentech and Dendreon shall have the responsibility to file,
          prosecute and maintain Collaboration Invention Patent Rights. Such
          outside counsel shall respond to both Parties' reasonable requests for
          information about the course of patent prosecution or other
          proceedings relating thereto, shall provide both Parties with copies
          of all communications relating thereto with a patent office, and shall
          reasonably and equally consider comments by both Parties thereon. The
          Parties shall cooperate reasonably in the prosecution thereof and
          shall share all material information relating thereto promptly after
          receipt of such information. Neither Party shall make a submission to
          a patent office that could materially affect the scope or validity of
          the patent coverage of any Collaboration Invention Patent Rights
          without providing a reasonable opportunity to the other Party to
          comment upon such submission. Notwithstanding the provisions of
          Exhibit B hereto, the expenses for such outside counsel and all
          filing, issue, maintenance and other fees and other costs of filing,
          prosecution and maintenance of Collaboration Invention Patent Rights
          shall be borne by the Parties in equal shares.

          8.4.3 SM Products. In the event Genentech does not exercises its
          option pursuant to Section 2.6 with respect to SM Products, then,
          effective upon the expiration of the option exercise period therein,
          Genentech hereby (i) assigns to Dendreon all of its right, title and
          interest in and to any Collaboration Invention Patent Rights Covering
          Dendreon Collaboration Inventions to the extent that they cover Small
          Molecules or SM Products and (ii) will grant to Dendreon a
          nonexclusive, world-wide license with right to sublicense through
          multiple tiers of sublicensees under Genentech's interest in Joint
          Collaboration Inventions and Genentech's Collaboration Inventions to
          the extent Covering Small Molecules or SM Products. Such nonexclusive
          license shall be royalty-bearing and subject to commercially
          reasonable terms to be negotiated by the Parties. Thereafter, Dendreon
          shall have the sole responsibility to file, prosecute, defend and
          maintain Collaboration Invention Patent Rights to the extent solely
          Covering Small Molecules and SM Products using outside patent counsel
          in accordance with the terms of Section 8.4.2 and shall bear all
          expenses associated therewith. Thereafter, the restrictions set forth
          in Section 8.2 shall no longer apply to jointly owned Collaboration
          Inventions Covering Small Molecules and SM Products.

          8.4.4 Abandonment. If a Party elects not to participate in the filing,
          prosecution or maintenance, or to otherwise abandon, any Joint Patent
          Rights (the "Abandoning Party") in a country for which the Parties had
          agreed to so file and prosecute the Joint Patent Rights, it shall
          notify the other Party. Thereafter, the other Party shall have the
          right to pursue, at its expense and sole discretion, prosecution or
          maintenance of such Joint Patent Rights in the relevant country using
          outside counsel in accordance with the terms of Section 8.4.2.

                                       42

<PAGE>

     8.5  Patent Interferences. In the event that an interference is declared by
          the U.S. Patent and Trademark Office (i) between (a) a claim in one or
          more patents or patent applications within the Dendreon Patent Rights
          and (b) a claim in one or more patents or patent applications within
          the Genentech Patent Rights, or (ii) between (a) or (b) above and (c)
          one or more patents or patent applications within the Joint Patent
          Rights, then the Parties shall in good faith establish within thirty
          (30) days of the declaration of such interference or such other time
          as agreed upon a mutually agreeable process to resolve such
          interference in a reasonable manner in conformance with all applicable
          legal standards

     8.6  Patent Enforcement.

          8.6.1 Notice. Each Party shall promptly notify the other Party in
          writing of any alleged infringement of which it becomes aware, of any
          intellectual property right licensed or sublicensed to a Party under
          this Agreement setting forth the facts of such alleged infringement
          known to the reporting Party with reasonable specificity.

          8.6.2 Enforcement of Genentech Patent Rights, Dendreon Patent Rights
          and Vaccine Product Patent Rights. Genentech shall have the sole
          responsibility to enforce Genentech Patent Rights worldwide and shall
          bear all expenses associated therewith, and Dendreon shall have the
          sole responsibility to enforce Dendreon Patent Rights and Vaccine
          Product Patent Rights worldwide and shall bear all expenses associated
          therewith. In the event of an alleged infringement of Dendreon Patent
          Rights, or in the event of an alleged infringement of Vaccine Product
          Patent Rights directly relating to Licensed Trp-p8 Vaccine Products
          after Genentech and Dendreon have entered into an agreement as
          contemplated in Section 2.7, Dendreon declines to enforce such
          Dendreon Patent Rights or Vaccine Product Patent Rights to abate the
          alleged infringement and such infringement causes a loss of net
          profits with respect to one or more Licensed Products in the Territory
          sold by Genentech or its sublicensees (and Dendreon if co-promoting
          hereunder), then Dendreon will reimburse Genentech for [...***...] of
          such loss as established by Genentech. Dendreon's reimbursement for
          such loss of net profits in any calendar year may first be paid by
          deduction from Dendreon's share of Operating Profits for such calendar
          year, with any remaining balance to be reimbursed for that calendar
          year to be paid to Genentech in cash within the following calendar
          year. If Dendreon is not sharing in Operating Profits at the time such
          reimbursement is payable to Genentech and in all cases in which
          Genentech establishes a loss of net profits in a country in the
          Territory other than the United States, Dendreon's reimbursement for
          such loss of net profits in any calendar year may first be paid by
          deduction from the royalties due to Dendreon under Section 6.5 for
          such calendar year, with any remaining balance to be reimbursed for
          that calendar year to be paid to Genentech in cash within the
          following calendar year.

          8.6.3 Enforcement of Collaboration Invention Patent Rights. Upon
          notice of an alleged infringement of Collaboration Invention Patent
          Rights, the Parties shall discuss in good faith and endeavor to reach
          consensus within a reasonable time upon an appropriate course of
          action to further the objectives of the Parties under this Agreement.
          Notwithstanding such discussions, Genentech shall have the right, but
          not the obligation, to take such steps as it shall deem appropriate in
          its sole discretion to cause an infringement of a Collaboration
          Invention Patent Right to abate, at its own expense and by counsel of

                                             ***Confidential Treatment Requested

                                       43

<PAGE>

          its choice, unless the Parties agree that no such steps are in their
          mutual best interests in light of their objectives under this
          Agreement. Such steps may include, but are not limited to, commencing
          a suit, proceeding or other legal action or initiating licensing
          discussions with the alleged infringer. If the infringed patent within
          the Collaboration Invention Patent Rights Covers a Licensed Product
          and Genentech fails to take commercially appropriate steps to abate
          the infringement within four (4) months following the date of the
          first discussion between the Parties regarding such infringement, then
          Dendreon shall have the right to take such steps as it shall deem
          appropriate in its sole discretion to abate such infringement at its
          own expense. If Genentech has commenced negotiations with an alleged
          infringer within such four (4) month period, Genentech will have an
          additional six (6) months to conclude its negotiation before Dendreon
          may take steps to abate such infringement.

          8.6.4 Collaboration Invention Patent Rights related to Small Molecules
          or SM Licensed Product. If Genentech does not exercise its option to
          SM Products under Section 2.6, Dendreon shall have the sole
          responsibility to enforce Collaboration Invention Patent Rights to the
          extent Covering solely Small Molecules and SM Products and shall bear
          all expenses associated therewith.

          8.6.5 Initiating Party for Collaboration Invention Enforcement. The
          Party initiating any legal action under Section 8.6.3 shall be termed
          the Initiating Party. The other Party shall fully cooperate with the
          Initiating Party in any steps taken to abate infringement, as
          applicable. Such cooperation shall include providing access to
          documents and personnel, and providing testimony and such other
          assistance, as the Initiating Party shall reasonably request, all of
          which shall be at the other Party's sole cost and expense. In
          addition, such other Party will, at its own expense, join in any such
          infringement action taken by the Initiating Party if required in order
          to enable such infringement action to be taken. The other Party shall
          have the right, at its own expense, to be represented in any such
          action by counsel of its choice.

          8.6.6 Control of Collaboration Invention Patent Action. The Initiating
          Party under Section 8.6.5 shall have full control of the steps taken,
          including prosecution of any action, to abate the infringement;
          provided, however, that the Initiating Party shall consider the
          interests of the other Party and shall not settle or consent to an
          adverse judgment in any action that would have a material adverse
          effect on the rights or interest of the other Party without its prior
          express written consent. Such consent shall not be unreasonably
          delayed or denied. Any damages, including punitive or other
          noncompensatory damages actually received from a Third Party shall
          first be applied to reimburse the Initiating Party for its incurred
          expenses, including reasonable attorney's fees and expert witness
          fees, and then to reimburse the other Party for such expenses, if any.
          The reimbursement shall first be made from any compensatory damages,
          including attorneys' fees and costs recovered. If any balance of the
          sum recovered from the Third Party remains, compensatory damages shall
          be deemed to be "Other Income/Expense" to the extent the Parties share
          Profits and Losses under this Agreement or Net Sales in the event that
          Genentech pays royalties to Dendreon in the country in which such
          enforcement action was taken. Any noncompensatory damages remaining
          shall be the property of the Initiating Party.

                                       44

<PAGE>

     8.7  Defense of a Claim of Infringement by Licensed Product

          8.7.1 Third Party Claims. If a claim of infringement is brought by a
          Third Party against a Party on account of the use, sale, offer for
          sale or import (the manufacture) of any Licensed Product, the Parties
          shall establish a plan for a common defense.

          8.7.2 Defense of Claims.

          (a)  If Dendreon has elected to share in Profit/Losses for a Licensed
               Product pursuant to Section 2.14 above and the Third Party has
               brought a claim of infringement in the United States, then the
               costs of any such action incurred by one or both of the Parties
               (including the costs of any judgment, award, decree or
               settlement) will be included in Other Operating Income/Expense in
               accordance with Exhibit B. If Dendreon has not elected to share
               in the Profits/Losses hereunder or the claim for infringement is
               in a country in the Territory other than the United States, then
               the Party responsible for implementing the plan of defense (the
               "Defending Party") shall pay for its expenses incurred and the
               other Party shall fully cooperate at its own expense. Cooperation
               shall include providing access to documents and personnel,
               providing testimony, and providing such other assistance as the
               Defending Party reasonably requests.

          (b)  The Defending Party shall not consent to a judgment or settlement
               that would materially impair the financial and other interests of
               the other Party under this Agreement without the other Party's
               consent, which shall not be unreasonably delayed or denied. If
               damages, including punitive or other non-compensatory damages are
               paid by the Third Party, they shall first be applied to reimburse
               the Defending Party for its incurred expenses, including
               reasonable attorney's fees and expert witness fees, and then to
               reimburse the other Party for such expenses. Such reimbursement
               shall first be made from any compensatory damages, including
               attorneys' fees and costs, recovered. If any balance of the sum
               recovered from the Third Party remains, compensatory damages
               shall be deemed to be "Other Income/Expense" if Dendreon is
               sharing Operating Profits and Losses with respect to the Licensed
               Product in the country at issue or Net Sales if Dendreon is not.
               Any remaining punitive or noncompensatory damages shall be the
               property of the Party that was the counterclaim plaintiff on the
               counterclaim that resulted in the recovery of damages. If the
               proceeding results in a settlement or judgment in favor of the
               Third Party, then any license fees or other amounts, including
               compensatory and noncompensatory damages, paid to such Third
               Party shall be "Other Operating Income/Expense" if the Parties
               are sharing Operating Profits and Losses with respect to the
               Licensed Product in the relevant country or a deduction from Net
               Sales (subject to the limitation in Section 6.5(b)) if they are
               not.

     8.8  Third Party Patents and Royalties. Except as provided in Section
          2.5.4, the Parties shall cooperate to obtain any license(s) under any
          Third Party patent(s) that the Parties jointly determine are necessary
          or desirable to manufacture, use, sell, offer for sale or import a
          Licensed Product in the United States. Any license fees, milestones or
          other costs of such license(s) in the United States for a Monoclonal
          Antibody, Small Molecule or Licensed Product incurred during the
          Preclinical Program for such Monoclonal Antibody, Small

                                       45

<PAGE>

          Molecule or Licensed Product shall be paid during such Preclinical
          Program by Party responsible for the costs of such Preclinical Program
          under Sections 2.8.1 and 2.8.2 above. Any license fees, milestones or
          other costs of such license(s) for a Licensed Product in the United
          States incurred during Phase I and Phase II Clinical Trials for such
          Licensed Product shall be shared during such Clinical Trials as the
          Parties shall agree until such time as Dendreon elects to share in
          DENDREON/GNE Development Costs and Operating Profit and Loss pursuant
          to Section 2.14 for such Licensed Product. At that time, any fees,
          milestones royalty payments, and other license costs will be included
          in Other Operating Income/Expense or Fully Burdened Manufacturing
          Costs, as the case may be, in accordance with Exhibit B. If Dendreon
          elects not to share in Operating Profit and Loss pursuant to Section
          2.14 with respect to such Licensed Product, any royalties payable on
          account of such license may be deducted from royalties otherwise due
          to Dendreon upon sales of such Licensed Product in the United States,
          subject to the limitations in Section 6.5(b). At all times, Genentech
          may enter into a license with a Third Party applicable to the
          manufacture, use, sale, offer for sale, or import of a Licensed
          Product in the Territory outside the United States without the consent
          or agreement of Dendreon, and all costs of any such license shall be
          borne solely by Genentech; provided however, that royalties payable
          under such license may be deducted from royalties due to Dendreon upon
          the sale of such Licensed Product in the Territory outside the United
          States, subject to the limitations in Section 6.5(b).

9.   Representation, Warranties and Indemnities.

     9.1  Dendreon's Representations and Warranties. Dendreon represents and
          warrants to Genentech the following as of the Effective Date:
          (a)  Dendreon has all necessary rights, powers and authorities to
               enter into this Agreement and to grant to Genentech the license
               rights herein.
          (b)  Dendreon's performance under this Agreement does not conflict
               with or create a breach or a default of any law or order of a
               court or governmental agency applicable to Dendreon, or any
               contract or other obligation of Dendreon to any Third Party.
          (c)  Dendreon has not, and until the expiration or earlier termination
               of this Agreement will not, grant any rights related to Licensed
               Products to any Third Party that would conflict with the rights
               granted to Genentech hereunder.

     9.2  Genentech's Representations and Warranties. Genentech represents and
          warrants to Dendreon the following as of the Effective Date:

          (a)  Genentech has all necessary rights, powers and authorities to
               enter into this Agreement.
          (b)  Genentech's performance under this Agreement does not conflict
               with or create a breach or a default of any law or order of a
               court or governmental agency applicable to Genentech, or any
               contract or other obligation of Genentech to any Third Party.

                                       46

<PAGE>

          (c)  Genentech has not, and during the expiration or earlier
               termination of the Agreement will not, grant any rights related
               to Licensed Products that would conflict with the rights granted
               to Dendreon hereunder.

     9.3  Disclaimers. Each Party expressly disclaims and does not represent,
          warrant or otherwise covenant to the other Party that:

          (a)  its rights under the Patent Rights will not be held invalid or
               unenforceable (in whole or in part) or that the Patent Rights
               will be of any particular scope or that the Patent Rights will be
               prosecuted, maintained, defended or enforced; or
          (b)  its right under the Patent Rights will not be infringed by a
               Third Party; or
          (c)  the exploitation or use by the other Party of the Patent Rights,
               including the contemplated commercialization of Patent Rights,
               will not interfere with or infringe any patent or other
               intellectual property rights of any Third Party; or
          (d)  the activities or products under this Agreement Covered by the
               Patent Rights will give any results in terms of merchantability,
               fitness, precision, accuracy, sensitivity, safety, efficacy or
               therapeutic, diagnostic or prognostic effect of any kind.

     9.4  EXCEPT AS EXPRESSLY SET FORTH HEREIN EACH PARTY DISCLAIMS ALL
          WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF
          MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT LICENSED
          PRODUCTS WILL NOT INFRINGE ANY PATENTS.

     9.5  Dendreon's Indemnities. Dendreon shall defend, indemnify, and hold
          harmless Genentech and its officers, directors, employees, and agents
          from any and all claims, suits, actions, demands, penalties, fines,
          costs, damages, expenses, fees, injuries, liabilities and losses,
          including reasonable attorneys' fees incurred to a Third Party
          (collectively "Losses") arising out of or related to:

          (a)  the negligence or willful misconduct, including acts of omission,
               by Dendreon relating to this Agreement; or
          (b)  a material breach by Dendreon of this Agreement or Dendreon's
               representations and warranties; or
          (c)  any failure by Dendreon or its licensees, sublicensees or
               contractors (other than Genentech), in the course of conducting
               activities under this Agreement, to comply with applicable
               governmental laws or regulations; or
          (d)  the use, handling, storage, distribution, promotion,
               manufacturing, marketing, sale or other commercialization of
               Licensed Product by Dendreon, its licensees, sublicenses or
               contractors (other than Genentech) in the United States and the
               Dendreon Territory.

          Provided, however, that Dendreon's obligation to indemnify under this
          Section 9.5 shall not extend to Losses that arise from the negligence
          or willful misconduct of Genentech, its breach of any provision of
          this Agreement or its representations and warranties, or the failure
          to comply with applicable laws or regulations by Genentech or its
          sublicensees or contractors. Further, Dendreon's obligation to
          indemnify Genentech under Section 9.5(d)

                                       47

<PAGE>

          shall not extend to Losses to the extent arising out of activities for
          which Genentech is obligated to indemnify Dendreon, if any, under the
          Clinical Supply Agreement or Commercial Supply Agreement.

     9.6  Genentech's Indemnities. Genentech shall defend, indemnify and hold
          harmless Dendreon and its officer, directors, employees and agents
          from any and all Losses arising out of or related to:

          (a)  negligence or willful misconduct, including acts of omission, by
               Genentech relating to this Agreement; or
          (b)  a material breach by Genentech of this Agreement or Genentech's
               representations and warranties; or
          (c)  any failure by Genentech or its licensees, sublicensees or
               contractors (other than Dendreon), in the course of conducting
               activities under this Agreement, to comply with applicable
               governmental laws or regulations; or
          (d)  the use, handling, storage, distribution, promotion, marketing,
               sale or other commercialization of Licensed Product by Genentech
               or its licensees, sublicensees or contractors (other than
               Dendreon) in the Territory.

          Provided, however, that Genentech's obligation to indemnify shall not
          extend to Losses that arise from the negligence or willful misconduct
          of Dendreon, its breach of any provision of this Agreement or its
          representations and warranties, or the failure to comply with
          applicable laws or regulations by Dendreon or its sublicensees or
          contractors (other than Genentech). In addition, Genentech's
          obligations to indemnify Dendreon under Section 9.6(d) shall not apply
          to the Losses arising from the use, handling, storage, distribution,
          promotion, marketing, sale or other commercialization of a Licensed
          Product in the United States if such Losses are charged to the
          collaboration in accordance with Section 9.9 below.

     9.7  Indemnity Conditions. The indemnification of the Parties above shall
          apply only if the following conditions are met. Promptly after
          becoming aware of a claim, the indemnified Party shall provide written
          notice to the indemnifying Party. Delay in providing such notice shall
          relieve the indemnifying Party of its indemnity obligations only if
          the indemnifying Party's ability to defend against such claim is
          thereby materially impaired. The indemnifying Party shall have the
          right to assume and control the defense of the claim at its own
          expense. The indemnified Party shall have the right to participate in,
          but not to control, such defense at its own expense. If the
          indemnifying Party does not assume the defense of the claim, the
          indemnified Party may defend the claim at the indemnifying Party's
          expense. The indemnified Party shall not settle or compromise the
          claim without the prior written consent of the indemnifying Party, and
          the indemnifying Party shall not settle or compromise the claim in any
          manner that would have a material adverse effect on the indemnified
          Party without the prior written consent of the indemnified Party. No
          consent required hereunder shall be unreasonably withheld or delayed.
          The indemnified Party shall reasonably cooperate with the indemnifying
          Party and shall, at the indemnifying Party's expense, make available
          to the indemnifying Party all pertinent information in its possession
          or under its control.

                                       48

<PAGE>

     9.8  Insurance. Each Party shall procure and maintain at its own cost
          comprehensive general liability (including coverage for products and
          maintained for a period of at least five (5) years after the
          expiration or termination of this Agreement), product liability,
          clinical trial liability, and property and casualty insurance, or
          self-insurance, providing commercially reasonable coverage for their
          respective activities under this Agreement and their equipment,
          premises and businesses. Each Party will maintain foreign local
          coverage in the Territory or Dendreon Territory where required by
          foreign law in an amount that, at a minimum, satisfies the legal
          requirements of that jurisdiction. The insurance policies in the
          United States shall be with financially strong insurance carriers (AM
          Best Rating of "A: VIII" or higher) and will be primary to any other
          insurance owned, secured or in place by such Party. Each Party shall
          cause its insurance policies to be endorsed to provide for thirty (30)
          days prior written notice to the other by the insurance carrier of
          cancellation, expiration or modification of the insurance policy. Each
          Party will name the other Party as an additional insured under all
          such coverages and will furnish to the other Party the corresponding
          certificates of insurance that evidence the foregoing within thirty
          (30) days of the Effective Date.

     9.9  Other Liabilities. If Dendreon is participating in Operating Profit
          and Loss under Exhibit B for a Licensed Product, any Losses resulting
          directly or indirectly from the use, handling, storage, distribution,
          promotion, marketing, sale or other commercialization of such Licensed
          Product in the United States that do not fall within the scope of the
          Parties' respective indemnification obligations in Sections 9.5(a),
          (b) or (c) or 9.6(a), (b), or (c) shall be charged to the
          collaboration as an Other Operating Income/Expense at the time such
          Losses are incurred.

10.  Term and Termination.

     10.1 Term. The Term of this Agreement (the "Term") shall begin on the
          Effective Date and, unless earlier terminated as provided in Sections
          10.3, 10.4, or 10.5 below, shall end in each country in the Territory,
          on a Licensed Product-by-Licensed Product basis, as follows.

          (a)  Except for those Licensed Products for which Dendreon has elected
               to share in DENDREON/GNE Development Costs and Operating Profits
               and Losses in the United States under Section 2.14 above, this
               Agreement and the royalty obligations of Genentech under Section
               6.5 will expire with respect to each Licensed Product upon the
               later of (i) ten (10) years after the first commercial sale of
               such Licensed Product in such country, or (ii) the expiration of
               the last to expire of the issued patents within the Dendreon
               Patent Rights or Collaboration Invention Patent Rights Covering a
               Dendreon Collaboration Invention in such country that contains a
               Valid Claim that Covers such Licensed Product.
          (b)  If Dendreon has elected to share in DENDREON/GNE Development
               Costs and Operating Profits and Losses in the United States with
               respect to a Licensed Product under Section 2.14 above, this
               Agreement will expire with respect to such Licensed Product in
               the United States on the date on which such Licensed Product is
               no longer marketed by Genentech or the Parties in such country
               and the Parties are no longer entitled to receive a share
               Operating Profits and Losses hereunder with respect to such
               Licensed Product.

                                       49

<PAGE>

          (c)  Upon the expiration of the term of this Agreement with respect to
               a Licensed Product in each country, all licenses to Genentech
               hereunder in such country applicable to such Licensed Product
               shall become fully paid and irrevocable. Subject to the survival
               provisions of Section 10.8 below, after expiration of this
               Agreement with respect to a Licensed Product, all obligations of
               Dendreon and Genentech hereunder with respect to such Licensed
               Product will cease.

     10.2 Term of Licenses to Dendreon and Royalties to Genentech. Unless this
          Agreement is earlier terminated as provided in Sections 10.3, 10.4 or
          10.5 below, the license rights granted to Dendreon in the Dendreon
          Territory under Section 5.2(b), and the royalties payable to Genentech
          pursuant to Section 6.6-6.12 shall end, on a Licensed Product by
          Licensed Product basis in each country in the Dendreon Territory, upon
          the later of (a) ten (10) years after the first commercial sale of
          such Licensed Product in such country or (b) the expiration of the
          last to expire of the issued patents within the Genentech Patent
          Rights or Collaboration Invention Patent Rights Covering a Genentech
          Collaboration Invention in such country that contains a Valid Claim
          that Covers such Licensed Product.

     10.3 INTENTIONALLY OMITTED

     10.4 Early Termination By Genentech Without Cause.

          10.4.1 Termination Following Phase II Clinical Trials. During the
          sixty (60) day period following the first Completion of Phase II
          Clinical Trials, Genentech, by written notice to Dendreon, may elect
          to terminate this Agreement and the Clinical Supply Agreement (and
          Commercial Supply Agreement and Quality Agreement, if they have been
          entered into) with respect to any or all Licensed Products for any
          reason. Such termination shall be effective one hundred twenty (120)
          days thereafter and shall be subject to the following conditions:

          (a)  Genentech shall reimburse Dendreon for all of Dendreon's Clinical
               Trial Costs for Phase I and Phase II Clinical Trials for the
               Licensed Product(s) terminated.
          (b)  Upon request by Dendreon within thirty (30) days of receiving
               Genentech's termination notice, Genentech shall sell to Dendreon
               up to eighteen (18) months of inventory of Clinical Supply of
               such Licensed Product(s) manufactured by Genentech, at a price
               equal to Genentech's Fully Burdened Manufacturing Costs plus
               [...***...]. If, at the date of Dendreon's receipt of such notice
               of termination, Genentech's then existing inventory of such
               Licensed Product(s) is less than 18 months, Genentech shall
               manufacture such Clinichal Supply of Licensed Product(s) to
               enable it to deliver, together with the existing inventory, a
               total of such eighteen (18) month inventory at such price.
          (c)  The Parties shall cooperate to ensure an orderly assumption of
               sole responsibility by Dendreon for further development of such
               Licensed Product(s), to transfer INDs for Licensed Product to
               Dendreon, and shall use reasonable efforts during such transition
               to minimize adverse impacts upon patients, investigators, and the
               Parties.

                                             ***Confidential Treatment Requested

                                       50

<PAGE>

          (d)  To the extent it is contractually able to do so, Genentech shall
               assign to Dendreon any then-existing Third Party contracts that
               govern goods or services solely for such Licensed Product(s) and
               that are necessary for the development or sale of such Licensed
               Product(s).
          (e)  Genentech shall extend to Dendreon, promptly following delivery
               of its notice of termination, the opportunity to acquire a
               license, on commercially-reasonable terms, for: (i) Manufacturing
               Know How Controlled by Genentech, existing on the date of
               Genentech's termination notice, to the extent it is Know-how
               developed specifically to make such Licensed Product(s), (ii)
               Genentech Patent Rights existing on the date of Genentech's
               termination notice, to the extent solely Covering the manufacture
               of such Licensed Product(s), and (iii) Genentech's interest in
               Collaboration Inventions developed specifically to make such
               Licensed Product. Genentech also shall extend to Dendreon,
               promptly following delivery of its notice of termination, the
               opportunity to acquire a license for other Genentech Patent
               Rights and Know-How Controlled by Genentech directly related to
               manufacturing of such Licensed Product(s) and to the extent
               necessary to manufacture such Licensed Product(s), but only to
               the extent that such licenses are made available to similar Third
               Parties for similar products, at that time, and under terms
               similar to those offered to such Third Parties which, in any
               case, shall be commercially reasonable terms.
          (f)  The Parties effect the assignments required by Section 10.10 with
               respect to such Licensed Product(s).
          (g)  Effective upon the date of termination Genentech will grant to
               Dendreon an exclusive (except as to Genentech), worldwide
               royalty-bearing license on commercially reasonable terms, with
               the right to sublicense through multiple tiers of sublicense,
               under Genentech Patent Rights, Genentech Collaboration Inventions
               and Genentech's interest in Joint Patent Rights to the extent
               necessary to use, sell, offer for sale and import such Licensed
               Product(s) then in existence or thereafter developed.
          (h)  Dendreon shall have the perpetual right to reference and the
               right to rely upon the Regulatory Filings for Licensed Product
               made by Genentech.

          10.4.2 Termination Following Phase III Clinical Trials. At any time
          following the first Completion of Phase III Clinical Trials, Genentech
          may, upon written notice to Dendreon, elect to terminate this
          Agreement and the Clinical Supply Agreement (and Commercial Supply
          Agreement and Quality Agreement, if they have been entered into) for
          any or all Licensed Product(s) for any reason. Such termination shall
          be effective one hundred twenty (120) days thereafter, and shall be
          subject to the following conditions:

          (a)  The JSC will cause to be developed for approval by the Parties a
               final financial statement with respect to such Licensed
               Product(s) in accordance with Exhibit B and/or the Parties will
               prepare a final royalty report in accordance with Section 6.8, as
               applicable.

                                       51

<PAGE>

          (b)  Either Party may exercise any applicable audit rights with
               respect to such Licensed Product(s).
          (c)  The Parties shall cooperate to ensure an orderly assumption of
               sole responsibility by Dendreon for such Licensed Product(s) at
               the stage of development or commercialization at the time of
               termination, to transfer to Dendreon ownership of any Regulatory
               Filings for Licensed Product made by Genentech, and to use
               reasonable efforts during such transition to minimize any adverse
               impact upon patients and the Parties.
          (d)  Upon request by Dendreon within thirty (30) days of receiving
               Genentech's termination notice, Genentech shall sell to Dendreon
               its then existing inventory of such Licensed Product(s) for a
               price equal to its Fully Burdened Manufacturing Costs
               [...***...].
          (e)  If, on the date of Dendreon's receipt of such notice of
               termination, Genentech's then existing inventory is not
               sufficient to provide Dendreon a total of eighteen (18) months
               inventory of Licensed Product, Genentech shall manufacture such
               additional Licensed Product(s) to enable it to deliver, together
               with the existing inventory of such Licensed Product, a total of
               eighteen (18) months supply of each Licensed Product. The
               purchase price shall be Genentech's Fully Burdened Manufacturing
               Costs [...***...].
          (f)  To the extent it is contractually able to do so, Genentech shall
               assign to Dendreon any then-existing Third Party contracts that
               govern goods or services solely for such Licensed Product(s) and
               are necessary for the development or sale of such Licensed
               Product(s).
          (g)  Genentech shall extend to Dendreon, promptly following delivery
               of its notice of termination, the opportunity to acquire a
               license, on commercially-reasonable terms, for: (i) Manufacturing
               Know How Controlled by Genentech, existing on the date of
               Genentech's termination notice, to the extent it is Know-how
               developed specifically to make such Licensed Product(s), (ii)
               Genentech Patent Rights existing on the date of Genentech's
               termination notice, to the extent solely Covering the manufacture
               of such Licensed Product(s), and (iii) Genentech's interest in
               Collaboration Inventions developed specifically to make such
               Licensed Product. Genentech also shall extend to Dendreon,
               promptly following delivery of its notice of termination, the
               opportunity to acquire a license for other Genentech Patent
               Rights and Know-How Controlled by Genentech directly related to
               manufacturing of such Licensed Product(s) and to the extent
               necessary to manufacture such Licensed Product(s), but only to
               the extent that such licenses are made available to similar Third
               Parties for similar products, at that time, and under terms
               similar to those offered to such Third Parties which, in any
               case, shall be commercially reasonable terms.
          (h)  The Parties shall effect the assignments required by Section
               10.10 with respect to such Licensed Product(s).
          (i)  Effective upon the date of such termination, Genentech will grant
               to Dendreon an exclusive (except as to Genentech), worldwide,
               royalty-bearing license, on commercially reasonable terms, with
               the right to sublicense through multiple tiers of sublicense,
               under the Genentech Patent Rights, Genentech Collaboration
               Inventions and Genentech's interest in Joint Patent Rights to the
               extent necessary to use, sell, offer for sale and import such
               Licensed Product(s) then in existence or thereafter developed.

                                             ***Confidential Treatment Requested

                                       52

<PAGE>

          (j)    Dendreon shall have the perpetual right to reference and right
                 to rely upon the Regulatory Filings for Licensed Product made
                 by Genentech under this Agreement.

     10.5 Termination for Cause. Notwithstanding the Term, this Agreement and
          the licenses granted in Article 5 herein, may be terminated for cause
          by either Party as follows.

          10.5.1 Material Breach. Either Party (the "Initiating Party") may
          terminate this Agreement for material breach by the other Party (the
          "Responding Party") on sixty (60) days written notice describing the
          nature of the alleged breach unless, within such sixty (60) day
          period, the Responding Party cures or takes substantial steps to cure
          the alleged breach if it is susceptible to cure. If the alleged
          material breach is a failure to timely commence or complete
          responsibilities under a Preclinical Plan or for Clinical Trials and
          the Responding Party fails to so cure, then the Initiating Party, in
          addition to any other remedy it may have, may assume sole
          responsibility for the commencement or completion of such Preclinical
          Program or Clinical Trials.

          10.5.2 Bankruptcy. If a proceeding is commenced against a Party
          without the application or consent of the other Party and remains
          pending for a period of sixty (60) days that seeks (i) the
          liquidation, reorganization, dissolution or winding-up, or the
          composition or adjustment of the debts of such Party, (ii) the
          appointment of a trustee, receiver, custodian, or the like for such
          Party, or (iii) similar relief under any law relating to bankruptcy,
          insolvency, reorganization, or the composition or readjustment of
          debts, then the other Party may terminate this Agreement upon thirty
          (30) days written notice.

     10.6 Effect of Termination For Cause Under Section 10.5.

          10.6.1 Termination by Genentech. If Genentech terminates this
          Agreement for cause under Section 10.5.1 or 10.5.2 then the following
          shall apply:

          (a)    Effective upon the date of termination, Dendreon hereby grants
                 to Genentech a royalty-bearing license with the right to
                 sublicense through multiple tiers of sublicense under Dendreon
                 Collaboration Inventions, Dendreon Patent Rights, and
                 Dendreon's interest in Joint Patent Rights to make, have made,
                 use, sell, offer for sale and import Licensed Products in the
                 Territory in the Field. Such license shall be exclusive (even
                 as to Dendreon) as to all Licensed Products. Such license shall
                 bear a royalty of [...***...] and shall be subject to the
                 provisions of Sections 6.5, 6.7 - 6.12. The term of such
                 license and royalties shall be that described in Section
                 10.1(a) above.
          (b)    The JSC will cause to be developed for approval by the Parties
                 a final financial statement pursuant to Exhibit B and/or the
                 Parties shall prepare a final royalty report in accordance with
                 Section 6.8.
          (c)    Either Party may exercise any applicable audit rights.
          (d)    The Parties will effect the assignments required by Section
                 10.10.

                                             ***Confidential Treatment Requested

                                       53

<PAGE>

          (e)  If requested by Genentech, Dendreon shall cooperate to ensure an
               orderly assumption of sole responsibility by Genentech for each
               Licensed Product(s) at the stage of development or
               commercialization at the time of such termination, transfer
               ownership or any Regulatory Filings for Licensed Products to
               Genentech, and use reasonable efforts during such transition to
               minimize any adverse impact upon patients and the Parties
          (f)  To the extent it is contractually able to do so, Dendreon shall
               assign to Genentech any then-existing Third Party contracts that
               govern goods or services solely for such Licensed Product(s) and
               are necessary for the development or sale of such Licensed
               Product(s).
          (g)  Genentech shall have a perpetual right to rely upon and right to
               cross reference any Regulatory Filings for Licensed Product made
               by Dendreon under this Agreement.

          10.6.2 Termination by Dendreon. If Dendreon terminates this Agreement
          for cause under Section 10.5.1 or 10.5.2, then the following shall
          apply:

          (a)  The JSC will cause to be developed for approval by the Parties a
               final financial statement pursuant to Exhibit B and/or the
               Parties shall prepare a final royalty report in accordance with
               Section 6.8.
          (b)  Either Party may exercise any applicable audit rights.
          (c)  If requested by Dendreon, Genentech shall cooperate to ensure an
               orderly assumption of sole responsibility by Dendreon for each
               Licensed Product(s) at the stage of development or
               commercialization at the time of such termination, transfer
               ownership of any Regulatory Filings made by Genentech for
               Licensed Products, and to use reasonable efforts during such
               transition to minimize any adverse impact upon patients and the
               Parties.
          (d)  Upon request by Dendreon within thirty (30) days of the effective
               date of such termination, Genentech shall sell to Dendreon its
               then existing inventory of Licensed Product(s) for a price equal
               to its Fully Burdened Manufacturing Costs [...***...].
          (e)  If, on the effective date of such termination, Genentech's then
               existing inventory is not sufficient to provide Dendreon a total
               of eighteen (18) months inventory of Licensed Product, Genentech
               shall manufacture such additional Licensed Product(s) to enable
               it to deliver, together with the existing inventory of such
               Licensed Product, a total of eighteen (18) months supply of such
               Licensed Product. The purchase price for such Licensed Product
               shall be Genentech's Fully Burdened Manufacturing Costs
               [...***...].
          (f)  To the extent it is contractually able to do so, Genentech shall
               assign to Dendreon any then-existing Third Party contracts that
               govern goods or services solely for such Licensed Product(s) and
               are necessary for the development or sale of Licensed Product(s).
          (g)  Effective upon the date of such termination, Genentech hereby
               grants to Dendreon an exclusive (except as to Genentech),
               worldwide, with the right to sublicense through multiple tiers of
               sublicense, under the Genentech Patent Rights, Genentech
               Collaboration Inventions and Genentech's interests in Joint
               Patent Rights to the extent necessary to use, sell, offer for
               sale and import any Licensed Product then in

                                             ***Confidential Treatment Requested

                                       54

<PAGE>

               existence or thereafter developed. Such license shall bear a
               royalty of [...***...] and shall be subject to the provisions of
               Sections 6.7-6.12. The term of such l0icense and royalties shall
               be that described in Section 10.1(a) above.
          (h)  Effective upon the date of such termination, Genentech will grant
               to Dendreon, on commercially reasonable terms, a nonexclusive
               license to make and have made Licensed Products under: (i)
               Manufacturing Know-how Controlled by Genentech, existing on the
               effective date of such termination, to the extent it is Know-How
               developed specifically to make such Licensed Product(s); (ii)
               Genentech Patent Rights, then existing, to the extent solely
               Covering the manufacture of Licensed Products, and (iii)
               Genentech's interest in Collaboration Inventions developed
               specifically to make Licensed Product(s). Genentech also shall
               extend to Dendreon, on the effective date of such termination,
               the opportunity to acquire a license for other Genentech Patent
               Rights and Know-how Controlled by Genentech, to the extent
               related to manufacturing of such Licensed Product(s) and to the
               extent necessary to manufacture such Licensed Product(s), but
               only to the extent that such licenses are made available to
               similar Third Parties for similar products at that time, and
               under terms similar to those offered to such Third Parties which,
               in any case, shall be commercially reasonable terms.
          (i)  Dendreon shall have a perpetual right to cross-reference and
               right to rely upon the Regulatory Filings for Licensed Product
               made by Genentech under this Agreement.
          (j)  The Parties will effect the assignments required by Section
               10.10.

    10.7  No Limitation. The provisions of 10.6.1 and 10.6.2 above shall not
          preclude either Party from seeking any other remedy to which it may be
          entitled under law or in equity for the material breach of the other
          Party, including, without limitation, recovery for damages caused
          directly by the material breach of the other Party.

    10.8  Survival. Expiration of any termination of this Agreement shall not
          relieve the Parties of any obligation that accrued prior to such
          expiration or termination. The provisions of Article 9, Section 6.9.
          8.1.1, 10.4, 10.6, 10.7, 10.10, 11.1 through 11.5, 12.9, 12.10, and
          12.12 shall survive the expiration or any termination of this
          Agreement.

    10.9  Bankruptcy. All rights and licenses granted under or pursuant to this
          Agreement are and shall be deemed to be, for purposes of Section
          365(n) of the U.S. Bankruptcy Code, licenses of rights to
          "intellectual property" as defined under Section 101 of the U.S.
          Bankruptcy Code. The Parties shall retain and may fully exercise all
          of its rights and elections under the U.S. Bankruptcy Code; provided
          that nothing herein shall be deemed to constitute a present exercise
          of such rights and elections.

    10.10 Effect of Expiration or Termination on Intellectual Property. Within
          thirty (30) days after the expiration or any other termination of this
          Agreement by either Party for any reason, including mutual agreement
          of the Parties, (but effective immediately prior to such termination),
          the Parties shall assign all Joint Collaboration Inventions and
          Collaboration Inventions Patent Rights subject to Section 8.1.2 to
          each Party in accordance with its relationship with the named
          inventors. For example, patent applications and patents naming only
          Dendreon employees as inventors shall be assigned to Dendreon.

                                             ***Confidential Treatment Requested

                                       55

<PAGE>

               Similarly, patent applications and patents naming only Genentech
               employees as inventors shall be assigned to Genentech. The
               assignments in this Section 10.10 shall not limit the rights of
               any Party resulting from any termination hereunder (for example,
               in the event of breach under Section 10.6.1).

     11.  Confidentiality; Use of Names.

          11.1 Confidential Information. In the course of this Agreement, either
               or both Parties may disclose Confidential Information to the
               other. The recipient of Confidential Information will use it only
               for the purposes of this Agreement, and will not disclose it
               except to its employees, consultants, or permitted sublicensees
               and designees for such purposes. Each of the Parties will ensure
               that its employees, consultants, or permitted sublicensees and
               designees who receive access to the other Party's Confidential
               Information are legally obligated to maintain the confidentiality
               of such Confidential Information under terms at least as
               restrictive as this Section 11.1, and each Party shall be
               responsible for the compliance of its employees, consultants, or
               permitted sublicensees and designees. Each Party represents to
               the other that the terms of this Section 11.1 do not conflict
               with any of the representing Party's obligations to any Third
               Party.

          11.2 Exceptions. The restrictions on use and disclosure of
               Confidential Information shall not apply to information as to
               which any of the following is true:

               (a)  the information is now, or hereafter becomes, through no act
                    or failure to act on the part of the recipient, generally
                    known or available to the public;
               (b)  the information is known by the recipient and evidenced by
                    written records before it receives the information from the
                    other Party;
               (c)  the information is furnished to the recipient by a Third
                    Party who did not acquire the information directly or
                    indirectly from the disclosing Party; or
               (d)  the information is independently developed by the recipient
                    without the use or knowledge of the Confidential
                    Information, as evidenced by written records.

          11.3 Permitted Disclosure. A Party may disclose Confidential
               Information received from the other Party if the information (i)
               is necessary for any Regulatory Filing or to comply with
               securities laws, regulations or guidances or (ii) is required by
               law or by order of any court or governmental authority to be
               disclosed by the recipient. In either case, the recipient may
               disclose only the minimum Confidential Information required to be
               disclosed and must take reasonable steps to obtain confidential
               treatment for such information if such treatment is available. In
               addition if disclosure is required by order of any court or
               governmental authority, the recipient shall give the disclosing
               party sufficient advance written notice to enable it to seek a
               protective order or other remedy to protect such Confidential
               Information.

          11.4 Term of Confidentiality. Confidential Information shall be
               maintained as confidential by the recipient for the Term of this
               Agreement and for five (5) years thereafter.

                                       56

<PAGE>

          11.5 Return of Information. Except with respect to Manufacturing
               Know-How transferred to Dendreon under Sections 10.4.1, 10.4.2,
               or 10.6.2, upon request of the disclosing Party the recipient
               Party shall promptly return or destroy all written or recorded
               material containing Confidential Information; provided, however,
               that the recipient Party may retain one (1) copy of such
               Confidential Information in a secure location solely for the
               purpose of verifying compliance with its duties under this
               Agreement.

          11.6 Press Releases and Announcements. Promptly after the Effective
               Date, Dendreon and Genentech may issue a press release announcing
               this Agreement and the relationship of the Parties. Each Party
               shall provide the other with a copy of any proposed press release
               in advance of distribution and shall in good faith consider any
               comments from such other Party. If the Parties issue a joint
               press release, then both Parties must agree to the content of
               such press release. Thereafter, press releases and like public
               announcement concerning this Agreement or the activities
               hereunder that contain information not previously disclosed to
               the public shall be made only when, and in the form, approved by
               the Parties; provided, however, if a press release or like public
               announcement is required by law, regulation or court or
               administrative order, the Parties shall, as is reasonably
               practicable under the circumstances, consult with one another in
               connection with such disclosure to allow the other Party an
               opportunity to comment thereon.

          11.7 Scientific Publications and Presentations. The JSC will establish
               a publication policy ("Publication Policy") regarding the results
               of the Product Development Program under this Agreement. Neither
               Party shall publish or present such results in a manner that does
               not comply with such Publication Policy. At a minimum, the
               Publication Policy will require each Party to provide sufficient
               time for the other Party to review any proposed manuscripts,
               abstracts, posters or other materials proposed for publication or
               presentation. Upon request, each Party agrees to delay any such
               submission for a period sufficient to permit adequate steps to be
               taken to prepare and file a patent application for any patentable
               subject matter referred to therein. In addition, each Party
               agrees to delete from any such proposed submission any
               Confidential Information of the other Party upon its request.

     12.  General Provisions.

          12.1 Future Acts. The Parties agree to execute and deliver all such
               further instruments, and to do all such other acts, as may be
               necessary or appropriate in order to carry out the intent and
               purposes of this Agreement.

          12.2 Independent Contractors. The Parties are and shall at all time be
               independent contractors. In performing under this Agreement,
               neither Party is an agent, employee, employer, joint venturer or
               partner of the other. Neither Party shall incur or hold itself
               out to Third Parties as having the authority to incur any
               expenses, liabilities or obligations on behalf of the other
               Party.

                                       57

<PAGE>

     12.3 Assignment. This Agreement may be assigned in whole or in part as
          follows:

          (a)  By Dendreon or Genentech to a successor by way of merger,
               consolidation, or reorganization leading to succession involving
               the transfer of all or substantially all of the assets and
               businesses of the assigning Party to which this Agreement relates
               so long as the assigning Party is the surviving corporation in
               such merger, consolidation or reorganization.
          (b)  By Dendreon to a party (the "Acquiring Party") that is a
               successor corporation resulting from any merger, consolidation or
               reorganization of Dendreon with or into such corporation such
               that Dendreon is not the surviving corporation or to a purchaser
               of all or substantially all of Dendreon's stock or assets (the
               "Acquisition Transaction"); provided that, in Genentech's
               reasonable judgment, such Acquiring Party: (i) is not a party
               with interests materially adverse to Genentech (for example,
               without limitation, a party adverse to Genentech in significant
               litigation, or a party commercializing or selling a product that
               competes with a Genentech product) and (ii) has the scientific
               staff, experience, laboratories and other facilities and assets
               to carry out Dendreon's then-existing obligations under this
               Agreement.
          (c)  By Dendreon to an Acquiring Party that does have the scientific
               staff, experience, laboratories and other facilities and assets
               to carry out Dendreon's then-existing obligations under this
               Agreement but is a party with interests materially adverse to
               Genentech, but only as follows:

               (1)  If the Acquisition Transaction closes prior to the approval
                    of the JSC to begin the first Phase I Clinical Trial
                    hereunder, such assignment of this Agreement may be made by
                    Dendreon to such Acquiring Party only with the prior written
                    consent of Genentech, which shall be in Genentech's sole
                    discretion.
               (2)  If the Acquisition Transaction closes after the approval of
                    the JSC to begin the first Phase I Clinical Trial hereunder
                    but before the FDA determines that the first Phase II
                    Clinical Trial is a Pivotal Trial or before the JSC
                    determines to proceed to the first Phase III Clinical Trial
                    hereunder, then, Dendreon may assign this Agreement with
                    Genentech's prior written consent, which shall not be
                    unreasonably withheld. If Genentech so consents, then upon
                    such assignment such Acquiring Party may elect to share
                    Profits and Losses as provided in Section 2.14 for the
                    Monoclonal Product and SM Product so long as it completes
                    the Phase I and II Clinical Trials for such Monoclonal
                    Product and SM Product in accordance with the Clinical Plan.
                    If the Acquiring Party does not complete such obligations as
                    described above, or does not elect to share Operating
                    Profits and Losses as provided in Section 2.14, then such
                    Acquiring Party shall be deemed to have elected to receive
                    the royalties provided in Section 6.5 on the terms provided
                    in Sections 6.7-6.12. If during the course of any Phase I
                    Clinical Trial or Phase II Clinical Trial conducted by such
                    Acquiring Party such Clinical Trial progress is delayed more
                    than six (6) months beyond the Clinical Plan timelines, then
                    Genentech shall have the right to step in and take full
                    responsibility for the conduct of, and complete, such
                    Clinical Trials. In such event, then such Acquiring Party
                    shall be deemed to have elected to receive the royalties
                    provided in Section 6.5 on the terms

                                       58

<PAGE>

                    provided in Sections 6.7-6.12. In no event shall such
                    Acquiring Party participate in the JSC or JPT after the
                    commencement of Phase III Clinical Trials nor have the right
                    to co-promote Licensed Products as provided in Section 7.2.
               (3)  If the Acquisition Transaction closes after the FDA
                    determines that the first Phase II Clinical Trial is a
                    Pivotal Trial or after the JSC determines to proceed to the
                    first Phase III Clinical Trial, Dendreon may assign this
                    Agreement to such Acquiring Party with Genentech's prior
                    written consent, which shall not be unreasonably withheld.
                    In such event, and if Dendreon has elected to share
                    Operating Profits and Losses for a Licensed Product as
                    provided in Section 2.14 prior to the closing of such
                    Acquisition Transaction, then the Acquiring Party shall also
                    have the right to share in Profits and Losses hereunder for
                    such Licensed Product. In no event will the Acquiring Party
                    have the right to participate on the JSC or JPT or the
                    opportunity to co-promote under Section 7.2 with respect to
                    any Licensed Product. With respect to Licensed Products, if
                    any, for which Dendreon has elected to receive the royalty
                    provided in Section 6.5, then the Acquiring Party shall also
                    receive such royalty on the terms and conditions provided in
                    Sections 6.7-6.12 in lieu of sharing in Operating Profits
                    and Losses.

          (d)  By Genentech to a successor in a transaction that does not fall
               within the scope of Section 12.3(a) if such successor has the
               expertise and scientific, commercial and financial capabilities
               equivalent to or better than Genentech's at the time of the
               execution of this Agreement.
          (e)  Except as provided above, this Agreement may not be assigned in
               whole or in part without the express written consent of the
               nonassigning Party which consent it may grant or refuse in its
               sole discretion.
          (f)  This Agreement will be binding upon the successors and permitted
               assigns of the Parties. Any assignment not in accordance with
               this Section 12.3 will be void.

     12.4 Waiver. No waiver by a Party in any one or more instances shall be
          deemed to be a continuing waiver, a further waiver, a waiver of any
          other provision of this Agreement, or a waiver of this Agreement as a
          whole. No waiver of any right under this Agreement shall be effective
          unless it is documented in writing signed by the Party providing the
          waiver.

     12.5 Force Majeure. A failure by a Party to perform any obligation under
          this Agreement that is prevented by an occurrence beyond the control
          of the non-performing Party (and which did not occur as a result of
          its financial condition, negligence or fault), including acts of God,
          embargoes, fires, floods, explosions, riots, wars, civil disorders,
          terrorist acts, rebellion or acts of sabotage, shall not constitute a
          breach of this Agreement so long as that Party notifies the other
          Party as soon as practicable and uses its best efforts to resume
          performance as soon as possible.

     12.6 Severability. If any term of this Agreement is held invalid, illegal
          or unenforceable in any jurisdiction, then, to the fullest extent
          permitted by law (i) all other terms shall remain in full force and
          effect in such jurisdiction, (ii) such invalidity, illegality or

                                       59

<PAGE>

          unenforceability shall not affect the validity, legality or
          enforceability of such provision in any other jurisdiction, and (iii)
          the Parties shall negotiate such terms as may be necessary in good
          faith in order to correct any imbalance of rights and obligations that
          results from such invalidity, illegality or unenforceability in the
          relevant jurisdiction.

     12.7 Headings. All headings within this Agreement appear for convenience
          only and shall not be used to construe, determine or interpret any
          term of this Agreement.

     12.8 Legal Counsel. Each Party is a sophisticated business entity which has
          involved legal counsel in the drafting of this Agreement. Any
          presumption or rule of interpretation disfavoring the drafter of an
          agreement shall not apply to the interpretation and application of
          this Agreement.

     12.9 Dispute Resolution and Governing Law.

          12.9.1 Disputes. The Parties recognize that disputes as to certain
          matters may from time to time arise during the Term of this Agreement
          which relate to either Party's contractual rights and/or obligations
          hereunder. It is the objective of the Parties to establish procedures
          to facilitate the resolution of disputes arising under this Agreement
          in an expedient manner by mutual cooperation and without resort to
          litigation. To accomplish this objective, the Parties agree to follow
          the procedures set forth in this Section 12.9 if and when a dispute
          arises under this Agreement.

          Unless otherwise specifically recited in this Agreement, disputes
          among members of the Joint Project Team will be resolved as recited in
          this Section 12.9. Any disputes relating to the collaboration
          hereunder shall be first referred to the JSC by either Party at any
          time after such dispute has arisen and such Party believes that there
          has been sufficient discussion of the matter at the Joint Project Team
          level. If the JSC is unable to resolve such a dispute within sixty
          (60) days of being requested by a Party to resolve the dispute or the
          JSC is unable to resolve a dispute among its members, the matter shall
          be presented to the chief executive officer of Genentech and Dendreon,
          or their respective designee, for resolution. In the event that the
          chief executive officer of Genentech and Dendreon, or their respective
          designees, cannot resolve the dispute within thirty (30) days of being
          requested by a Party to resolve a dispute, either Party may, by
          written notice to the other, invoke the provisions of Section 12.9.2
          below.

          12.9.2 Arbitration. Subject to Section 12.9.3 below, the Parties agree
          that any dispute, controversy or claim arising out of or relating to
          this Agreement, or the breach, termination, or invalidity thereof,
          shall be resolved through binding arbitration. If the dispute arises
          between the Parties, and if such dispute cannot be resolved pursuant
          to Section 12.9.1 above, any unresolved controversy or claim between
          the Parties shall be resolved by binding arbitration in accordance
          with the Commercial Arbitration Rules of the American Arbitration
          Association as presently in effect, except as modified herein. Each
          such arbitration shall be conducted by a panel of three arbitrators
          appointed in accordance with the Commercial Arbitration Rules as
          presently in effect; provided that at least one such arbitrator shall
          have had, by the time of the actual arbitration, at least ten

                                       60

<PAGE>

          (10) years of experience as an attorney and experience in the
          pharmaceuticals industry so as to better understand the legal,
          business and scientific issues addressed in the arbitral proceeding. A
          reasoned arbitration decision shall be rendered in writing within
          thirty (30) days of the conclusion of the arbitration hearing and
          shall be binding. The prevailing Party may enter such decision in any
          court having competent jurisdiction. Unless otherwise mutually agreed
          upon by the Parties, the arbitration proceedings shall be conducted at
          the location of the Party not originally requesting the resolution of
          the dispute. Each Party must bear its own attorneys' fees and
          associated costs and expenses. The arbitrators shall have the
          authority to grant temporary and permanent injunctive and equitable
          relief, including specific performance and to allocate costs between
          the Parties (excluding attorney's fees).

          12.9.3 Determination of Patents and Other Intellectual Property.
          Notwithstanding the foregoing, the provisions of Sections 12.9.1 and
          12.9.2 above shall not apply to any dispute, controversy or claim
          relating to: (1) the determination of validity of claims, infringement
          or claim interpretation relating to a Party's patents, trademarks or
          copyright; or (2) any antitrust, anti-monopoly or competition law or
          regulation, whether or not statutory.

          12.9.4 Governing Law. This Agreement shall be governed by the law of
          the State of New York, without giving effect to conflict of law
          considerations.

    12.10 Notices. A notice required or permitted under this Agreement shall be
          in writing, addressed to a Party at the address listed below. Notices
          may be (i) mailed within he United Stated registered or certified;
          (ii) delivered in-person to the addressee; or (iii) delivered via
          next-business day service by a well-established courier. All properly
          addressed notices shall be deemed received three (3) business days
          after the notice is placed in the hands of a Third Party for delivery.
          A Party, by notice complying with this Section, may change its notice
          address or addressee.

          Notices to Dendreon:                 Notice to Genentech:

          General Counsel                      Genentech, Inc.
          Dendreon Corporation                 1 DNA Way
          3005 First Avenue                    South San Francisco, CA  94080
          Seattle, WA 98121                    Attn: Corporate Secretary

    12.11 Amendment. This Agreement may be amended or modified only by a writing
          signed by each of the Parties.

    12.12 Entire Agreement. This Agreement and the Equity Investment Agreement
          attached as Exhibit D, and the Confidentiality Agreement dated
          September 13, 2001 between the Parties constitute the entire
          understanding between the Parties as of the Effective Date with
          respect to the subject matter hereof and thereof and supersede all
          related prior or contemporaneous oral communications, agreements or
          discussions with respect to the

                                       61

<PAGE>

                subject matter hereof or thereof. Each of these agreements
                must be read, interpreted, and applied in light of and with
                the others. Together they constitute one, single business
                transaction.

       12.13    Counterparts. This Agreement may be executed simultaneously in
                any number of counterparts, any one of which need not contain
                the signature of more than one Party but all such counterparts
                taken together will constitute one and the same agreement.

       Dendreon Corporation                 Genentech, Inc.

       By  /s/ Mitchell H. Gold, M.D.       By /s/ Arthur D. Levinson
         ----------------------------         -----------------------

       Mitchell H. Gold, M.D.               Arthur D.  Levinson

       Chief Business Officer               Chairman and Chief Executive Officer

                                       62

<PAGE>

                                    Exhibit A

                                     Trp-p8

aagaaaatcctgcttgacaaaaacctcacttaggaaaagatgtcctttcgggcagccgggctcagcatgaggaacagaag
gaat
gacactctggacagcacccggaccctgtactccagcgcgtctcggagcacagacttgtcttacagtgaaagcgacttggt
gaatt
ttattcaagcaaattttaagaaacgagaatgtgtcttctttaccaaagattccaaggccacggagaatgtgtgcaagtgt
ggctatg
cccagagccagcacatggaaggcacccagatcaaccaaagtgagaaatggaactacaagaaacacaccaaggaatttcct
ac
cgacgcctttggggatattcagtttgagacactggggaagaaagggaagtatatacgtctgtcctgcgacacggacgcgg
aaat
cctttacgagctgctgacccagcactggcacctgaaaacacccaacctggtcatttctgtgaccgggggcgccaagaact
tcgc
cctgaagccgcgcatgcgcaagatcttcagccggctcatctacatcgcgcagtccaaaggtgcttggattctcacgggag
gcac
ccattatggcctgacgaagtacatcggggaggtggtgagagataacaccatcagcaggagttcagaggagaatattgtgg
ccat
tggcatagcagcttggggcatggtctccaaccgggacaccctcatcaggaattgcgatgctgagggctattttttagccc
agtac
cttatggatgacttcacaagggatccactgtatatcctggacaacaaccacacacatttgctgctcgtggacaatggctg
tcatgg
acatcccactgtcgaagcaaagctccggaatcagctagagaagcatatctctgagcgcactattcaagattccaactatg
gtggc
aagatccccattgtgtgttttgcccaaggaggtggaaaagagactttgaaagccatcaatacctccatcaaaaataaaat
tccttgt
gtggtggtggaaggctcgggccggatcgctgatgtgatcgctagcctggtggaggtggaggatgccccgacatcttctgc
cgt
caaggagaagctggtgcgctttttaccccgcacggtgtcccggctgcctgaggaggagactgagagttggatcaaatggc
tca
aagaaattctcgaatgttctcacctattaacagttattaaaatggaagaagctggggatgaaattgtgagcaatgccatc
tcctacg
ctctatacaaagccttcagcaccagtgagcaagacaaggataactggaatgggcagctgaagcttctgctggagtggaac
cag
ctggacttagccaatgatgagattttcaccaatgaccgccgatgggagtctgctgaccttcaagaagtcatgtttacggc
tctcata
aaggacagacccaagtttgtccgcctctttctggagaatggcttgaacctacggaagtttctcacccatgatgtcctcac
tgaactc
ttctccaaccacttcagcacgcttgtgtaccggaatctgcagatcgccaagaattcctataatgatgccctcctcacgtt
tgtctgga
aactggttgcgaacttccgaagaggcttccggaaggaagacagaaatggccgggacgagatggacatagaactccacgac
gt
gtctcctattactcggcaccccctgcaagctctcttcatctgggccattcttcagaataagaaggaactctccaaagtca
tttggga
gcagaccaggggctgcactctggcagccctgggagccagcaagcttctgaagactctggccaaagtgaagaacgacatca
at
gctgctggggagtccgaggagctggctaatgagtacgagacccgggctgttgagctgttcactgagtgttacagcagcga
tga
agacttggcagaacagctgctggtctattcctgtgaagcttggggtggaagcaactgtctggagctggcggtggaggcca
cag
accagcatttcaccgcccagcctggggtccagaattttctttctaagcaatggtatggagagatttcccgagacaccaag
aactgg
aagattatcctgtgtctgtttattatacccttggtgggctgtggctttgtatcatttaggaagaaacctgtcgacaagca
caagaagct
gctttggtactatgtggcgttcttcacctcccccttcgtggtcttctcctggaatgtggtcttctacatcgccttcctcc
tgctgtttgcct
acgtgctgctcatggatttccattcggtgccacacccccccgagctggtcctgtactcgctggtctttgtcctcttctgt
gatgaagt
gagacagtggtacgtaaatggggtgaattattttactgacctgtggaatgtgatggacacgctggggcttttttacttca
tagcagg
aattgtatttcggctccactcttctaataaaagctctttgtattctggacgagtcattttctgtctggactacattattt
tcactctaagatt
gatccacatttttactgtaagcagaaacttaggacccaagattataatgctgcagaggatgctgatcgatgtgttcttct
tcctgttcct
ctttgcggtgtggatggtggcctttggcgtggccaggcaagggatccttaggcagaatgagcagcgctggaggtggatat
tccg
ttcggtcatctacgagccctacctggccatgttcggccaggtgcccagtgacgtggatggtaccacgtatgactttgccc
actgca
ccttcactgggaatgagtccaagccactgtgtgtggagctggatgagcacaacctgccccggttccccgagtggatcacc
atcc
ccctggtgtgcatctacatgttatccaccaacatcctgctggtcaacctgctggtcgccatgtttggctacacggtgggc
accgtcc
aggagaacaatgaccaggtctggaagttccagaggtacttcctggtgcaggagtactgcagccgcctcaatatccccttc
ccctt
catcgtcttcgcttacttctacatggtggtgaagaagtgcttcaagtgttgctgcaaggagaaaaacatggagtcttctg
tctgctgtt
tcaaaaatgaagacaatgagactctggcatgggagggtgtcatgaaggaaaactaccttgtcaagatcaacacaaaagcc
aac
gacacctcagaggaaatgaggcatcgatttagacaactggatacaaagcttaatgatctcaagggtcttctgaaagagat
tgctaa
taaaatcaaataaaactgtatgaaactctaatggagaaaaatctaattatagcaagatcatattaaggaatgctgatgaa
caattttg
ctatcgactactaaatgagagattttcagacccctgggtacatggtggatgattttaaatcaccctagtgtgctgagacc
ttgagaat
aaagtgtgtgattggtttcatacttgaagacggatataaaggaagaatatttcctttatgtgtttctccagaatggtgcc
tgtttctctct

<PAGE>

gtgtctcaatgcctgggactggaggttgatagtttaagtgtgttcttaccgcctcctttttcctttaatcttatttttga
tgaacacatatat
aggagaacatctatcctatgaataagaacctggtcatgctttactcctgtattgttattttgttcatttccaattgattc
tctacttttccctt
ttttgtattatgtgactaattagttggcatattgttaaaagtctctcaaattaggccagattctaaaacatgctgcagca
agaggaccc
cgctctcttcaggaaaagtgttttcatttctcaggatgcttcttacctgtcagaggaggtgacaaggcagtctcttgctc
tcttggact
caccaggctcctattgaaggaaccacccccattcctaaatatgtgaaaagtcgcccaaaatgcaaccttgaaaggcacta
ctgac
tttgttcttattggatactcctcttatttattatttttccattaaaaataatagctggctattatagaaaatttagacca
tacagagatgtaga
aagaacataaattgtccccattaccttaaggtaatcactgctaacaatttctggatggtttttcaagtctattttttttc
tatgtatgtctca
attctctttcaaaattttacagaatgttatcatactacatatatactttttatgtaagctttttcacttagtattttatc
aaatatgtttttattatat
tcatagccttcttaaacattatatcaataattgcataataggcaacctctagcgattaccataattttgctcattgaagg
ctatctccagt
tgatcattgggatgagcatctttgtgcatgaatcctattgctgtatttgggaaaattttccaaggttagattccaataaa
tatctatttatt
attaaatattaaaatatcgatttattattaaaaccatttataaggctttttcataaatgtatagcaaataggaattatta
acttgagcataa
gatatgagatacatgaacctgaactattaaaataaaatattatatttaaccctagtttaagaagaagtcaatatgcttat
ttaaatattat
ggatggtgggcagatcacttgaggtcaggagttcgagaccagcctggccaacatggcaaaaccacatctctactaaaaat
aaaa
aaattagctgggtgtggtggtgcactcctgtaatcccagctactcagaaggctgaggtacaagaattgctggaacctggg
aggc
ggaggttgcagtgaaccaagattgcaccactgcactccagccggggtgacagagtgagactccgactgaaaataaataaa
taa
ataaataaataaataaataaataaatattatggatggtgaagggaatggtatagaattggagagattatcttactgaaca
cctgtagt
cccagctttctctggaagtggtggtatttgagcaggatgtgcacaaggcaattgaaatgcccataattagtttctcagct
ttgaatac
actataaactcagtggctgaaggaggaaattttagaaggaagctactaaaagatctaatttgaaaaactacaaaagcatt
aactaa
aaaagtttattttccttttgtctgggcagtagtgaaaataactactcacaacattcactatgtttgcaaggaattaacac
aaataaaag
atgcctttttacttaaacgccaagacagaaaacttgcccaatactgagaagcaacttgcattagagagggaactgttaaa
tgttttca
acccagttcatctggtggatgtttttgcaggttactctgagaattttgcttatgaaaaatcattatttttagtgtagttc
acaataatgtatt
gaacatacttctaatcaaaggtgctatgtccttgtgtatggtactaaatgtgtcctgtgtacttttgcacaactgagaat
cctgcggctt
ggtttaatgagtgtgttcatgaaataaataatggaggaattgtcaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaa
aaaaaaaaaaaaaaaaaaaaaaaa

<PAGE>

                                    Exhibit B

                  FINANCIAL PLANNING, ACCOUNTING AND REPORTING
                           FOR THE DENDREON/GENENTECH
                COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENT

This Exhibit B to the Collaborative Development and Marketing Agreement (the
"Agreement") made as of August 1, 2002 between Dendreon Corporation ("Dendreon")
and Genentech, Inc. ("Genentech") covers financial planning, accounting policies
and procedures to be followed in determining DENDREON/GNE Development Costs and
Operating Profits or Losses pursuant to the Agreement.

For such purpose, this Exhibit B sets forth the principles for reporting actual
results and budgeted plans of the combined operations in the United States, the
frequency of reporting, the methods of determining payments to the Parties,
auditing of accounts and other matters.

For purposes of this Exhibit B only, the consolidated accounting of operations
for the collaboration of the Parties hereunder shall be referred to as the
"Collaboration." The Collaboration is not a legal entity, pass through or
otherwise, for financial accounting, income tax reporting, or any other
purposes, and has been defined for identification purposes only.

This Exhibit B also provides agreed upon definitions of financial terms
applicable to the Parties for purposes of the Agreement; provided, however, that
the definition of "Fully Burdened Manufacturing Costs" shall apply to Genentech,
to the extent it manufactures any Licensed Product under the Agreement or to
Dendreon if Dendreon becomes responsible for manufacturing under the Agreement
or either of the supply agreements referred to in the Agreement. The definition
of "DENDREON/GNE Development Costs" shall apply to the development work by both
Parties to the extent to be shared under this Exhibit B pursuant to the terms of
the Agreement. All capitalized terms used herein without definition shall have
the meanings ascribed thereto in the Agreement, unless otherwise expressly
provided herein. References in this Exhibit B to a "Party" or "Parties" shall be
construed to mean Genentech or Dendreon, as the case may be, and in every case
shall be deemed to include a Party's permitted sublicensees and assigns as
applicable under the Agreement.

The contents of this Exhibit B are hereby incorporated into the Agreement and
are governed by the terms and conditions of the Agreement, including, without
limitation, the confidentiality provisions set forth therein.

<PAGE>

B.1 Principles of Reporting. With respect to each Monoclonal Product or SM
Product, including the first and any Additional Product, and with respect to
each New Molecule, the Parties will share DENDREON/GNE Development Costs,
[...***...] to Dendreon and [...***...] to Genentech. Until the first commercial
sale of the first Licensed Product in the United States, expenses to be shared
by the Parties hereunder shall largely be reported as DENDREON/GNE Development
Costs. Commencing with the commercial sale of the first Licensed Product in the
United States, the Parties will report their respective results of operations in
the United States based on each Party's respective financial information
presented separately and on a consolidated basis in the reporting format
depicted below and will share the resulting Operating Profit and Loss
[...***...] to Dendreon and [...***...] to Genentech:

                                                    Dendreon   Genentech   Total
                                                    --------   ---------   -----

          Gross Sales
          less Sales Returns and Allowances
              = Net Sales
          less Cost of Sales
              = Gross Profits
          less Marketing Costs
          less Sales Costs
          less DENDREON/GNE Development Costs
          less Other Operating Income/Expense
          less Distribution Costs
          less General and Administrative Costs
              = Operating Profit (Loss)

It is the intention of the Parties that the interpretation of the definitions in
this Exhibit B will be consistent with generally accepted accounting principles
("GAAP") in the United States.

If necessary, a Party will make the appropriate adjustments to the financial
information it supplies under the Agreement to conform to the above format of
reporting results of operations. The JSC will approve the balancing payments
necessary to achieve the agreed-upon sharing of Operating Profit and Loss
pursuant to the Agreement.

B.2 Frequency of Reporting.

The fiscal year of the Collaboration will be a calendar year.

                                             ***Confidential Treatment Requested

<PAGE>

Reporting by each Party for Collaboration revenues and expenses will be
performed as follows:

Reporting Event                    Frequency          Timing of Submission
---------------                    ---------          --------------------

Actuals (including draft           Quarterly        Q1-Q3:          +45 days
   settlement statements)                           Q4:             +45 days

Forecasts                          Quarterly        Q1-Q3           +60 days
(rest of year - by month)

Settlement payments between
the Parties                        Quarterly        Quarter end     +60 days

Preliminary Budgets                Annually         September 15
(one year)

Final Combined Commercial          Annually         October 15
And Development Budget
(one year - by quarter)

Long Range Plan                    Annually         April 15
(current year plus 5 years)

Reports of actual results compared to budget will be made by the Parties to the
Joint Project Team on a quarterly basis. After approval by the Joint Project
Team as to amounts, the Joint Project Team will forward the report to the JSC
for its approval. Variances from the total overall budgets, and significant
variances in budget line items for DENDREON/GNE Development Costs and other
costs or revenue line items, will be included in the calculation of Operating
Profits and Losses only when approved by the JSC.

Genentech will be responsible for the preparation of consolidated reporting of
the Collaboration (including DENDREON/GNE Development Costs and any Operating
Profit or Loss), calculation of the sharing and initial determination of the
cash settlement (subject to approval by the JSC). Within forty-five (45) days of
each quarter end, Genentech will provide the financial representatives from each
Party with a statement showing the consolidated results and calculations of the
Operating Profit or Loss sharing (or calculation of expenses to be shared) and
cash settlement required in a format substantially as depicted above.

Genentech shall record sales in the United States. On a monthly basis, Genentech
will supply Dendreon with each month's Gross Sales and Net Sales of Licensed
Products in units and U.S. dollars in the United States. Each such report shall
be provided as early as possible, but no later than ten (10) days after the last
day of the month in question, and shall provide monthly and year-to-date
cumulative figures.

<PAGE>

                                The financial representatives from the Parties
                                will meet as appropriate but at least quarterly
                                to review and approve the following:
                                -    DENDREON/GNE Development Costs
                                -    Costs of Sales and other costs
                                -    actual results
                                -    forecasts
                                -    budgets
                                -    inventory levels
                                -    Sales Returns and Allowances
                                -    other financial matters, including each
                                     Party's methodologies for charging costs to
                                     the Collaboration, for determination of
                                     actuals, forecasts, budgets and long range
                                     plans and the results of applying such
                                     methodologies.

B.3      Budget and Commercialization Plans.

Budgets will be prepared annually. Responsibility for the Clinical Plans,
Commercialization Plans and their related budgets will rest with the Joint
Project Team (except for Preclinical Programs), subject to final approval by the
JSC, in accordance with the Agreement.

Budgets under this Exhibit B will be supplemented with detailed business plans
for clinical trials, drug approval applications, and overall strategy plans for
product introduction, sales and promotion efforts, as determined by the Joint
Project Team in accordance with the Agreement. Budgets, once approved by the
JSC, can only be changed with the approval of the JSC, as provided in the
Agreement.

The Joint Project Team, with the assistance of the financial representatives of
each Party, will be responsible for identifying, analyzing and reporting all
significant line item budget variances and all overall, total budget variances.
Except as provided otherwise in the Agreement, only the JSC may approve
materially unfavorable line item budget variations, as defined by the Joint
Project Team, and all overall, total budget variations, chargeable to the
Collaboration during the course of the year.

A five (5)-year Commercialization Plan for the Collaboration will be established
on a yearly basis under the direction of the JSC and submitted to Genentech and
Dendreon by April 15 each year.

B.4      Definitions.

B.4.1    "Allocable Overhead" means costs incurred by a Party or for its account
         which are attributable to a Party's supervisory services, occupancy
         costs, corporate cash bonus (to the extent not charged directly to
         department), and its payroll, information systems, human relations or
         purchasing functions and which are

<PAGE>

         allocated to company departments based on space occupied or headcount
         or other activity-based method consistently applied by a Party, or a
         standard rate if agreed to by the Parties. Allocable Overhead shall not
         include any costs attributable to general corporate activities
         including, by way of example, executive management, investor relations,
         business development, legal affairs and finance, and shall not
         duplicate G&A hereunder.

B.4.2    "Cost of Sales" shall mean the sum of (i) Fully Burdened Manufacturing
         Cost (as defined below), (ii) freight, insurance and other costs of
         shipping Licensed Product to customers, (iii) any Third Party royalties
         payable with respect to the manufacture, use or sale of Licensed
         Product, excluding any royalties already accounted for in Fully
         Burdened Manufacturing Cost, and (iv) the cost of free Licensed Product
         for indigent persons.

B.4.3    "DENDREON/GNE Development Costs" means the development costs incurred
         (including accruals) by Genentech or Dendreon to be shared pursuant to
         the terms of the Agreement, from the Effective Date of the Agreement
         through the later of (a) the date of Regulatory Approval (including
         thereafter costs to maintain or expand such Regulatory Approval) in the
         United States, or (b) the date of termination of development efforts of
         the final indication for which Regulatory Approval is sought in the
         United States. Such costs shall comprise those costs required to
         obtain, maintain and/or expand the authorization and/or ability to
         manufacture, formulate, fill, ship and/or sell a Licensed Product in
         commercial quantities to Third Parties in the United States.

         "DENDREON/GNE Development Costs" shall include, but are not limited to,
         costs of development including costs of studies (but only to the extent
         to be shared pursuant to the terms of the Agreement) on the
         toxicological, pharmacokinetical, metabolical or clinical aspects of a
         Licensed Product conducted internally, or by individual investigators
         or consultants, necessary for the purpose of obtaining, maintaining
         and/or expanding marketing approval of a Licensed Product, process
         development, process improvement and recovery costs, qualification
         lots, costs for preparing, submitting, reviewing or developing data or
         information for the purpose of submission to a Regulatory Agency to
         obtain, maintain and/or expand marketing approval of a Licensed Product
         in the United States, and applicable Allocable Overhead.

         "DENDREON/GNE Development Costs" shall include expenses for data
         management, CROs, statistical designs and studies, document
         preparation, and other administration expenses associated with the
         clinical testing program or post-marketing studies required to maintain
         product approvals. In determining "DENDREON/GNE Development Costs"
         chargeable under this Agreement, each Party will use its respective
         project accounting systems, and will review and approve its respective
         project accounting systems and methodologies with the other Party.

<PAGE>

         "DENDREON/GNE Development Costs" shall include all Preclinical Program
         Costs and Clinical Trial Costs for Phase I, II and III Clinical Trials
         for Additional Products and New Molecules.

B.4.4    "Distribution Costs" means the costs, including applicable Allocable
         Overhead, specifically identifiable to the distribution of a Licensed
         Product by a Party including customer services, collection of data
         about sales to hospitals and other end users, order entry, billing,
         credit and collection and other such activities. For the purpose of
         this Agreement, Genentech will charge the Collaboration for
         Distribution Costs an amount equal to [...***...] of Net Sales in any
         year.

B.4.5    "Fully Burdened Manufacturing Cost" means one hundred percent (100%) of
         a Party's manufacturing cost (as defined in the manufacturing Party's
         accounting policies consistently applied), which shall comprise the sum
         of:

         (a)      the cost of goods produced as determined by the Party
                  manufacturing or contracting with a Third Party for each stage
                  of the manufacturing process in accordance with GAAP
                  consistently applied by such Party, including without
                  limitation labor and material cost, product quality
                  assurance/control costs, applicable Allocable Overhead, and
                  other costs borne by the Party for transport, customs
                  clearance and storage of product at the request of the other
                  Party prior to the time of sale (i.e. freight, customs, duty
                  and insurance); and
         (b)      all of the Party's allocable intellectual property acquisition
                  and licensing costs (including royalties) paid to Third
                  Parties as it relates to the manufacture of Licensed Product.

         For purposes of this Exhibit B, the amount to be charged to the
         Collaboration for Clinical Supply and Commercial Supply of Monoclonal
         Product under the Agreement shall be Genentech's Fully Burdened
         Manufacturing Cost plus [...***...] of such Fully Burdened
         Manufacturing Cost. The amount to be charged to the Collaboration for
         Clinical Supply and Commercial Supply of SM Product under the Agreement
         when manufactured by Genentech shall be Genentech's Fully Burdened
         Manufacturing Cost plus [...***...] of such Fully Burdened
         Manufacturing Cost, and when manufactured by a Third Party contract
         manufacturer the amount charged shall be the Third Party manufacturing
         contracted cost plus [...***...] of such Third Party manufacturing
         contracted cost. Either Party holding inventory for commercial sales
         shall be permitted to bill the collaboration a reasonable and customary
         carrying charge to compensate it for its financing and logistical
         product support, which amount shall be further defined and agreed upon
         in the Commercial Supply Agreement between the Parties.

B.4.6    "General and Administrative Costs" means costs chargeable to the
         Collaboration equal to [...***...] of the sum of the Marketing Costs,
         Sales Costs, and DENDREON/GNE Development Costs of either Genentech and
         of Dendreon, but only to the extent these costs are chargeable to the
         Collaboration.

                                             ***Confidential Treatment Requested

<PAGE>

B.4.7     "Gross Profit" means Net Sales less Cost of Sales of a Licensed
          Product by a Party to Third Parties in the United States.

B.4.8     "Gross Sales" means the gross amount invoiced by either Party, and/or
          their permitted sublicensees for sales of a Licensed Product to Third
          Parties in the United States.

B.4.9     "Marketing Costs" means the direct costs of marketing, promotion,
          advertising, Licensed Product promotional materials, professional
          education, product related public relations, relationships with
          opinion leaders and professional societies, market research (before
          and after product approval), healthcare economics studies,
          post-marketing studies not required to maintain product approvals, and
          other similar activities related to the Licensed Products. Such costs
          will include internal costs (e.g., salaries, benefits, travel,
          supplies and materials, etc.), applicable Allocable Overhead, and
          outside services and expenses (e.g., consultants, agency fees, meeting
          costs, etc.). "Marketing Costs" shall also include activities related
          to obtaining reimbursement from payers and costs of sales and
          marketing data. "Marketing Costs" will specifically exclude the costs
          of activities which promote either Party's business as a whole without
          being product specific (such as corporate image advertising).

B.4.10    "Net Sales" means Gross Sales of a Licensed Product less applicable
          Sales Returns and Allowances.

B.4.11    "Operating Profits or Losses" means Net Sales of all Licensed Products
          less the following items with respect to each Product, all for a given
          period: Cost of Sales, Marketing Costs, Sales Costs, DENDREON/GNE
          Development Costs (to the extent chargeable to the Collaboration),
          General and Administrative Costs, Distribution Costs, and Other
          Operating Income/Expense.

B.4.12    "Other Operating Income/Expense" means other operating income or
          expense from or to Third Parties which is not part of the primary
          business activity of the Collaboration, but is designated as such in
          the Agreement or considered and approved by the Joint Project Team and
          the JSC as income or expense for purposes of the Collaboration and
          including the following:

               -    actual inventory write-offs of any Licensed Product
               -    trademark infringement recoveries (as provided in Section
                    7.8 of the Agreement)
               -    product liability insurance to the extent the Parties obtain
                    a joint policy

                    patent infringement expenses and recoveries as provided in
                    Sections 8.6.6 and 8.7
               -    other (to be approved by JSC)

<PAGE>

B.4.13    "Trademark Costs" means the fees and expenses paid to outside legal
          counsel and experts, and filing and maintenance expenses, incurred
          after the Effective Date to establish and maintain Licensed Product
          Trademarks, to the extent chargeable to the Collaboration.

B.4.14    "Sales Costs" means costs, including Allocable Overhead, approved by
          the Joint Steering Committee with the annual budget, incurred by the
          Parties or for their account and specifically identifiable to the
          sales efforts of Licensed Products to all markets in the United
          States, including, without limitation, the managed care market. "Sales
          Costs" shall include costs associated with sales representatives for
          Licensed Product, including compensation, benefits and travel,
          supervision and training of the sales representatives, sales meetings,
          and other sales expenses. "Sales Costs" will not include the start-up
          costs associated with either Party's sales force, including
          recruiting, relocation and other similar costs.

B.4.15    "Sales Returns and Allowances" means the sum of (a) and (b), where:
          (a) is a provision, determined by a Party under GAAP for sales of
          Licensed Products in the Unites States for (i) trade, cash and
          quantity discounts or rebates on Licensed Products (other than price
          discounts granted at the time of invoicing and which are included in
          the determination of Gross Sales), (ii) credits or allowances given or
          made for rejection or return of, and for uncollectable amounts on,
          previously sold Licensed Products or for retroactive price reductions
          (including Medicare and similar types of rebates and chargebacks),
          (iii) taxes (excluding local, state, or federal incomes taxes on the
          income of a Party), duties or other governmental charges levied on or
          measured by the billing amount for Licensed Products, as adjusted for
          rebates and refunds, (iv) charges for freight and insurance directly
          related to the distribution of Licensed Products, to the extent
          included in Gross Sales, (v) credits for allowances given or made for
          wastage replacement, and (vi) other special sales programs agreed to
          by the Parties for Licensed Products; and (b) is a periodic adjustment
          of the provision determined in (a) to reflect amounts actually
          incurred by a Party in the United States for items (i), (ii), (iii),
          (iv), (v) and (vi) in clause (a). The provision allowed in clause (a)
          and adjustments made in clause (b) (if any) will be reviewed and
          approved by the financial representatives of the Parties.

B.5       Audits and Interim Reviews.

Either Party shall have the right to request that its independent accounting
firm perform an audit of the other Party's books of accounts, no more than once
every calendar year, for the sole purpose of verifying compliance with this
Agreement. Such audits may include, without limitation the reporting and
accounting for accruals and testing of a Party's algorithms and systems for
determining Allocable Overhead. Only one audit will be conducted with respect to
any given set of financial transactions supporting the income statement for the
collaboration for any given year. In such audit the firm may review books of
accounts covering no more than the two (2) years just prior to such audit. Such
audits will be conducted at the expense of the requesting Party and with thirty
(30) days prior written notice to the other Party. The audited Party shall have
the right to

<PAGE>

participate in scope determination in accordance with generally accepted
auditing standards. Audit results will be shared with both Parties. If
accounting errors are found which exceed an overall net of five percent (5%) or
more of the total due such that the Party being audited has been overpaid by
five percent (5%) or more, then the costs of such audit shall be borne by the
Party being audited. Any overpayment or underpayment will be settled within
thirty (30) days after receipt of the audit results by the Party required to
make the balancing payment

B.6       Payments between the Parties.

Payments to each Party of the agreed upon percentages of Operating Profit or
Loss as provided under Section B.9 below will be made quarterly, based on actual
results within sixty (60) days after the end of each quarter. A report, as
approved by the JSC, specifying how each payment was calculated shall also be
submitted with each payment to both Parties. Balancing payments by one Party to
reimburse the other Party for purposes of the sharing of Operating Loss,
including DENDREON/GNE Development Costs, under the Agreement will be approved
by the JSC and shall be made within sixty (60) days of receipt of the approved
JSC report. In the event any payment is made after the time period specified
herein, the paying Party shall increase the amount otherwise due and payable by
adding interest thereon, computed at the Prime Rate plus [...***...]. Genentech
will perform the consolidation and settlement calculations for submission to the
JSC.

B.7       Responsibility for Reporting.

The responsibility for the consolidated reporting of the Collaboration to the
JSC shall be with Genentech in close cooperation with Dendreon and the financial
representatives of the Parties. This will be the basis for Collaboration
accounting and determining of payments to the Parties. Genentech shall provide
Dendreon with a copy of the Collaboration consolidated reporting and the
calculation serving as the basis of determining payments to the Parties.
Dendreon will provide Genentech with financial statements within thirty (30)
days after the end of the quarter for its activities in the United States,
prepared in accordance with the terms contained in this Exhibit B in order for
Genentech to prepare the consolidated reports.

B.8       Accounting for DENDREON/GNE Development Costs, Marketing Costs and
          Sales Costs.

All DENDREON/GNE Development Costs, Marketing Costs and Sales Costs will be
based on the appropriate costs definition stated in Section B.4 of this Exhibit
B.

Each Party shall report DENDREON/GNE Development Costs within thirty (30) days
after the end of each quarter in a manner consistent with its project cost
system. In general, these project cost systems report actual time spent on
specific projects, apply the actual labor costs, capture actual costs of
specific projects and allocate other expenses to projects.

                                             ***Confidential Treatment Requested

<PAGE>

For Marketing and Sales Costs, Genentech (and Dendreon if Dendreon markets
Licensed Product pursuant to the Agreement) will report costs based on internal
and external spending in Marketing and Sales departments. The Parties
acknowledge that the methodologies used will be based on systems in place.

B.9      Operating Profits and Loss Sharing.

Genentech and Dendreon agree to share the Operating Profit or Loss in the
Territory resulting from the Agreement in the following manner:

         (a) Genentech shall be allocated [...***...] of the Operating Profits
             or Losses from the sale of Licensed Products and

         (b) Dendreon shall be allocated [...***...] of the Operating Profits or
             Losses from the sale of Licensed Products.

B.10     Development Cost Sharing.

Genentech and Dendreon agree to share the DENDREON/GNE Development Costs in the
United States, to the extent shared pursuant to the terms of the Agreement, as
provided in Section 2.14 of the Agreement and this Exhibit B.

B.11     Start of Operations and Effective Accounting Date Termination.

Operation of the Collaboration will be deemed to have commenced as of the date
that Dendreon gives Genentech written notice of its election, in accordance with
Section 2.14 of the Agreement, to participate in the sharing of DENDREON/GNE
Development Costs and Profits and Losses hereunder. Costs and expenses incurred
prior to such date are not chargeable to the Collaboration under this Exhibit B.

For reporting and accounting purposes with respect to the Collaboration, the
effective termination date of the Agreement with regard to the last detailing
year in the United States will be the nearest month end to which such
termination takes place.

                                             ***Confidential Treatment Requested

<PAGE>

                                    Exhibit C

                              Itakura/Riggs Patents

The patents listed below are the "Itakura/Riggs Patents." The Itakura/Riggs
Patents shall mean any of the U.S. patents listed below and any and all
divisionals, continuations, continuations-in-part, reissues, reexaminations or
extensions of these patents or of any application from which these U.S patents
claim priority, as well as foreign counterparts of the foregoing.

U.S. 4,356,270
U.S. 4,366,246
U.S. 4,425,437
U.S. 4,431,739
U.S. 4,563,424
U.S. 4,571,421
U.S. 4,704,362
U.S. 4,812,554
U.S. 5,221,619
U.S. 5,420,020
U.S. 5,583,013Equity Investment Agreement

  
 Exhibit 10.2 
  
 EQUITY INVESTMENT AGREEMENT 
  
 THIS EQUITY INVESTMENT AGREEMENT (the “Agreement”) is made as of July 31, 2002, by and between DENDREON
CORPORATION, a Delaware corporation (the “Company”), and GENENTECH, INC., a Delaware corporation (the “Purchaser”). 

 
 WHEREAS, the Company and the Purchaser have entered into that certain Collaborative
Development and Marketing Agreement (the “Collaboration Agreement”) of even date herewith;and 
  
 WHEREAS, in connection with the Collaboration Agreement, the Company wishes to sell to the Purchaser, and Purchaser wishes to purchase from the Company, shares of the Company’s Common Stock,
par value $0.001 per share (the “Common Stock”), on the terms and subject to the conditions set forth in this Agreement. 
  
 Capitalized terms not defined herein shall have the meaning assigned in the Collaboration Agreement. 
  
 AGREEMENT 
  
 In consideration of the mutual
covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Purchaser hereby agree as follows: 
  
 1.  AGREEMENT TO SELL AND PURCHASE THE SECURITIES.

  
 1.1  At the Closing (as defined below), the Company will sell to the Purchaser, and the
Purchaser will purchase from the Company that number of shares of Common Stock (the “Shares”) equal to $2,000,000 divided by the Price Per Share. For purposes of this Article 1, the Price Per Share equals the average closing price of the
Common Stock as reported on the Nasdaq for the thirty (30) working days prior to the Closing Date (as defined below). 
  
 1.2  At the Milestone Closing (as defined below), the Company will sell to the Purchaser, and the Purchaser will purchase from the Company, that number of shares of Common Stock (the “Milestone
Shares”) equal to $2,500,000 divided by the average closing price of the Common Stock as reported on the Nasdaq for the thirty (30) working days prior to the date on which the Milestone Trigger occurs. The Shares and Milestone Shares
are collectively referred to herein as the “Securities.”  
  
 1.3  Notwithstanding the foregoing, in the event the purchase of all or a portion of the Milestone Shares will result in a Prohibited Issuance (as defined below), the Purchaser will purchase up to only that number of
Milestone Shares as may be purchased without effecting a Prohibited Issuance. For purposes of this Agreement, a “Prohibited Issuance” shall mean an issuance of Common Stock to Purchaser that results in Purchaser owning in the
aggregate that number of shares of the Company that is the lesser of (i) 19.9% of the outstanding equity securities of the Company or (ii) that percentage determined by Nasdaq which will result in a 

 change of control of the Company requiring approval of the stockholders of the Company. In the event that an issuance of some or all Milestone
Shares will result in a Prohibited Issuance, the Purchaser will purchase and the Company will sell up to that number of Milestones Shares that will not result in a Prohibited Issuance and the balance of the consideration of $2,500,000 under Section
1.2 shall be paid in cash to the Company. 
  
 2.  CLOSING AND
DELIVERY. 
  
 2.1  Closing.    The closing of
the purchase and sale of the Shares (the “Closing”) shall be held at the offices of Cooley Godward LLP, 4401 Eastgate Mall, San Diego, California 92121-9109 on the later of August 5, 2002 or that date that is ten (10) working
days following the full execution of the Collaboration Agreement, or on such other date and place as may be agreed to by the Company and the Purchaser (the “Closing Date”). The Closing Date shall be the effective date of this
Agreement. At or prior to the Closing, the Purchaser and the Company shall execute any related agreements or other documents required to be executed hereunder, dated as of the Closing Date. 
  
 2.2  Milestone Closing.    The closing of the purchase and sale of the Milestone Shares (the “Milestone
Closing”) shall be held within thirty (30) days of receipt by the Purchaser of notice from the Company that the Milestone Trigger has occurred (the “Milestone Closing Date”). For purposes of this Agreement, the
“Milestone Trigger” is the event set forth in Section 6.2 of the Collaboration Agreement. 
  
 2.3  Delivery. 
  
 (a)  At the Closing, the Company shall deliver
to the Purchaser the stock certificates registered in the name of the Purchaser, and/or in such nominee name(s) as designated in writing by the Purchaser, representing the Shares against payment of the purchase price. 
  
 (b)  At the Milestone Closing, the Company shall deliver to the Purchaser stock certificates registered in the name of
the Purchaser, and/or in such nominee name(s) as designated by the Purchaser in writing, representing the Milestone Shares against payment of the purchase price. 
  
 3.  REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

 
 The Company hereby represents and warrants as of the date hereof to, and covenants to, the Purchaser as follows: 

 
 3.1  Organization and Good Standing.    The Company has been duly incorporated and
is validly existing as a corporation in good standing under the laws of the State of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign
corporation and in good standing in all jurisdictions in which the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a
material adverse effect on the business, properties, financial condition or results of operations of the Company. 

 
 2 

  
 3.2  Corporate Power;
Authorization.    The Company has all requisite corporate power, and has taken all requisite corporate action, to execute and deliver this Agreement, sell and issue the Securities and carry out and perform all of its
obligations under this Agreement. This Agreement constitutes a legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally, including any specific performance and (iii) to the extent that the enforceability of the indemnification
provisions of Section 8.7 may be limited by applicable laws. As of the Effective Date, the execution and delivery of this Agreement and the performance and compliance with the provisions hereof will not (x) conflict with, result in a breach or
violation of, or default (with the passage of time or otherwise) under, or in the event of (i) below, require the approval of the stockholders under the terms, conditions or provisions of (i) the Certificate of Incorporation or Bylaws of the
Company, (ii) any material indenture, mortgage, lease, license or other material agreement or instrument to which the Company or any of its properties is subject (collectively, “Material Agreements”), or (iii) any statute, law, rule or
regulation (including without limitation, the rules and regulations applicable to the Nasdaq and applicable securities laws) applicable to the Company or any order, judgment or decree of any court, governmental agency, arbitration panel or authority
applicable to the Company; or (y) result in the creation or imposition of any lien, encumbrance, security interest or other restriction on the material properties or assets of the Company or give rise to a right of termination, cancellation,
modification of or acceleration under, or pursuant to any Material Agreement. 
  
 3.3  Valid
Issuance.    The Securities, when issued and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable and free and clear of all encumbrances and restrictions on
transfer, except for restrictions on transfer imposed by this Agreement or by applicable federal or state securities laws. The issuance of the Securities is not subject to any preemptive rights in any present stockholders of the Company.

  
 3.4  SEC Documents; Financial Statements.    The Company has filed in
a timely manner all documents that the Company was required to file with the United States Securities and Exchange Commission (the “SEC”) under Sections 13, 14(a) and 15(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), during the twelve (12) months preceding the Effective Date. As of their respective filing dates (or, if amended, when amended), all documents filed by the Company with the SEC (the “SEC
Documents”) complied in all material respects with the requirements of the Exchange Act. As of their respective filing dates, none of the SEC Documents contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Documents (the
“Financial Statements”), as of the date of such statements, comply as to form and substance in all material respects with applicable accounting requirements and with the published rules and regulations of the SEC with respect
thereto. The Financial Statements were prepared in accordance with generally accepted accounting principles consistently applied and fairly present the financial position of the Company at the dates thereof and the results of its operations,
stockholders’ equity and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal, recurring adjustments). 

 
 3 

  
 3.5  Capitalization.    The
capitalization of the Company is described in the Company’s SEC Documents. Except as set forth in the SEC Documents, the Company has not issued any capital stock other than pursuant to employee stock option and stock purchase plans The
outstanding shares of capital stock of the Company have been duly and validly issued and are fully paid and nonassessable and were not issued in violation of any preemptive rights. 
  
 3.6  Litigation.    There is no pending or, to the Company’s knowledge, threatened, action, suit or other proceeding to
which the Company is a party or to which its property or assets are subject that is not disclosed in the SEC Documents that is required to be so disclosed. 
  
 3.7  Governmental Consents.    No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state, or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement except for compliance with the securities and blue sky laws in the states
and other jurisdictions in which Securities are offered and/or sold, which compliance will be effected in accordance with such laws. 
  
 3.8  Nasdaq.    The Company’s Common Stock is listed on Nasdaq and the Company shall use its commercially reasonable efforts to maintain such listing. 
  
 3.9  Offering Valid.    Assuming the accuracy of the representations and warranties of the
Purchaser contained in Section 4.1 hereof, the offer and issuance of the Securities will be exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities
Act”), and will have been registered or qualified (or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. Neither the
Company nor any agent on its behalf has solicited or will solicit any offers to sell or has offered to sell or will offer to sell all or any part of the Securities to any person or persons so as to bring the sale of such Securities by the Company
within the registration provisions of the Securities Act or any state securities laws. 
  
 3.10  Governmental Permits.    The Company owns, possesses or has obtained all material licenses, permits, certificates, consents, orders, approvals and other authorizations from, and has
made all material declarations and filings with, all federal, state, local and other governmental authorities (including foreign regulatory agencies), all self-regulatory organizations and all courts and other tribunals, domestic or foreign,
necessary to own or lease, as the case may be, and to operate its properties and to carry on its business as conducted as of the date hereof. Except with respect to certain action by the FDA announced on April 30, 2002, the Company has not received
any actual notice of any proceeding relating to revocation or modification of any such license, permit, certificate, consent, order, approval or other authorization except where such revocation or modification, if effected, could not be reasonably
expected to have a material adverse effect on the business, assets, operations or prospects of the Company. To the best of its knowledge, the Company is in compliance with all laws and regulations of the United States Food and Drug Administration or
any foreign, state or local governmental body exercising comparable authority where failure to so comply could reasonably be expected to have a material adverse effect on the business, assets, operations or prospects of the Company. 

 
 4 

  
 3.11  Intellectual Property.    The
Company, to the best of its knowledge in the course of diligent inquiry, owns or is licensed to use all patents, patent applications, inventions, trademarks, trade names, applications for registration of trademarks, service marks, service mark
applications, copyrights, know-how, manufacturing processes, formulae, trade secrets, licenses and rights in any thereof and any other intangible property and assets that are material to the business of the Company as now conducted (collectively,
the “Proprietary Rights”) as such business is described in the SEC Reports. The Company does not have any actual knowledge of, and the Company has not given or received any notice of, any pending conflicts with or infringement of the
rights of others with respect to any Proprietary Rights or with respect to any license of Proprietary Rights that are material to the business of the Company as now conducted. No action, suit, arbitration, or legal, administrative or other
proceeding, or investigation (an “Action”) is pending, or, to the best of the Company’s knowledge, threatened, which involves any Proprietary Rights and which, if resolved adversely to the Company, would reasonably be expected to have
a material adverse effect upon the business, assets, operations or prospects of the Company. 
  
 3.12  No Material Adverse Change.    Since the filing of the Company’s most recent Annual Report on Form 10-K and except as set forth in the Company’s Quarterly Report on Form
10-Q for the period ending March 31, 2002, the Company’s Form S-3 filed on June 13, 2002, and press releases issued by the Company on January 11, 2002 and April 30, 2002 there has not been (a) any material adverse change in the financial
condition or earnings of the Company and its subsidiaries considered as one enterprise nor has any material adverse event occurred to the Company or its subsidiaries, (b) any material adverse event affecting the Company, (c) any obligation, direct
or contingent, that is material to the Company and its subsidiaries considered as one enterprise, incurred by the Company, except obligations incurred in the ordinary course of business, (d) any dividend or distribution of any kind declared, paid or
made on the capital stock of the Company or any of its subsidiaries, or (e) any loss or damage (whether or not insured) to the physical property of the Company or any of its subsidiaries which has been sustained, which has a material adverse effect.

  
 3.13.  Milestone Closing.    As of the Milestone Closing, the Company shall
certify that the representations and warranties in Sections 3.1 through 3.12 remain true and correct in all material respects except as otherwise provided in writing to the Purchaser. 
  
 4.  REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
PURCHASER. 
  
 4.1  The Purchaser hereby represents and warrants as of the date
hereof (and as of the date of the Milestone Closing) to, and covenants to, the Company that: 
  
 (a)  The Purchaser is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities representing an investment decision like that involved in
the purchase of the Securities, including investments in securities issued by the Company, and has requested, received, reviewed and considered, either alone or with the Purchaser’s representative, all information the Purchaser deems relevant
(including the SEC Documents) in making an informed decision to purchase the Securities. 

 
 5 

  
 (b)  The Purchaser is acquiring the Securities
being acquired by the Purchaser pursuant to this Agreement for its own account for investment only and with no present intention of distributing any of such Securities or any arrangement or understanding with any other persons regarding the
distribution of such Securities, except in compliance with Section 4.1(c). 
  
 (c)  The Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Securities
purchased hereunder except in compliance with the Securities Act, applicable blue sky laws, and the rules and regulations promulgated thereunder. 
  
 (d)  The Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act or a Qualified Institutional Buyer within
the meaning of Rule 144A promulgated under the Securities Act. 
  
 (e)  The
Purchaser has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement.
Upon the execution and delivery of this Agreement by the Purchaser, this Agreement shall constitute a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally, including any specific performance, and (iii) to the extent that
the enforceability of the indemnification provisions of Section 8.7 may be limited by applicable laws. 
  
 4.2  The Purchaser represents and warrants to and covenants with the Company that it has not engaged in any short sales of the Company’s Common Stock within the three (3) month period prior to the Closing Date
and will not engage in any short sales of the Company’s Common Stock during the term of the Collaboration. 
  
 4.3  The Purchaser understands that nothing in the SEC Documents, this Agreement or any other materials presented to the Purchaser in connection with the purchase and sale of the Securities constitutes legal, tax or
investment advice and that independent legal counsel has reviewed these documents and materials on the Purchaser’s behalf. The Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary
or appropriate in connection with its purchase of the Securities. 
  
 5.  SURVIVAL
OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. 
  
 5.1  Survival.    Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Purchaser
herein and in the certificates for the Securities delivered pursuant hereto shall survive the execution of this Agreement, the delivery to the Purchaser of the Securities being purchased and the payment therefore. 
  
 5.2  Limitation of Liability.    Neither Party shall be entitled to recover from the other party any
punitive or exemplary damages or attorneys’ fees in connection with this Agreement. 

 
 6 

  
 6.  CONDITIONS TO
COMPANY’S OBLIGATIONS AT CLOSING. 
  
 6.1  Closing.    The Company’s obligation to sell, issue and deliver the Shares to the Purchaser at the Closing shall be subject to the following conditions to the extent not waived by
the Company: 
  
 (a)  Receipt of Payment.    The Company
shall have received payment, by check or wire transfer of immediately available funds, in the full amount of the purchase price. 
  
 (b)  Collaboration Agreement.    The Company shall have received a copy of the Collaboration Agreement executed by the Purchaser. 
  
 (c)  Representations, Warranties and Covenants.    The representations and
warranties made by the Purchaser in Section 4 hereof shall be true and correct in all material respects when made at the Closing and shall be true and correct in all material respects on the Closing Date. The Purchaser shall have performed and
complied with all obligations and conditions required to be performed and complied with by the Purchaser under this Agreement on or prior to the Closing Date. 
  
 (d)  Consents, Permits and Waivers.    The Purchaser shall have obtained any and all consents, permits and
waivers necessary or appropriate for consummation of the transactions contemplated by this Agreement. 
  
 (e)  Proceedings and Documents.    All corporate and other proceedings in connection with the transactions contemplated at the Closing hereby and all documents and instruments incident to
such transactions shall be reasonably satisfactory in substance and form to the Company and its counsel, and the Company and its counsel shall have received all such counterpart originals or certified or other copies of such documents as they may
reasonably request. 
  
 6.2  Milestone Closing.    The Company’s
obligation to sell, issue and deliver the Milestone Shares to the Purchaser at the Milestone Closing shall be subject to the conditions set forth in Sections 6.1(a), (c), (d) and (e) above. 
  
 7.  CONDITIONS TO PURCHASERS’ OBLIGATIONS AT CLOSING.

  
 7.1  Closing.    The Purchaser’s obligation to accept
delivery of and pay for the Shares at the Closing shall be subject to the following conditions to the extent not waived by such Purchaser: 
  
 (a)  Issuance of Stock.    The Purchaser shall have received evidence of the issuance of a certificate representing the Shares in the name of the Purchaser.

  
 (b)  Representations, Warranties and
Covenants.    The representations and warranties made by the Company in Section 3 hereof shall be true and correct in all material respects when made and shall be true and correct in all material respects on the Closing Date
except as otherwise provided in writing to the Purchaser. The Company shall have performed and complied with all obligations and conditions to be performed and complied with by the Company under this Agreement on or prior to the Closing Date.

 
 7 

 (c)  Collaboration Agreement.    The Purchaser shall have
received a copy of the Collaboration Agreement executed by the Company. 
  
 (d)  Consents, Permits and Waivers.    The Company shall have obtained any and all consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated
by this Agreement. 
  
 (e)  Proceedings and
Documents.    All corporate and other proceedings in connection with the transactions contemplated at the Closing hereby and all documents and instruments incident to such transactions shall be reasonably satisfactory in
substance and form to the Purchaser and its counsel, and the Purchaser and its counsel shall have received all such counterpart originals or certified or other copies of such documents as they may reasonably request. 
  
 7.2  Milestone Closing.    The Purchaser’s obligation to accept delivery of and pay for
the Milestone Shares at the Milestone Closing shall be subject to the conditions set forth in Section 7.1 (a), (b), (d) and (e) above. 
  
 8.  REGISTRATION. 
  
 8.1  Piggyback
Rights.    If at any time or from time to time, the Company proposes to register any of its Common Stock on Form S-1, S-2, or S-3 under the Securities Act in connection with an underwritten offering of such securities solely
for cash (“Underwritten Offering”), and shares of Common Stock held by persons other than the Company are to be included in such Underwritten Offering, the Company shall, each such time, promptly give the Purchaser written notice of such
proposed Underwritten Offering. Upon written request of the Purchaser given within twenty (20) days after mailing of any such notice by the Company, the Company shall use its reasonable best efforts to cause to be registered under the Securities Act
all of the Securities that Purchaser has requested be registered. The Company shall cause the Securities subject to a timely request by Purchaser to be included in such Underwritten Offering on the same terms as other Common Stock included in such
underwriting. For purposes of this Agreement, an Underwritten Offering means a registration in which Common Stock of the Company is sold to an underwriter or underwriters on a firm commitment or best efforts basis for reoffering to the public;
provided, however, that it does not include a registration of Common Stock in connection with an “equity line financing” under a so-called resale S-3 or like registration. 
  
 8.2  Underwriting Requirements.    The Company shall not be required to include any of the Purchaser’s Securities in any
Underwritten Offering under Section 8.1 unless the Purchaser accepts the terms of the underwriting as agreed upon between the Company and the underwriters selected by the Company. If the total amount of Securities that the Purchaser and other
shareholders of the Company with registration rights (the “Other Shareholders”) request to be included in an Underwritten Offering exceeds the amount of securities that the underwriters believe compatible with the success of the offering,
there shall be included in such 

 
 8 

 registration that number of Securities which in the opinion of the underwriters can be sold, giving effect to the rights of the Other
Shareholders, and the securities so included shall be apportioned pro rata among the selling shareholders and according to the total amount of securities owned by said selling shareholders. 
  
 8.3  Obligations of the Company.    Whenever required under Section 8.1 to use its reasonable best efforts to effect the registration
of any Securities, the Company shall, as expeditiously as reasonably possible: 
  
 (a)  Prepare and file with the SEC a registration statement with respect to such Securities and use its reasonable best efforts to cause such registration statement to become and remain effective; provided, however,
that in connection with any proposed registration intended to permit an offering of any securities from time to time (i.e. a “shelf registration”), the Company shall in no event be obligated to cause any such registration to remain
effective for more than ninety (90) days. 
  
 (b)  Prepare and file with the SEC
such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such
registration statement. 
  
 (c)  Furnish to the Purchaser and deliver as directed
such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as it may reasonably request in order to facilitate the disposition of Securities owned
by the Purchaser. 
  
 (d)  Use its best efforts to register and qualify the
Securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution for the securities covered by the registration statement, provided that the
Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and further provided that (anything in this Agreement
to the contrary notwithstanding with respect to the bearing of expenses) if any jurisdiction in which the securities shall be qualified shall require that expenses incurred in connection with the qualification of the securities in that jurisdiction
be borne by selling shareholders, then such expenses shall be payable by the Purchaser and the other selling shareholders pro rata, to the extent permitted in such jurisdiction. 
  
 8.4  Furnish Information.    It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Article 8 that the Purchaser shall furnish such information regarding the Purchaser, the Securities held by it, and the intended method of disposition of such Securities as the underwriters shall request, and as the Company shall reasonably
request and as shall be reasonably required in connection with the action to be taken by the Company. 

 
 9 

  
 8.5  Company Registration
Expenses.    In any registration effected pursuant to Section 8.1, the Company shall bear all registration and qualification fees and expenses (including underwriters’ discounts and commissions), including any additional
costs and disbursements of counsel for the Company that result from the inclusion of Securities held by the Purchaser in such registration; provided, however, that the Purchaser shall bear the fees and costs of its own counsel and any expenses
expressly required to be borne by selling shareholders pursuant to Section 8.3(d). 
  
 8.6  Delay
of Registration.    The Purchaser shall not have the right to take any action to restrain, enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or
implementation of this Agreement or the Collaboration Agreement. 
  
 8.7  Indemnification and
Contribution.    In the event any Securities are included in a registration statement pursuant to this Article 8: 
  
 (a)  To the extent permitted by law, the Company will indemnify and hold harmless the Purchaser, any underwriter (as defined in the Securities Act) for it, and each person, if any, who
controls the Purchaser or its underwriter (within the meaning of the Exchange Act) against any losses, claims, damages or liabilities, joint or several, to which they may become subject under the Securities Act, the Exchange Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based on any untrue or alleged untrue statement of any material fact contained in such registration statement, including any preliminary
prospectus or final prospectus, or any amendments or supplements thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein
not misleading or arise out of any violation by the Company of any rule or regulation promulgated under the Securities Act or the Exchange Act applicable to the Company and relating to action or inaction required of the Company in connection with
any such registration; and will reimburse the Purchaser, such underwriter, or such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability
or action; provided, however, that the indemnity agreement contained in this Section shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company
(which consent shall not be unreasonably withheld) nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in connection with such registration statement, preliminary prospectus, final prospectus, or amendments or supplements thereto, in reliance upon and in conformity with written information furnished by
the Purchaser, underwriter or a controlling person specifically for use in preparation of the registration statement, including any preliminary prospectus or final prospectus, or any amendments or supplements thereto. 
  
 (b)  To the extent permitted by law, the Purchaser will indemnify and hold harmless the Company, each of
its directors, each of its officers who have signed the registration statement, and each person, if any, who controls the Company (within the meaning of the Securities Act or the Exchange Act) against any losses, claims damages or liabilities, joint
or several, to which the Company or any such director, officer, or controlling person, may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or 

 
 10 

 liabilities (or actions in respect thereto) arise out of or are based upon any untrue statement or omission of any
material fact contained in such registration statement, including any preliminary prospectus or final prospectus, or any amendments or supplements thereto, or arise out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or omission was made in such registration statement, preliminary
or final prospectus, or amendments or supplements thereto, in reliance upon and in conformity with written information furnished by the Purchaser specifically for use in preparation of the registration statement and such statement or omission was
not corrected, in writing, by the Purchaser and delivered to the Company at least ten (10) days before the sale or sales from which such loss occurred. Purchaser will reimburse any legal or other expenses reasonably incurred by the Company or any
such director, officer, controlling person, underwriter in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Purchaser (which consent shall not be unreasonably withheld); provided, however, Purchaser’s
obligation to indemnify the Company shall be limited to the proceeds received by Purchaser from the sale of its Securities, after deducting underwriting discounts. 
  
 (c)  After receipt by an indemnified party under this Section of notice of the commencement of any action, such indemnified party will, if
a claim in respect thereof is to be made against any indemnifying party under this Section, promptly notify the indemnifying party in writing of the commencement thereof and (unless the interest of the indemnifying party conflicts with that of the
indemnified party) the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to his ability to defend such action, shall relieve such indemnifying party, to the extent that it is prejudiced
thereby, of any liability to the indemnified party under this Section, but the omission so to notify the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section.

  
 (d)  In order to provide for just and equitable contribution to joint liability
under the Securities Act in any case in which either (i) the Purchaser, or any controlling person of the Purchaser, makes a claim for indemnification pursuant to this Section but it is judicially determined (by entry of a final judgment or decree by
a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right or appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section provides for indemnification in
such case, or (ii) contribution under the Securities Act may be required on the part of the Purchaser or any such controlling person in circumstances for which indemnification is provided under this Section; then, and in each such case, the Company
and the Purchaser will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) is such proportion as is appropriate to reflect the relative fault of the indemnifying party on
the one hand and the indemnified party on the other hand in connection with the statements or omissions which resulted in losses, claims, damages or 

 
 11 

 liabilities, as well as any other relevant equitable considerations. The relative fault shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or the indemnified party and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statements or omissions. The parties agree that it would not be just and equitable if contributions pursuant to this clause were to be
determined by pro rata allocation or by any other method or allocation which does not take account of the equitable considerations referred to in the first sentence of this clause. The amount paid by an indemnified party as a result of the losses,
claims, damages or liabilities referred to in the first sentence of this subsection shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, or defending any loss, claim,
damage, liability or proceeding which is the subject of this subsection. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. 
  
 (e)  Notwithstanding any of the
foregoing, if the Company, the Purchaser, and the underwriter(s) enter into an underwriting agreement relating to an Underwritten Offering which contains provisions covering indemnification and contribution among the parties, the indemnification and
contribution provisions of this Section shall be deemed inoperative for purposes of such offering. 
  
 (f)  The obligations of the Company and the Purchaser under this Section shall survive completion of any offering of Securities in a registration statement. No indemnifying party, in the defense of any such claim or
litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release of all liability in respect to such claim or litigation. 
  
 9.  RESTRICTIONS ON TRANSFER. 
  
 9.1  Restrictions on Transfer. 
  
 (a)  The
Purchaser agrees not to make any disposition of all or any portion of the Securities except in compliance with this Article 9 and unless and until: (i) there is then in effect a registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration statement; or (ii) the Purchaser shall have furnished the Company with such assurances as it may reasonably require (including, but not limited to, an opinion of counsel)
that such disposition is exempt from registration under Rule 144, will not require registration of such Securities under the Securities Act. 
  
 (b)  With respect to any disposition of securities of the Company, the Purchaser shall comply with all federal, state and other securities laws and shall not make any sale of such
securities if the Purchaser is in possession of material non-public information relating to the Company by virtue of the Purchaser’s access to information under the Collaboration Agreement or otherwise. In order to enforce the provisions of
this subsection, the Company may impose stop-transfer instructions with respect to securities held by Purchaser that are subject to the foregoing restriction until the end of the applicable period. 

 
 12 

  
 (c)  Each certificate representing Securities
shall be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): 
  
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT UNLESS SUCH SALE, PLEDGE OR HYPOTHECATION IS MADE IN COMPLIANCE WITH RULE 144 UNDER THE ACT OR THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED.” 
  
 The Company shall be obligated to reissue promptly unlegended certificates at
the request of the Purchaser if the Purchaser shall have provided assurances, including an opinion of counsel reasonably acceptable to the Company to the effect that the Securities proposed to be disposed of may lawfully be so disposed of (with no
need for compliance with Rule 144) without registration, qualification or legend. 
  
 9.2  “Market Stand-Off” Agreement.    If requested by the representative of the underwriters of Common Stock (or other securities) of the Company in connection with an
Underwritten Offering under Section 8.1, the Purchaser shall not sell or otherwise transfer or dispose of any Common Stock (or other securities) of the Company held by the Purchaser for a period specified by the representative of the underwriters,
in any case not to exceed one hundred eighty (180) days following the Underwritten Offering of the Common Stock of the Company under Section 8.1. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said periods. 
  
 9.3  Restricted
Transactions.    Except with respect to Securities registered pursuant to Article 8, for the one (1) year period beginning on the date of acquisition of the Shares or Milestone Shares, as the case may be, the Purchaser shall
not, and shall not authorize, instruct, facilitate or permit any of its subsidiaries to engage in any of the following: (a) offer, sell or contract to sell Securities; (b) sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant for the sale of the Securities, or (c) enter into any swap or any other agreement or any transaction that transfers, in whole or in part directly or indirectly, the economic consequence of ownership of the
Securities, whether any such swap or transaction is to be settled by delivery of Common Stock. 

 
 13 

  
 10.  BROKER’S
FEE.    The Company and the Purchaser hereby represent that, there are no brokers or finders entitled to compensation in connection with the sale of the Securities, and shall indemnify each other for any such
fees for which they are responsible. 
  
 11.  NOTICES.    All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed facsimile or mailed by first-class
registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of facsimile transmission, or when so received in the case of mail or courier, and addressed as
follows: 
  
 (a)  if to the Company, to: 
  
 General Counsel 
 Dendreon Corporation

 3005 First Avenue 
 Seattle, WA 98121 
  
 Fax No.: (206) 256-0571 
  
 or to such other person at such other place as the Company shall designate to the Purchaser in writing; and 

 
 (b)  if to the Purchaser, to: 
  
 Genentech, Inc. 
 1 DNA Way 
 South San Francisco, CA 94080 
 Attention:
Treasurer 
  
 Fax No.: (650) 225-6930 
  
 with a copy to the Corporate Secretary of Purchaser at the same address listed above. 
  
 or to such other person at such other place as the Purchaser shall designate to the Company in writing. 
  
 12.  MISCELLANEOUS. 
  
 12.1  Waivers and Amendments.    Neither this Agreement nor any provision hereof may be changed, waived, discharged, terminated,
modified or amended except upon the written consent of the Company and the Purchaser. 
  
 12.2  Headings.    The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement.

 
 14 

  
 12.3  Severability.    In case any
provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby.

  
 12.4  Dispute Resolution.    The Parties recognize that disputes as to
certain matters may from time to time arise under this Agreement which relate to either Party’s contractual rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes
arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 12.4 if and when a dispute arises under
this Agreement. 
  
 (a)  When a dispute arises under this Agreement, the matter be presented to the
chief executive officer of the Company and the Purchaser, or their respective designees, for resolution. In the event that the chief executive officer of the Purchaser and the Company, or their respective designees, cannot resolve the dispute within
thirty (30) days of the request either party may, by written notice to the other, invoke the provisions of Section 12.4(b) below. 
  
 (b)  The Purchaser and the Company agree that any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination, or invalidity thereof, shall be resolved through binding
arbitration. If the dispute arises between the parties, and if such dispute cannot be resolved pursuant to Section 12.4(a) above, any unresolved controversy or claim shall be resolved by binding arbitration in accordance with the Commercial
Arbitration Rules of the American Arbitration Association as presently in effect, except as modified herein. Each such arbitration shall be conducted by a panel of three arbitrators appointed in accordance with the Commercial Arbitration Rules as
presently in effect; provided that at least one such arbitrator shall have had, by the time of the actual arbitration, at least ten (10) years of experience as an attorney practicing in the area of securities regulation. A reasoned arbitration
decision shall be rendered in writing within thirty (30) days of the conclusion of the arbitration hearing and shall be binding. The prevailing party may enter such decision in any court having competent jurisdiction. Unless otherwise mutually
agreed upon by the parties, the arbitration proceedings shall be conducted at the location of the party not originally requesting the resolution of the dispute. The governing law shall be that of the State of New York without giving effect to
conflict of laws considerations. Each party must bear its own attorneys’ fees and associated costs and expenses. The arbitrators shall have the authority to grant specific performance and allocate costs between the Parties (excluding
attorney’s fees). 
  
 12.5  Counterparts.    This Agreement may be executed
in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and
delivered to the other parties. 
  
 12.6  Successors and Assigns.    Except as
otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 

 
 15 

  
 12.7  Entire Agreement.    This Agreement,
the Collaboration Agreement, and the related Clinical Supply Agreement, Commercial Supply Agreement, and Quality Agreement to be entered into by the parties constitute the entire understanding of the parties with respect to the subject matter hereof
and thereof and supercede all related prior or contemporaneous oral communications, agreements or discussions with respect to the subject matter hereof or thereof. Each such agreement must be read, interpreted, and applied with the others and
together they constitute one business transaction. 
  
 12.8  Payment of Fees and
Expenses.    Each of the Company and the Purchaser shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby. 
  
 12.9  Fractional Shares.    No fractional shares shall be issued in connection with the
purchases of Securities hereunder. 

 
 16 

  
 IN WITNESS
WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives as of the day and year first above written. 
  

 
 
	 DENDREON CORPORATION
 
	 
	 By:
 	 	 /s/    Mitchell H. Gold, M.D.
 

	 Name:
 	 	 Mitchell H. Gold, M.D.
 
	 Title:
 	 	 Chief Business Officer
 

 
  
 
	 GENENTECH, INC.
 
	 
	 By:
 	 	 /s/    Arthur D. Levinson, Ph.D.
 

	 Name:
 	 	 Arthur D. Levinson, Ph.D
 
	 Title:
 	 	 Chief Executive Officer
 

 

 
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]